Official Protocol Title:
NCT number:                [STUDY_ID_REMOVED]
Document Date:           26-Sep-2022
A Phase 3, Randomized, Clinical Study in HIV-1-
Infected Heavily Treatment-Experienced Participants 
Evaluating the Antiretroviral Activity of Blinded Islatravir 
(ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/
ISL), Each Compared to Placebo, and the Antiretroviral 
Activity, Safety, and Tolerability of Open-Label DOR/ISL
Compared to
Placebo, and the Antiretroviral Activity, Safety,
and Tolerability of Open-Label DOR/ISL

PRODUCT: MK-8591A  1
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD).
Protocol Title: A Phase 3, Randomized, Clinical Study in HIV-1- Infected Heavily 
Treatment -Experienced Participants Evalua ting the Antiretroviral Activity of Blinded 
Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to 
Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open -Labe lDOR/ISL
Protocol Number: 019-09
Compound Number: MK-8591A
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_437582] , NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND 134,[ADDRESS_437583] 2019- 000588- 26
Approval Date: [ADDRESS_437584]: MK-8591A  2
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08BJ8V
PRODUCT: MK-8591A  3
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 09 26-SEP-2022 [COMPANY_006] Sharp & Dohme Corp. underwent an entity name [CONTACT_193455] & Dohme LLC, Rahway, NJ, [LOCATION_003]. This conversion resulted only 
in an entity name [CONTACT_26406].
Amendment 08 20-JAN-2022 Given the findings of decreases in CD4+ T -cell and total lymphocyte counts in 
clinical studies evaluating ISL, the protocol is being amended t o increase the 
frequency of monitoring of CD4+ T -cell andtotal lymphocyte counts and to 
specify the management of participants who meet protocol -defined decreases 
in CD4+ T -cell and/or total lymphocyte counts . 
Amendment 07 07-DEC -2021 To increase frequency of monitoring of CD4+ T -cell counts and lymphocyte 
counts and add criteria for management of participants in response to findings 
of decreases in CD4+ T -cell counts (in studies of participants with HIV) an d 
lymphocytes (in studies of participants with or without HIV) in ISL clinical 
studies.
Note: The changes made in Amendment [ADDRESS_437585]: MK-8591A  4
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Document Date of Issue Overall Rationale
Amendment 04 16-MAR -2021 A country- specific amendment for Russia. As required by [CONTACT_351901], if a participant becomes pregnant (has a positive serum pregnancy 
test), study intervention must be discontinued.
Amendment [ADDRESS_437586] -2020 Extend Part 2 of the study from 48 weeks to 96 weeks of open -label 
intervention with DOR/ISL + OBT, permit continued administration of study 
intervention in participants who become pregnant, add a discontinuation 
criterion if a participant chooses to breastfeed, and add a Per -Protocol analysis 
to the SAP.
Amendment 02 12-MAY -2020 Allow participants to rescreen following consultation with the Sponsor. The 
lower age limit of 12 years was removed. 
Amendment 01 10-MAR -2020 Assessment of fasting lipid and glucose profiles were a dded to the protocol to 
comply with the DHHS “Guidelines For the Use of Antiretroviral Agents in 
Adult and Adolescents with HIV.” 
Original Protocol 18- NOV- [ADDRESS_437587]: MK-8591A  5
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 09
Overall Rationale for the Amendments:
Sponsor underwent an entity name [CONTACT_26406].
Summary of Changes Table:
Section # and Name [CONTACT_351947] 10.1.[ADDRESS_437588] for Clinical Trials
ThroughoutSponsor entity name [CONTACT_148231] .[COMPANY_006] Sharp & Dohme Corp. underwent an entity name 
[CONTACT_19520] & Dohme LLC, 
Rahway, NJ, [LOCATION_003]. This conversion resulted only in an 
entity name [CONTACT_26406].
08BJ8V
PRODUCT: MK-8591A  6
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 5
1 PROTOCOL SUMMARY ............................................................................................ 15
1.1 Synopsis ................................................................................................................. 15
1.2 Schema .................................................................................................................. 20
1.3 Schedule of Activities (SoA) ................................................................................ 22
1.3.1 Schedule of Activities .................................................................................. 22
1.3.2 Schedule of Activities – Viremia Confirmation and End of Treatment  
(All Participants Except Those With Specified Decreases in CD4+ T -
cell and/or Total Lymphocyte Counts) ........................................................ 32
1.3.3 Schedule of Activities for Participants Whose Pregnancy or Postpartum 
Visit(s) Extends Beyond Week 97 ............................................................... 35
1.3.4 Schedule of Activities – Participants With Specified Decreases in CD4+ 
T-cell Counts and/or Total Lymphocyte Counts .........................................37
2 INTRODUCTION .......................................................................................................... 40
2.1 Study Rationale ....................................................................................................40
2.2 Background .......................................................................................................... 40
2.2.1 Islatravir .......................................................................................................40
2.2.2 Doravirine ....................................................................................................41
2.2.3 Doravirine/Islatravir..................................................................................... 41
2.2.4 Information on Other Study -related Therapy .............................................. 42
2.3 Benefit/Risk Assessment ...................................................................................... 42
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 43
4 STUDY DESIGN ............................................................................................................ 47
4.1 Overall Design ......................................................................................................47
4.2 Scientific Rationale for Study Design ................................................................ .48
4.2.1 Rationale for Endpoints ............................................................................... 49
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 49
[IP_ADDRESS].1 HIV-1 RNA Measurements ..................................................... 49
[IP_ADDRESS] Patient -reported Outcomes ................................................................ .49
[IP_ADDRESS] Safety Endpoints ................................................................................ 50
[IP_ADDRESS] Laboratory Markers ........................................................................... 50
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 50
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................50
[IP_ADDRESS].[ADDRESS_437589]: MK-8591A  7
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
[IP_ADDRESS] Future Biomedical Research .............................................................. 51
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 51
4.2.3 Rationale for the Selected Participant Population .......................................51
4.2.4 Rationale for Collecting Race and Ethnicity Data .......................................52
4.2.5 Rationale for Collecting Gender Identity Data ............................................ 52
4.2.6 Rationale for Infant Safety Data Collection ................................................. 53
4.2.7 Rationale for Continuing Study Intervention During Pregnancy ................ 53
4.3 Justification for Dose ........................................................................................... 53
4.4 Beginning and End of Study Definition ............................................................. 54
4.4.1 Clinical Criter ia for Early Study Termination ............................................. 55
5 STUDY POPULATION ................................................................................................ 55
5.1 Inclusion Criteria ................................................................................................ .55
5.2 Exclusion Criteria ................................................................................................ 57
5.3 Lifestyle Considerations ...................................................................................... 59
5.4 Screen Failures .....................................................................................................59
5.5 Participant Replacement Strategy ......................................................................59
6 STUDY INTERVENTION ............................................................................................ 59
6.1 Study Intervention(s) Administered ...................................................................59
6.2 Preparation/Handling/Storage/Accountability ................................................. 62
6.2.1 Dose Preparation .......................................................................................... 62
6.2.2 Handling, Storage, and Accountability ........................................................ 62
6.3 Measures to Min imize Bias: Randomization and Blinding .............................. 63
6.3.1 Intervention Assignment.............................................................................. 63
6.3.2 Stratification ................................................................................................ .63
6.3.3 Blinding ........................................................................................................63
6.4 Study Intervention Compliance .......................................................................... 64
6.5 Concomitant Therapy .......................................................................................... 64
6.5.1 Rescue Medications and Supportive Care ................................................... 66
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_437590]: MK-8591A  8
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
8.1.1 Informed Consent/Assent ............................................................................. 69
[IP_ADDRESS] General Informed Consent/Assent ..................................................... 69
[IP_ADDRESS] Consent/Assent and Collection of Specimens for Future 
Biomedical Research ......................................................................... 70
[IP_ADDRESS] Consent/Assent for Postnatal Infant Safety Data Collection 
Through On e Year of Age ................................................................ .70
[IP_ADDRESS] Consent/Assent for Continuation of Study Intervention During 
Pregnancy ........................................................................................... 70
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_437591] .....................................................................71
8.1.4 Medical History ........................................................................................... 71
8.1.5 Prior and Concomitant Medications Review ............................................... 71
[IP_ADDRESS] Prior Medications ............................................................................... 71
[IP_ADDRESS] Concomitant Medications ..................................................................71
8.1.6 Assignment of Screening Number ............................................................... 72
8.1.7 Assignment of Treatment/Randomization Number .....................................72
8.1.8 Study Intervention Administration .............................................................. 72
[IP_ADDRESS] Timing of Dose Administration ......................................................... 72
8.1.9 Discontinuation and Withdrawal ................................................................ .73
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 73
8.1.10 Participant Blinding/Unblinding ..................................................................74
8.1.11 Calibration of Equipment ............................................................................. 74
8.1.12 Administration of Patient Questionnaires .................................................... 75
8.2 Efficacy Assessments ........................................................................................... 75
8.2.1 HIV-1 RNA ..................................................................................................75
8.2.2 Management of Study Participants with Viremia ........................................75
[IP_ADDRESS] Viremia Confirmation ........................................................................75
[IP_ADDRESS] Viral Drug Resistance Testing ........................................................... 76
8.2.3 T-and B -Lymphocyte and Natural Killer Cell Profile (TBNK) ................. 76
8.3 Safety Assessments ............................................................................................... 76
8.3.1 Physical Examinations ................................................................................. 76
8.3.2 Vital Signs ....................................................................................................77
8.3.3 Electrocardiograms ...................................................................................... 77
8.3.4 Confirmation of Menarche, Contraception, and Pregnancy Testing ........... 77
8.3.5 Clinical Safety Laboratory Assessments ..................................................... 78
8.3.6 HBV Assessments ........................................................................................ 78
8.3.7 Tobacco and Alcohol Assessments .............................................................. 78
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... [ADDRESS_437592]: MK-8591A  9
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Inf ormation .......................................................... 79
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......81
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...81
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 81
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 82
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_437593] (ECIs) ................................................................ 82
8.5 Treatment of Overdose ........................................................................................ 83
8.6 Pharmacokinetics ................................................................................................ .83
8.6.1 Blood Collection for Plasma ISL and DOR................................................. 83
8.7 Pharmacodynamics .............................................................................................. 84
8.8 Biomarkers ........................................................................................................... 84
8.8.1 Planned Genetic Analysis Sample Collection.............................................. 84
8.8.2 Inflammation ................................................................................................ 84
8.8.3 Fasting Lipid and Metabolic Profiles ........................................................... 85
8.9 Future Biomedical Research Sample Collection ............................................... 85
8.10 Health Economics Medical Resource Utiliz ation and Health Economics .......85
8.11 Visit Requirements ............................................................................................... 85
8.11.1 Screening/Rescreening ................................................................................. 85
8.11.2 Run-in Period ............................................................................................... 86
8.11.3 Treatment Period .......................................................................................... 87
[IP_ADDRESS] Fasting ................................................................................................ 87
[IP_ADDRESS] Double -blind (Part 1) ......................................................................... 87
[IP_ADDRESS] Open -label (Part 2) ............................................................................. 87
[IP_ADDRESS] Optional Nurse Visits and Telephone Visits ......................................87
[IP_ADDRESS] End of Study Week 97 Visit .............................................................. 88
8.11.4 Participants Who Discontinue Study Intervention .......................................88
[IP_ADDRESS] Early Discontinuation of Treatment ................................................... 89
[IP_ADDRESS] End of Treatment Follow -Up Visit .................................................... 89
8.11.5 Viremia Confirmation .................................................................................. 89
8.11.6 Management of Participants with Decreases in CD4+ T -cell Counts 
and/or Total Lymphocyte Counts ................................................................ 89
[IP_ADDRESS] Participants Whose CD4+ T- cell Count and/or Total Lympho cyte 
Count Decreases Meet Criteria for Events of Clinical Interest 
While on Study Intervention .............................................................. 89
[IP_ADDRESS] Participants Discontinued from Study Intervention Due to
Decreased CD4+ T- cell Count and/or Total Lymphocyte Count ......[ADDRESS_437594]: MK-8591A  10
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
[IP_ADDRESS] Participants Discontinued from Study Intervention For Other 
Reasons AND Have Decreases in CD 4+ T -cell Count and/or 
Total Lymphocyte Count ................................................................... 90
8.11.7 Clinical Management of Participants Who Become Pregnant ..................... 90
[IP_ADDRESS] Continuing Study Intervention ........................................................... 91
[IP_ADDRESS] Discontinuing Study Intervention ...................................................... 92
[IP_ADDRESS] Participants Who Choose to Breastfeed ............................................. 92
[IP_ADDRESS] InfantSafety Data Collection............................................................. 92
[IP_ADDRESS].1 Schedule of Activities: Infant Safety Data Collection ............. 93
9 STATISTICAL ANALYSIS PLAN ............................................................................. 93
9.1 Statistical Analysis Plan Summary .....................................................................93
9.2 Responsibility for Analyses/In -house Blinding ................................................. 96
9.3 Hypotheses/Estimation ........................................................................................ 96
9.4 Analysis Endpoints ............................................................................................... 96
9.4.1 Efficacy/Pharmacokinetics Endpoints ......................................................... 96
[IP_ADDRESS] Primary Efficacy Endpoint ................................................................ 96
[IP_ADDRESS] Secondary Efficacy Endpoints ........................................................... 97
[IP_ADDRESS] Pharmacokinetics Endpoints .............................................................. 98
9.4.2 Safety Endpoints .......................................................................................... 98
9.4.3 Patient -reported Outcome Endpoints ........................................................... 99
9.5 Analysis Populations ............................................................................................ 99
9.5.1 Efficacy Analysis Populations .....................................................................99
[IP_ADDRESS] Full Analysis Set ................................................................................ 99
[IP_ADDRESS] Per-protocol Analysis Set ..................................................................99
[IP_ADDRESS] Resistance Analysis Subset .............................................................. 100
9.5.2 Safety Analysis Population ........................................................................100
9.6 Statistical Methods ............................................................................................. 100
9.6.1 Statistical Methods for Efficacy Analyses................................................. 100
9.6.2 Statistical Methods for Safety Analyses .................................................... 107
9.6.3 Summaries of Baseline Characteristics, Demographic, and other 
Analyses .....................................................................................................108
[IP_ADDRESS] Demographic and Baseline Characteristics .....................................[ADDRESS_437595]: MK-8591A  11
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
9.9 Sample Size and Power Calculations ............................................................... 111
9.9.1 Sample Size and Power for Efficacy Analyses .......................................... 111
[IP_ADDRESS] Futility Criteria and Superiority Testing .......................................... 111
[IP_ADDRESS] Evaluat ion of the Primary Hypotheses ............................................ 112
9.9.2 Sample Size and Power for Safety Analyses ............................................. 113
9.10 Subgroup Analyses ............................................................................................. 115
9.11 Compliance (Medication Adherence) ............................................................... 115
9.12 Extent of Exposure ............................................................................................. 116
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ...................................................................................................117
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ......[ADDRESS_437596] for Clinical Trials ........................................................... 117
10.1.2 Financial Disclosure ................................................................................... 119
10.1.3 Data Protection ........................................................................................... 119
[IP_ADDRESS] Confidentiality of Data ....................................................................120
[IP_ADDRESS] Confidentiality of Participant Records............................................. 120
[IP_ADDRESS] Confidentiality of IRB/IEC Information .......................................... 120
10.1.4 Committees Structure ................................................................................. 120
[IP_ADDRESS] Scientific Advisory Committee (SAC) ............................................ 120
[IP_ADDRESS] Executive Oversight Committee ...................................................... 121
[IP_ADDRESS] External Data Monitoring Committee ............................................. 121
10.1.5 Publication Policy ...................................................................................... 121
10.1.6 Compliance with Study Registration and Results Posting Requirements .121
10.1.7 Compliance with Law, Audit, and Debarment .......................................... 122
10.1.8 Data Quality Assurance ............................................................................. 122
10.1.9 Source Documents ..................................................................................... 123
10.1.10 Study and Site Closure ............................................................................... 124
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 125
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 132
10.3.1 Definition of AE ........................................................................................ 132
10.3.2 Definition of SAE ...................................................................................... 133
10.3.3 Additional Events Reported .......................................................................134
10.3.4 Recording AE and SAE ............................................................................. 134
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ......................................................................................................138
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ..................................139
10.5 Appendix 5: Contraceptive Guidance .............................................................. [ADDRESS_437597]: MK-8591A  12
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.5.1 Definitions .................................................................................................. 140
10.5.2 Contraception Requirements ......................................................................142
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 143
10.7 Appendix 7: Country -specific Requirements .................................................. [ADDRESS_437598] for Ukraine ....................................................... 148
10.8 Appendix 8: Calculation of Creatinine Clearance .......................................... 149
10.9 Appendix 9: Abbreviations ............................................................................... [ADDRESS_437599]: MK-8591A  13
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437600] OF TABLES
Table 1 Laboratory Exclusion Criteria .................................................................... 58
Table 2 Study Interventions .................................................................................... 60
Table 3 Prohibited Therapi[INVESTIGATOR_014] .................................................................................. 65
Table 4 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events ................................................................ .80
Table 5 Collection of Population PK Samples ........................................................ 83
Table 6 Collection of Population PK Samples During Pregnancy and 
Postpartum ................................................................................................ .92
Table 7 Definitions of Study Time Points ............................................................ 101
Table 8 Analysis Stra tegy for Key Efficacy Variables .........................................106
Table 9 Analysis Strategy for Safety Parameters .................................................. 108
Table 10 Futility Boundary That Would Trigger Ad Hoc eDMC Review 
Corresponding to Current Possible Sample Size in DOR/ISL Group .....110
Table 11 Probability of Meeting Futility Criteria and the Overall Study Power 
for Various Underlying True Response Rates Assuming the Response 
Rate is 3% or 10% for Placebo Recipi[INVESTIGATOR_840] .............................................. 112
Table 12 Power (%) to Establish Superiority†Under Various Response Rate 
Assumptions ( 20 DOR /ISL Recipi[INVESTIGATOR_842] 20 Placebo Recipi[INVESTIGATOR_840]) .......[ADDRESS_437601] One Event in a Treatment Group for 
a Given Sample Size and a Variety of Underlying AE Incidence Rates .113
Table 14 Estimate of Incidence of AEs and 95% Upper Confidence Bound 
Based on Hypothetical Numbers of Participants with AEs ..................... 114
Table 15 Protocol -required Laboratory Asses sments ............................................. 125
Table 16 Blood Volume by [CONTACT_4838] ............................................................................ 129
Table 17 Blood Volumes: Participants Whose Pregnancy or Postpartum Visit(s) 
Extends Beyond Week [ADDRESS_437602]: MK-8591A  14
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437603]: MK-8591A  15
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
1 PROTOCO L SUMMARY
1.1 Synopsis
Protocol Title: A Phase 3, Randomized, Clinical Study in HIV-1- Infected Heavily 
Treatment -Experienced Participants Evaluating the Antiretroviral Activity of Blinded 
Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to 
Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open -Label DOR/ISL
Short Title: DOR/ISL in heavily treatment -experienced participants
Acronym: Not applicable
MK-8591A (hereafter referred to as DOR/ISL) is a novel 2- drug FDC of DOR and ISL.
Hypotheses, Objectives ,and Endpoints :
The following objectives will be evaluated in HTE adult participants and in pediatric 
participants weighing ≥35 kg with pre -study HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL and currently on 
failing ART. 
Primary Objectives Primary Endpoints
To evaluate the antiretroviral activity of 
DOR/ISL compared to placebo, each given in 
combination with failing ART as assessed by [CONTACT_351902] ≥0.5 log10 
decrease in HIV -1 RNA from study baseline 
(Day 1) to Day 8 (Part 1).
Hypothesis: The percentage of participants receiving 
DOR/ISL and achieving ≥0.5 log10 decrease in 
HIV-1 RNA from study baseline (Day 1) to Day 8 is 
superior to placebo, each given in combination with 
failing ART.HIV-1 RNA
To evaluate the safety and tolerability of 
DOR/ISL as assessed by [CONTACT_181773] 25 and 
Week 49.AEs
AEs leading to discontinuation 
of study intervention
08BJ8V
PRODUCT: MK-8591A  16
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Primary Objectives Primary Endpoints
Secondary Objectives Secondary Endpoints
To evaluate the safety and tolerability of 
DOR/ISL as assessed by [CONTACT_181773] 97.AEs
AEs leading to discontinuation 
of study intervention
To evaluate the antiretroviral activity of ISL and 
DOR, each compared to placebo, when each is 
given in combination with failing ART, as 
assessed by [CONTACT_351903] ≥0.5 log10 decrease in HIV- 1 RNA 
from study baseline (Day 1) to Day 8 (Part 1).HIV-1 RNA
To further evaluate the antiretroviral activity of 
DOR/ISL, ISL, and DOR each compared to 
placebo, when each is given in combination with 
failing ART (Part 1) as assessed by:
-mean change in HIV -1 RNA from study 
baseline (Day 1) to Day 8
-percentage of participants achieving ≥1.0 
log10 decrease in HIV -1 RNA from study 
baseline (Day 1) to Day 8HIV-1 RNA
To further evaluate the antiretroviral activity of 
DOR/ISL compared to ISL and DOR, when each 
is given in combination with failing ART (Pa rt 
1) as assessed by:
-percentage of participants achieving ≥0.5 
log10 decrease in HIV -1 RNA from study 
baseline (Day 1) to Day 8
-mean change in HIV -1 RNA from study 
baseline (Day 1) to Day 8
-percentage of participants achieving ≥1.0 
log10 decrease in HIV -1RNA from study 
baseline (Day 1) to Day 8HIV-[ADDRESS_437604]: MK-8591A  17
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Primary Objectives Primary Endpoints
To evaluate the antiretroviral activity of 
DOR/ISL + OBT in Part 2 as assessed by [CONTACT_351904] 25, Week 49, and Week 97 
compared to study baseline (Day 1) and Part 2 
baseline (Day 8):
-percentage of participants achieving ≥0.5 
log10 decrease in HIV -1 RNA
-percentage of participants achieving ≥1.0 
log10 decrease in HIV -1 RNA
-mean change in HIV -1 RNA
-percentage of participants achieving HIV -1 
RNA <200 copi[INVESTIGATOR_014]/mL
-percentage of participants ac hieving HIV -1 
RNA <50 copi[INVESTIGATOR_014]/mL
-percentage of participants achieving HIV -1 
RNA <40 copi[INVESTIGATOR_014]/mLHIV-1 RNA
To evaluate the development of viral drug 
resistance to DOR, ISL, or components of OBT 
through the study duration (Part 1 and Part 2).Viral resistance -associated 
substitutions
To evaluate the impact of study baseline (Day 1) 
antiviral resistance on virologic outcome at 
Week 25, Week 49, and Week 97 (Part 2).Viral resistance -associated 
substitutions
HIV-1 RNA
To evaluate the change in CD4+ T -cell counts 
from both study baseline (Day 1) and Part 2 
baseline (Day 8) at Week 25, Week 49, and 
Week 97 (Part 2).CD4+ T- cell count
Overall Design:
Study Phase Phase 3
Primary Purpose Treatment
Indication HIV-1 infection
Population HTE adult participants and pediatric participants weighing 
≥35kg currently on failing ART with pre-study HIV-1
RNA ≥ 500 copi[INVESTIGATOR_014]/mL
Study Type Interventional
08BJ8V
PRODUCT: MK-8591A  18
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Intervention Model Parallel followed by [CONTACT_25505] -group
This is a multi- sitestudy.
Type of Control Placebo control (Part 1 only)
Study Blinding Double -blind double -dummy (Part 1) followed by 
[CONTACT_351905] -label (Part 2)
Masking Sponsor (Part 1 only)
Investigator (Part 1 only)
Participant (Part 1 only)
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately [ADDRESS_437605] participant 
(or their legally acceptable representative) provides 
documented informed consent /assent until the last 
participant’s last study- related contact .
Number of Participants :
Approximately [ADDRESS_437606]: MK-8591A  19
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Intervention Groups and Duration :
Interven -
tion 
GroupsIntervention 
Group Name [CONTACT_351948] -Blind Period (Part 1)
Group 1 ISL+ ART 0.75 mg QD OralDay 1 to 
Day 7Experimental
Group 2DOR + 
ART100mg QD OralDay 1 to 
Day 7Experimental
Group 3DOR/ISL + 
ART100mg 
DOR/ 0.75 mg
ISLQD OralDay 1 to 
Day 7Experimental
Group 4Placebo + 
ART0 mg QD OralDay 1 to 
Day 7Placebo 
comparison
Open -Label Period (Part 2)
Open -LabelDOR/ISL + 
OBT100 mg 
DOR/ 0.75 mg
ISLQD OralDay 8 
through 
Week 97aExperimental
Abbreviations: ART= antiretroviral therapy; DOR=doravi rine; ISL= islatravir; OBT=o ptimized background 
therapy; QD=once daily .
The Sponsor will not provide ART during Part 1or OBT during Part 2. Participants will provide their own 
medications.
aFor participants who are pregnant at the last regularly scheduled study vis it (Week 97), study intervention will 
be dispensed at Week 97. In addition, their visit schedule will be extended through the duration of the 
pregnancy and study intervention will be dispensed at Weeks 109, 121, and 133, as applicable.
Total 
Number5
Duration of 
Participa -
tionEach participant will participate in the study for approximately 112weeks
from the time the participant provides documented informed c onsent /assent
through the final contact. After a screening period of up to 60days and a 
Run-in Period prior to randomization, each participant will receiv eassigned 
double -blind intervention for [ADDRESS_437607]: MK-8591A  20
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Scientific Advisory Committee Yes
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 9.
1.2 Schema
The study design is depi[INVESTIGATOR_6517] 1.
Figure 1Study Schema and Treatment Plan
ART=antiretroviral therapy; DOR=d oravirine; HIV-1=Human Immunodeficiency Virus Type 1; ISL=islatravir; 
n=number of participa nts per group; OBT=optimized background therapy; QD=once daily ; RNA=ribonucleic 
acid.
*HIV-1 RNA testing will be repeated during the Run -in Period to confirm eligibility for randomization (defined 
as HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL). Participants with ≥ 500 copi[INVESTIGATOR_014]/mL on confirmation testing but with ≥0.5 log 10
decline in HIV -1 RNA from the Screening Visit (Visit 1) will have an additional HIV -[ADDRESS_437608] 
within 7 to 14 days. Participants with a further decline in HIV -1 RNA ≥0.[ADDRESS_437609] will be excluded from t he study.
Note: Participants are treated with open -label DOR/ISL + OBT for [ADDRESS_437610]: MK-8591A  21
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Figure 2HIV-1 RNA Study Entry Eligibility Schema
HIV-1=Human Immunodeficiency Virus Type 1; RNA=ribonucleic acid.
08BJ8V
PRODUCT: MK-8591A  22
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
1.3 Schedule of Activities (SoA)
1.3.1 Schedule of Activities
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437611] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437612] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Administrative Procedures
Informed 
Consent/AssentX
Informed 
Consent/Assent 
for Future 
Biomedical 
ResearchX
Informed 
Consent /Assent
for Study 
Intervention 
During 
Pregnancy<------------------------------------- X------------------------------------ >Obtain upon confirmation of 
pregnancy if participant wants 
to continue receiving study 
intervention.
08BJ8V
PRODUCT: MK-8591A  23
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437613] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437614] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Collect and enter 
data from 
prenatal provider<------------------------------------- X------------------------------------ >For female participants who 
become pregnant and consent 
to continue DOR/ISL, obtain 
relevant prenatal clinical & 
laboratory data to monitor the 
safety of the mother & fetus 
per Section 8.11. 7.
Inclusion/Exclus
ion CriteriaX X X XReview prior to randomization 
on Day [ADDRESS_437615] .
Medical History X
Prior/
Concomitant 
Medication 
ReviewX X X X X X X X X X X X X X X X
Register study 
visit in IRTX X X X X X X X X X X X X X
08BJ8V
PRODUCT: MK-8591A  24
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437616] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437617] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Intervention 
RandomizationXAll procedures should be 
completed prior to dose on 
Day 1.
Randomization should occur 
within 10 days of 
confirmation of HIV -1 RNA 
eligibility .
Dispense study 
intervention 
using IRTX X X X X X X X X X X XDispense DOR/ISL at Week 
97 to any pregnant participant 
whose pregnancy or 
postpartum visit(s) extend 
beyond Week 97. See Section 
1.3.3.
Evaluation to 
receive 
continued study 
interventionX See Section 6.[ADDRESS_437618]: MK-8591A  25
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437619] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437620] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
ART/OBT 
compliance 
reviewX X X X X X X X X X X X X X X
Completion of 
participant 
questionnaire 
(FAHI)X X X XAdministered to participants 
≥[ADDRESS_437621] results.
Efficacy/Immunogenicity Procedures
Plasma HIV -1 
RNA 
Quantification 
(Real Time 
PCR) X X X X X X X X X X X X X X X X
CD4+ T -cell 
count /TBNK 
PanelX X X X X X X X X X XDecreases in CD4+ T- cell 
count that meet ECI criteria 
should be managed per 
Section 8.11.[ADDRESS_437622]: MK-8591A  26
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437623] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437624] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Blood (plasma) 
for HIV -1 drug 
resistanceX X X X X X X X X X X X X XTesting performed via central 
laboratory at Screening , Day 
1, Day 8, and thereafter on 
samples with HIV -1 RNA 
≥200 copi[INVESTIGATOR_014]/mL for 
participants who never 
suppressed at Week 25 ,Week 
49, and Week 9 7and those 
that were collected either to 
confirm viremia after 
suppression (VL<50 
copi[INVESTIGATOR_014]/mL) or at 
discontinuation.
08BJ8V
PRODUCT: MK-8591A  27
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437625] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437626] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Whole Blood for 
Proviral DNA 
Resistance 
TestingX X X XTesting to be performed via 
central laboratory at a) 
Screening Visit for all 
partici pants and b) on
postrandomization samples
with HIV -1 RNA ≥200 
copi[INVESTIGATOR_014]/mL at Week 25 , Week 
49,and Week 97and samples
collected either to confirm 
viremia after suppression (VL 
<50 copi[INVESTIGATOR_014]/mL) or at 
discontinuation.
Safety Procedures
Full physical 
examinationX
Height X X X
Weight X X X X X X X X
Directed 
physical 
examinationX X X X X X X X X X X X X
Vital Signs X X X X X X X X X X X X X XIncludes pulse, bp, temp, and 
rr.
12-lead ECG X May be read locally .
08BJ8V
PRODUCT: MK-8591A  28
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437627] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437628] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Confirmation of 
menarche status 
(females only)X X X X X X X X X X X X X XNot required once menarche 
has been confirmed.
Contraception 
Use 
Confirmation 
(WOCBP only)X X X X X X X X X X X X XTo be done per local 
guidelines .
Serum 
Pregnancy Test 
(β-hCG; 
WOCBP only)X
Urine Pregnancy 
Test (WOCBP 
only)X X X X X X X X X X X X XConfirm with serum test if 
urine test is positive .If 
confirmatory serum test is
positive, participants will be 
managed per Section 8.11. [ADDRESS_437629]: MK-8591A  29
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437630] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437631] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Hepatitis 
Serology 
(HBsAg, 
HBsAb, Anti -
HBc, HCV Ab)X XParticipants who do not 
demonstrate immunity to 
HBV should be encouraged to 
be vaccinated against HBV.
HBV DNA X X
HCV RNA X X
HIV-1 & -2 
SerologyX
Hematology X X X X X X X X X X XDecreases in total lymphocyte 
counts that meet ECI criteria 
should be managed per 
Section 8.11.6 and Section 
1.3.4.
PT/INR X
Urinalysis X X X X X X X X X X X
Fasting 
Lipid/GlucoseX X X X XIf abnormal profile at Day 8, 
repeat the abnormal test at 
TW [ADDRESS_437632]: MK-8591A  30
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437633] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437634] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Pharmacokinetics
Blood (plasma) 
for DOR and 
ISL PKX X X X X X XAt Weeks 25 and 49, a 
predose and postdose sample 
will be taken.
Blood (plasma) 
for 
Investigational 
PKX XAnalysis triggered by [CONTACT_351906].
Blood (Plasma) 
for DOR and 
ISL PK in 
Pregnant 
Participants<--------------------------------------- X----------------------------------- >Collected during the 1st, 2nd, & 
3rdtrimesters & postpartum 
per Section 8.11. 7.1.
Biomarkers
Blood for 
Genetic 
AnalysisbX
Whole Blood for 
Future 
Biomedical 
ResearchX X X XOptional participation; 
requires FBR consent . 
08BJ8V
PRODUCT: MK-8591A  31
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study 
PeriodScreening/Run -In Period Intervention NotesScreening
HIV -1 
Confirmation 
Visitc
Repeat HIV-1 
Confirmation 
Visitd
Double-blind 
(Part 1)Open -label 
(Part 2)Visit [ADDRESS_437635] for 
participants with 500 
copi[INVESTIGATOR_014]/mL on confirmation 
testing but with 0.5 log 10
decline in HIV -1 RNA from 
the Screening Visit (Visit 1)
Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Each visit should be 
calculated from date of 
Randomization (Day 1). A 
visiting nurse may be u sedfor 
visits after randomization per 
Section [IP_ADDRESS].Scheduled 
Day/Week
Screen
NA
NA
Day 1 
(Fasting) 
Day 8
(Fasting)
TW3
TW7
TW13
TW19 TW25 TW37
TW49
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Visit Window ≤60 daysa≤10 days 
prior to
Day 17-14 days 
after 
Visit 2NA +3 days ±[ADDRESS_437636] occur within 
10 days of Visit 2 (or Visit 3, 
if required).
Blood for 
Inflammatory 
MarkersX X X X
Anti-HBc= hepatitis B core antibody; ART=antiretroviral therapy; β -hcg-beta human chorionic gonadotropin; bp=blood pressure; D/C=discontinuation; DNA=deoxyribonucleic acid; DOR=doravirine; 
ECG=electrocardiogram; ECI=Events of Clinical Interest; FAHI=Functional Assessment of HIV Infection; FBR=Future Biomedical Research; F/U=follow -up; HBsAb= hepatitis B surface antibody; 
HBsAg= hepatitis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HIV -1=human immunodeficiency virus Type 1; INR=international 
normalized ratio; IRT=Interactive Response Technology; ISL=islatravir; NA=not applicable; OBT=optimized background therapy; PCR=polymerase chain reaction; PK=pharmacokinetic; 
PT=prothrombin time; RNA=ribonucleic acid; rr=respi[INVESTIGATOR_697]; temp=body temperature; TBNK=T -and B -lymphocyte and natural killer cell profile; TW=treatment week; VL=viral load; 
WOCBP=women of childbearing potential.
aParticipants are expected to enroll as soon as possible after eligibility is confirmed. In cases of unexpected delays in rece iving repeat screening laboratory results, a sc reening period of up to 60 
days is allowed.
bThis sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This s ample will not be collected at that site if there is either a local law 
or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes. If the sample is collected, leftover extracted DNA will be stored for future 
biomedical research if the participant (or their legally acceptable re presentative) provides documented informed consent for future biomedical research. If the planned genetic analyses are not 
approved, but future biomedical research is approved and consent is given, this sample will be collected for the purpose of f uture bi omedical research.
cFollowing confirmation of eligibility at Screening, a repeat HIV -[ADDRESS_437637] will be performed to confirm HIV -1 RNA eligibility for randomization (HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL with a <0.5 
log 10decline from the Screening Visit [Visit 1]). I f there is ≥0.[ADDRESS_437638] is required (see footnote d below).
dThe Repeat HIV -1 Confirmation Visit is only for those participants with HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL at Visit 2 AND with a ≥0.5 log 10decline in HIV -1 RNA from the Screening Visit; these 
participants will be required to return to the site for a Repeat HIV -1 RNA Confirmation Visit (Visit 3). At Visit 3, in order to be eligible for randomization, participants must have HIV -1 RNA 
≥500 copi [INVESTIGATOR_014]/mL and a <0.[ADDRESS_437639]: MK-8591A  32
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
1.3.2 Schedule of Activities –Viremia Confirmation and End of Treatment
(All Participants E xcept Those W ith Specified D ecreases in CD4+ T -celland/or T otalLymphocyte Counts)
Study Period Viremia Confirmation End of Treatment Notes
Visit Number Unscheduled UnscheduledThe End of Treatment Follow -up visit 
should also be performed for participants 
who will not continue study intervention 
after Week 97.Scheduled Day/WeekViremia ConfirmationEarly Discontinuation of 
TreatmentEnd of Treatment
Follow -up
Visit Window Within ~1 month of 
HIV-1 Initial ViremiaNA42 (+7) days after the 
end of treatment
Administrative Procedures
Prior and Concomitant 
Medications ReviewX X X
Register Study Visit in IRT X X
Study Intervention Compliance 
Review X XReconcile doses and assess study 
intervention compliance .
ART/OBT compliance review X X
Completion of Participant 
Questionnaire (FAHI)XAdministered to participants ≥[ADDRESS_437640] results.
Efficacy Procedures
Plasma HIV -1 RNA 
Quantification (Real Time PCR)X X X
CD4+ T -cell Count /
TBNK PanelXParticipants with decreases in CD4+ 
T-cell count >10% from average 
baseline valueaor who meet relevant 
ECI criteria at the Early Discontinuation 
of Treatment visit should be managed 
per Section 8.11.[ADDRESS_437641]: MK-8591A  33
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study Period Viremia Confirmation End of Treatment Notes
Visit Number Unscheduled UnscheduledThe End of Treatment Follow -up visit 
should also be performed for participants 
who will not continue study intervention 
after Week 97.Scheduled Day/WeekViremia ConfirmationEarly Discontinuation of 
TreatmentEnd of Treatment
Follow -up
Visit Window Within ~1 month of 
HIV-1 Initial ViremiaNA42 (+7) days after the 
end of treatment
Blood (plasma) for HIV -1 Drug 
Resistance TestingX X XTesting performed on samples with HIV-
1 RNA ≥200 copi[INVESTIGATOR_014]/mL that were 
collected either to confirm viremia after 
suppression (VL <50 copi[INVESTIGATOR_014]/mL) or at 
discontinuation.
Whole Blood for Proviral DNA 
Resistance TestingX X XTesting performed on samples with HIV -
1 RNA ≥200 copi[INVESTIGATOR_014]/mL that were 
collected either to confirm viremia after 
suppression (VL <50 copi[INVESTIGATOR_014]/mL) or at 
discontinuation.
Blood (Plasma) for 
Investigational PKX X XAnalysis triggered by [CONTACT_180599].
Safety Procedures
Directed Physical Examination X X
Vital Signs X X Includes weight, pulse, bp, temp, and rr .
Confirmation of Menarche 
Status (Females Only)X X XNot required once menarche has been 
confirmed .
Contraception Use Confirmation 
(WOCBP Only)X X X To be done per local guidelines .
Urine Pregnancy Test (WOCBP 
Only)X XConfirm with serum test if positive. If 
serum test is positive, participants will 
be managed per Section 8.11. 7and 
safety of her infant collected per Section 
8.11. 7.4.1.
Chemistry X X
08BJ8V
PRODUCT: MK-8591A  34
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study Period Viremia Confirmation End of Treatment Notes
Visit Number Unscheduled UnscheduledThe End of Treatment Follow -up visit 
should also be performed for participants 
who will not continue study intervention 
after Week 97.Scheduled Day/WeekViremia ConfirmationEarly Discontinuation of 
TreatmentEnd of Treatment
Follow -up
Visit Window Within ~1 month of 
HIV-1 Initial ViremiaNA42 (+7) days after the 
end of treatment
Hematology XParticipants with decreases in total
lymphocyte counts >10% from average 
baseline valueaor who meet relevant 
ECI criteria at the Early Discontinuation 
of Treatment visit should be managed 
per Section 8.11.[ADDRESS_437642] another sample at Early 
Discontinuation visit.
ART=antiretroviral therapy; β-hcg=beta human chorionic gonadotropin; bp=blood pressure; DOR=doravirine; ECI=Events of Clinical Interest; 
FAHI= Functional Assessment of HIV Infection ;FBR=Future Biomedical Research; HIV=human immunodeficiency virus; HIV- 1=hu man immunodeficiency
virus Type 1; IRT=Interactive Response Technology; NA=not applicable; OBT=optimized background therapy; PCR=polymerase chain reaction; 
PK=pharmacokinetic; RNA=ribonucleic acid; rr=respi[INVESTIGATOR_697]; TBNK=T -and B -lymphocyte and natural killer cell profile; temp=body temperature; 
VL=viral load; WOCBP=a woman/women of childbearing potential.
a.The average baseline value is defined as the average value between screening (within 60days prior to the first dose of study intervention) and Day 1.
08BJ8V
PRODUCT: MK-8591A  35
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
1.3.3 Schedule of Activities for Participants Whose Pregnancy or Postpartum V isit(s)Extends Beyond Week [ADDRESS_437643] regularly 
scheduled stu dy visit (TW97) and consents to continue
DOR/ISL , the visit schedule will be extended through the 
duration of the pregnancy to allow assessments through 
each trimester and postpartum . Extension visits will only be 
performed through pregnancy & a single postpartum 
timepoint, as applicable for each participant .
Visit Window ±[ADDRESS_437644] and enter data from prenatal care provider <------------------------------- X----------------------------- >For female participants who become pregnant and consent 
to continue DOR/ISL, obtain relevant prenatal clinical & 
laboratory data to monitor the safety of the mother & fetus 
per Section 8.11. 7
Register Study Visit in IRT X X X X
Dispense DOR/ISL Using IRT X X X
Study intervention compliance review X X X X Reconcile doses and assess study intervention compliance .
OBT compliance review X X X X
Prior and Concomitant Medications Review X X X X
Evaluation to receive continued study intervention X X X XAt the end of pregnancy, continued access to DOR/ISL will 
be offered per Section 6.7.
Efficacy Procedures
Plasma HIV -1 RNA Quantification (Real Time 
PCR)X X X X
CD4+ T -cell Count/TBNK Panel X X X XDecreases in CD4+ T cell count that meet ECI criteria
should be managed per Section 8.11.6 and Section 1.3.4
Blood (p lasma )for HIV -1 drug resistance X X X XTesting performed via central laboratory at S creening and 
thereafter on samples for participants who never suppressed 
(HIV -1 RNA ≥200 copi[INVESTIGATOR_014]/mL )and those that were 
collected either to confirm viremia after suppression (VL
<50 copi[INVESTIGATOR_014]/mL) or at discontinuation.
Whole Blood for Proviral DNA Resistance Testing X X X XTesting performed via central laboratory on samples for 
participants who never suppressed (HIV -1 RNA ≥200 
copi[INVESTIGATOR_014]/mL )and those that were collected either to confirm 
viremia after sup pression (VL <50 copi[INVESTIGATOR_014]/mL) or at 
discontinuation.
Safety Procedures
Weight X X X X
Directed Physical Examination X X X X
08BJ8V
PRODUCT: MK-8591A  36
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437645] regularly 
scheduled stu dy visit (TW97) and consents to continue
DOR/ISL , the visit schedule will be extended through the 
duration of the pregnancy to allow assessments through 
each trimester and postpartum . Extension visits will only be 
performed through pregnancy & a single postpartum 
timepoint, as applicable for each participant .
Visit Window ±7 days
Vital Signs X X X X
Chemistry X X X X
Hematology X X X XDecreases in total lymphocyte count sthat meet ECI criteria 
should be managed per Section 8.11.6 and Section 1.3.4
Urinalysis X X X X
Review of Adverse Events X X X X
Pharmacokinetics
Blood (Plasma) for DOR and ISL PK X X X XCollected during the 1st, 2nd, & 3rdtrimesters & postpartum 
per Section 8.11. 7.1.
Biomarkers
Whole Blood for Future Biomedical Research X X X X Optional participation; requires FBR consent .
DNA=deoxyribonucleic acid; DOR=doravirine; ECI=Events of Clinical Interest; HIV=human immunodeficiency virus; IRT=Interactive Response Technology; ISL=islatravir; 
OBT=optimized background therapy; PCR=polymerase chain reaction; PK=pharmacokinetic; RNA=ribonucleic acid ; TBNK=T -and B -lymphocyte and natural killer cell 
profile; VL=viral load .
08BJ8V
PRODUCT: MK-8591A  37
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
1.3.4 Schedule of Activities –Participants With Specified Decreases in CD4+ T -cell Counts and/or Total Lymphocyte 
Counts
Study PeriodCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
ConfirmationEnd of TreatmentCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
MonitoringNotes
Visit Number Unscheduled Unscheduled Unscheduled
Scheduled Day/Week CD4+ T -cell and/or 
Total Lymphocyte 
ConfirmationEarly Discontinuation 
of TreatmentEnd of Treatment 
Follow -upCD4+ T -cell and/or 
Total Lymphocyte 
MonitoringSee Section s8.1.9 and 
8.11.6 for details 
regarding 
discontinuation and 
monitoring.Visit WindowWithin 3-4 weeks of 
initial decreaseNA42 (+ 7) days after 
discontinuing 
study interventionEvery 4 weeks ( 7 
days)
Administrative Procedures
Prior and Concomitant 
Medications ReviewX X X X
Register Study Visit in IRT X X X
Study Intervention
Compliance Review XReconcile doses and assess 
study intervention 
compliance.
ART/OBT Compliance
ReviewX
Completion of Participant
Questionnaire (FAHI)XAdministered to 
participants ≥[ADDRESS_437646] results.
Efficacy Procedures
Plasma HIV -1 RNA 
Quantification (Real Time 
PCR)X X
CD4+ T -cell Count /TBNK 
PanelX X X X
08BJ8V
PRODUCT: MK-8591A  38
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study PeriodCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
ConfirmationEnd of TreatmentCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
MonitoringNotes
Visit Number Unscheduled Unscheduled Unscheduled
Scheduled Day/Week CD4+ T -cell and/or 
Total Lymphocyte 
ConfirmationEarly Discontinuation 
of TreatmentEnd of Treatment 
Follow -upCD4+ T -cell and/or 
Total Lymphocyte 
MonitoringSee Section s8.1.9 and 
8.11.6 for details 
regarding 
discontinuation and 
monitoring.Visit WindowWithin 3-4 weeks of 
initial decreaseNA42 (+ 7) days after 
discontinuing 
study interventionEvery 4 weeks ( 7 
days)
Blood (p lasma) for HIV -1
Drug Resistance TestingX XAnalysis of samples 
collected at End of 
Treatment visits triggered 
by [CONTACT_180597].
Whole Blood for Proviral
DNA Resistance TestingX XTesting performed on 
samples with HIV -1 RNA 
≥200 copi[INVESTIGATOR_014]/mL that were 
collected either to confirm 
viremia after suppression 
(VL <50 copi[INVESTIGATOR_014]/mL) or at 
discontinuation.
Safety Procedures
Directed Physical 
Examination X X
Vital Signs X XIncludes weight, pulse, bp, 
temp, and rr.
Confirmation of Menarche 
Status (Females Only)X XNot required once 
menarche has been 
confirmed.
Contracepti ve Use 
Confirmation (WOCBP 
Only)X XTo be performed per local 
guidelines.
08BJ8V
PRODUCT: MK-8591A  39
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study PeriodCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
ConfirmationEnd of TreatmentCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
MonitoringNotes
Visit Number Unscheduled Unscheduled Unscheduled
Scheduled Day/Week CD4+ T -cell and/or 
Total Lymphocyte 
ConfirmationEarly Discontinuation 
of TreatmentEnd of Treatment 
Follow -upCD4+ T -cell and/or 
Total Lymphocyte 
MonitoringSee Section s8.1.9 and 
8.11.6 for details 
regarding 
discontinuation and 
monitoring.Visit WindowWithin 3-4 weeks of 
initial decreaseNA42 (+ 7) days after 
discontinuing 
study interventionEvery 4 weeks ( 7 
days)
Urine Pregnancy Test 
(WOCBP Only)X XConfirm with serum test if 
positive. If serum test is 
positive, participants will 
be managed per Section 
8.11.7 and safety of her 
infant collected per Section 
[IP_ADDRESS].1.
Chemistry X X
Hematology X X X X
Urinalysis X X
Review of Adverse Events X X X X
Pharmacokinetics
Blood (Plasma) for 
Investigational PKX XAnalysis triggered by 
[CONTACT_180597].
Biomarkers
Whole Blood for Future 
Biomedical ResearchX
ART=antiretroviral therapy; bp=blood pressure; FAHI=Functional Assessment of HIV Infection ; FBR= Future B iomedical Research; HIV=human 
immunodeficiency virus; IRT=Interactive Response Technology; NA=not applicable; OBT=optimized background therapy; PCR=polymerase chain reaction; 
PK=pharmacokinetic; RNA=ribonucleic acid; rr=respi[INVESTIGATOR_697]; TBNK=T -and B -lymphocyte and natural killer cell profile; temp=body temperature; 
WOCBP=a woman/women of childbearing potential.
08BJ8V
PRODUCT: MK-8591A  40
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
2 INTRODUCTION
DOR/ISL (also known as MK -8591A or MK- 8591 /DOR) is a novel 2 -drug FDC of DOR (a 
recently approved NNRTI) and ISL (a first -in-class investigational NRTTI) . DOR/ISL is 
being developed for QD treatment of HIV -1 infection in adult s and pediatric participants
35kg.
2.1 Study Rationale
Heavily treatment- experienced (HTE) individuals are a small but important population of 
patients with HIV-1. These individuals have exhausted all or nearly all antiretroviral options 
for constructing a viable HIV treatment regimen primarily because of extensive multidrug 
resistance but also because of drug intolerance ,lack of access to key drugs ,or 
unacceptability to the participant (eg,parenteral agents) . There is consequently an unmet 
medical need in this population for better treatment options. Preliminary data suggest ISL
may be useful in this population and the purpose of the P019 study is to evaluate the safety 
and efficacy of DOR/ISL in the HTE popula tion.
The HTE population in this clinical study isdefined by [CONTACT_179331]: 1) HI V 
heavily treatment -experienced, 2) failing their current antiretroviral regimen, 3) drug 
resistan ceto antiretrovirals belonging to at leas t 3 antiretroviral classes, 4) inability to 
construct a fully suppressive regimen with available AR Ts, and 5) having no more than 
2fully active antiretroviral agent sremaining to construct a viable regimen . 
DOR/ISL has the potential to be an agent for th e treatment of HIV -1 infection in the HTE 
population due to its potent antiretroviral activity (including activity against common NRTI -
and NNRTI -resistant variants) by [CONTACT_180601] , lack of food requirements, 
and favorable DDI profiles observed to date .
2.2 Background
Refer to the IB s/approved labeling for detailed b ackground information on DOR and ISL.
2.2.[ADDRESS_437647] member of a new class of antiretroviral agents, known as N RTTIs, thatblock 
HIV-1 reverse transcriptase by [CONTACT_180602]. Itis an inactive nucleoside 
analog that is converted to the pharmacologically active triphosphate (ISL -TP)form via 
endogenous intracellular kinases. It acts through multiple mec hanisms, including immediate 
chain termination by [CONTACT_180603] [Michailidis E 2014] .
ISLis differentiated from other HIV -1 antiretrovira ls by [CONTACT_180604], long intracellular 
half-life, and favorable drug resistance profile . ISL(at the proposed dose of 0.75 mgQD) 
achieves higher steady -state IQs(the ratio of drug exposure to viral susceptibility 
[Ctrough/IC 50]) against wild-type HIV -[ADDRESS_437648]: MK-8591A  41
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437649] both 
wild-type HI V-1 virus and frequently transmitted NNRTI -resistant variants including
K103N, Y181C, G190A , and E138K .
2.2.3 Doravirine /Islatravir
DOR/ISL is an FDC containing DOR (100 mg) and ISL (0.75 mg), administere d as a single
tablet QD. DOR and ISL represent [ADDRESS_437650] classes of antiretrovirals that inhibit reverse 
transcription by [CONTACT_129427]. Based on the profiles of each of these drugs and data 
available to date , the combination DOR/ISL is expected to be well tolerated and highly 
efficacious with a high barrier to resistance . The combination has demonstrated additive 
antiretro viral activity in vitro and has suppressed emergence of resistance at clinically
relevant concentrations.
The combination of DOR and ISL (administered as single entities, DOR+ISL) is being 
evaluated in an ongoing randomized Phase 2 study (MK -8591 Protocol 011) in 
approximately 90 treatment -naïve adult participants with HIV -1. Participants were initially 
assigned t o receive either DOR+ISL and 3TC or an FDC of DOR, 3TC, and TDF 
(DOR/3TC/TDF). Participants receiving DOR+ISL+3TC who achieved HIV- 1 RNA <50 
copi[INVESTIGATOR_014]/mL at Week 20 (or later) discontinued 3TC at their next study visit (most were able to 
discontinue 3TC at We ek 24) while continuing DOR+ISL. At Weeks 48and 96 , the 
percentage of participants with HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL among those who received the 
2-drug regimen of DOR+ISL was comparable to those who received the 3 -drug regimen of 
DOR/3TC/TDF. 
The majority of participants maintained virologic suppression through Week 
144. None of the participants with protocol -defined virologic failure rebounded above the 
clinically relevant HIV-1 RNA >200 copi[INVESTIGATOR_014]/mL cutoff. As such, no participant met the 
criteria for resistanc e testing. DOR+ISL, administered with 3TC or alone as a 2 -drug 
regimen, had a favorable safety and tolerability profile through Week 96, comparable to that 
of DOR/3TC/TDF. Mean changes from baseline in CD4+ T- cell count were comparable for 
DOR/3TC/TDF and each dose of ISL as a 3 -drug regimen (at Week 24) or a 2 -drug regimen 
(at Weeks 48, 96, 144).
In addition to this study, the clinical development program of DOR/ISL includes ongoing 
studies in treatment -naïve adults (Protocol 020), virologically suppressed adults (Protocol 
017 and Protocol 018), and participants <18 years of age and weighing 35 kg
(Protocol 028).
08BJ8V
PRODUCT: MK-8591A  42
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
2.2.4 Information on Other Study -related Therapy
ART continued at baseline andOBT will be administered at the approved marketed dose . 
Refer to local labeling for detailed information on baseline ART and OBT.
2.3 Benefit/Risk Assessment
Although i t cannot be guaranteed that participants in clinical studies will directly benefit 
from treatment during participation, as clinical studies are designed to provide information 
about the safety and effectiveness of an investigational medicine ,thetotality of available 
nonclinical and clinical data supports continued evaluation of DOR/ISL in Phase 3 clinical 
studies. 
The comprehensive nonclinical safety evaluations of DOR (an approved NNRTI) and ISL 
(an investigational NRTTI) as mono -entities have not revealed toxicities of concern for daily 
dosing. Nonclinical developmental and reproductive toxicity studies did not identify any 
clinically relevant concerns that would preclude continued dosing of DOR/ISL in participants 
who become pregnant during t he study. Both mono- entities are differentiated by a high 
barrier to resistance in vitro with DOR exhibiting potent activity against the most prevalent 
NNRTI -resistant mutations (eg, K103N, Y181C, G190A, and E138K) and ISL against 
common NRTI -resistant mut ations (eg ,M184V and TAMs). Both may be administered 
without regard to food, have a low potential for DDIs, and have favorable PK and tolerability 
profiles.
High potency against wild- type and resistant variants of HIV -1 virus and a long half -life 
make ISL a suitable candidate for development for the treatment of HIV -1 infection. Across 
the clinical development program, ISLadministered alone or with DOR was generally well -
tolerated. In the dose -ranging study ( MK-8591 P rotocol 011), ISL+DOR+3TC (as a 3-drug 
regimen) achieved virological suppression in most (>90%) of treatment -naïve participants by 
[CONTACT_10585] 24. ISL+DOR (as a 2 -drug regimen) maintained virologic suppression of HIV -1 RNA 
24 and 48 weeks after switching from the 3 -drug regimen and through Week 144. In 2
ongoing Phase 3 studies evaluating DOR/ISL for daily treatment of HIV -1 in virologically 
suppressed participants ( MK-8591A Protocol 017 and MK-8591A P rotocol 018),
approximately 95% of 658 participants enrolled in the DOR/ISL arm completed the 4 8weeks
of treatment in both studies . In Protocol 017 and P rotocol 018, t he percentage of participants 
with HIV- 1 RNA ≥50 copi[INVESTIGATOR_014]/mL was <1% for the DOR/ISL group, and a high percentage of 
participants ( >93%to 95% )in the DOR/ISL group maintained virologic suppression (HIV -1 
RNA <50 copi[INVESTIGATOR_014]/mL) comparable to baseline ART (Protocol 017) and BIC/FTC/TAF
(Protocol 018) , respectively, at Week 48. To date, no viral resistance to either component of 
DOR/ISL has been shown i n the Phase 2 (P rotocol 011) and Phase 3 studies (Protocol 017 
and P rotocol 018). At the doses administered for daily treatment, DOR/ISL has been well -
tolerated and associated with low rates of drug -related AEs.
Downward trends of total lymphocytes counts and CD4+ T -cell counts were observed in 
studies with ISL alone or in combination with other antiviral agents. In a Phase 2 study 
(MK- 8591 Protocol 013) for once weekly HIV -1 treatment, decreases in total lymphocyte 
and CD4+ T -cell counts from baseline were observed in the ISL 20 mg + MK -[ADDRESS_437651]: MK-8591A  43
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
arms at Week 12 and Week 24 .Decreases from baseline in total lymphocyte count swere 
observed in all dosing arms of ISL+MK -8507 starting at Week 8 with further decreases 
continuing through Week 24. Twenty of 58participants on ISL+MK -8507 ha d a decrease in 
total lymphocyte count sof >30% (of wh om9 had a >50% reduction) by [CONTACT_10585] 24. These 
reductions were more pronounced in the 2 higher MK -8507 dose arms (200 and 400 mg), 
potentially indicating a dose -response relationship. Dosing of ISL+MK -8507 in P rotocol 013 
has been discontinued.
In the Phase 2 randomized, double -blind, placebo- controlled study evaluating 60 mg and 
120mg of ISL monthly for PrEP in participants at low -risk of HIV -1 infection (MK -8591
Protocol 016), there was a 21% mean decre ase in total lymphocytes observed in the 60 mg 
arm (the dose being evaluated in Phase 3 PrEP studies )and a 36% decrease in total 
lymphocytes observed in the 120 mg arm. In this population of HIV -1 uninfected 
participants, mean decreases were in the normal range and there was no increase in clinical 
AEs related to infection. Dosing of oral ISL  60 mg QM has been discontinued  in PrEP  
clinical studies.
In an interim analysis for each of the Phase 3 studies studying DOR/ISL 100 mg/0.75 mg for 
HIV-1 treatment (Protocol 017 and P rotocol 018) , there were mean decreases from baseline 
in total lymphocyte counts at Week 48 of 10.6% and 8.5% , respectively, in the DOR/ISL 
groups compared with mean increases of 2.27% and 3.46% in the comparator arms. In the 
same studies, DOR/ISL -treated participants hada mean change in CD4+ T -cell counts 
of -0.7% and +0.9% , compared with an increase of 8.7% in the baseline ART group 
(Protocol 017) and 12.8% in the BIC/FTC/TAF group (Protocol 018) . These decreases in 
CD4+ T- cell a nd total lymphocyte counts have not been associated with an increase d
incidence of infection or other AEs. The clinical impact of these laboratory changes over the 
long term is unknown , and the S ponsor is assessing the reversibility of the reductions in 
CD4+ T-cell and total lymphocyte counts. To mitigate the risk, increased monitoring of 
CD4+ T- cell and total lymphocyte count sand strict stoppi[INVESTIGATOR_351885]/ISL studies. At this time , the data review support continuation of the Phase 3 clinical 
studies for the DOR/ISL 100 mg/0.[ADDRESS_437652] to this 
Phase 3 study in the HTE population, review of the available data and benefit/risk assessment 
support c ontinuing DOR/ISL 100 mg/0.[ADDRESS_437653] exhausted all or nearly all antiretroviral 
options for constructing a viable HIV treatment regimen.
Additional details regardi ng specific benefits and risks for participants in this clinical study 
may be found in the accompanying IBs and informed consent /assent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table. 
The following objectives will be evaluated in HTE adult participants and in pediatric 
participants weighing ≥35 kg with pre -study HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL and currently on 
failing ART. 
08BJ8V
PRODUCT: MK-8591A  44
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Objectives Endpoints
Primary
To evaluate the antiretroviral activity of DOR/ISL
compared to placebo, each given in combination 
with failing ART as assessed by [CONTACT_351907] ≥0.5 log 10decrease in 
HIV-1 RNA from study baseline (Day 1) to Day 8
(Part 1).
Hypot hesis: The percentage of participants 
receiving DOR/ISL and achieving ≥0.5 log 10
decrease in HIV -1 RNA from study baseline 
(Day 1) to Day 8is superior to placebo, each 
given in combination with failing ART.HIV-1 RNA
To evaluate the safety and tolerability of 
DOR/ISL as assessed by [CONTACT_181773] 25 and 
Week 49 .AEs
AEs leading to discontinuation
of study intervention
Secondary
To evaluate the safety and tolerability of 
DOR/ISL as assessed by [CONTACT_181773] 97.AEs
AEs leading to discontinuation 
of study intervention
To evaluate the antiretroviral activity of ISLand 
DOR, each compared to placebo, when each is 
given in combination with failing ART ,as 
assessed by [CONTACT_351903] ≥0.5 log 10decrease in HIV -1 RNA from 
study baseline (Day 1) to Day 8 (Part 1) .HIV-1 RNA
To further evaluate the antiretroviral activity of 
DOR/ISL, ISL, and DOR each compared to 
placebo, when each is given in combination with 
failing ART (Part 1) as assessed by:
-mean change in HIV -1 RNA from study 
baseline (Day 1) to Day 8
-percentage of participants achieving ≥1.0 log 10
decrease in HIV -1 RNA from study baseline 
(Day 1) to Day 8HIV-[ADDRESS_437654]: MK-8591A  45
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Objectives Endpoints
To further evaluate the antiretroviral activity of 
DOR/ISL compared to ISL and DOR, when each 
is given in combination with failing ART (Part 1) 
as assessed by:
-percentage of participants achieving ≥0.5 
log10decrease in HIV -1 RNA from study 
baseline (Day 1) to Day 8
-mean change in HIV -1 RNA from study 
baseline (Day 1) to Day 8
-percentage of participants achieving ≥1.0 log 10
decrease in HIV -1 RNA from study baseline 
(Day 1) to Day 8HIV-1 RNA
To evaluate the antiretroviral activity of DOR/ISL
+ OBT in Part 2 as assessed by [CONTACT_351908] 25, Week 49, and Week 97compared to 
study baseline (Day 1) and Part 2 baseline (Day 
8):
-percentage of participants achieving ≥0.5 
log10decrease in HIV -1 RNA
-percentage of participants achieving ≥1.0 
log10decrease in HIV -1 RNA
-mean change in HIV- 1 RNA
-percentage of participants achieving HIV-1 
RNA < 200 copi[INVESTIGATOR_014]/mL
-percentage of participants achieving HIV-1 
RNA <50 copi[INVESTIGATOR_014]/mL
-percentage of participants achieving HIV-1 
RNA <40 copi[INVESTIGATOR_014]/mLHIV-1 RNA
To evaluate the development of viral drug 
resistance to DOR, ISL, or components of OBT 
through the study duration (Part 1 and Part 2).Viral resistance -associated 
substitutions
To evaluate the impact of study baseline (Day 1)
antiviral resistance on virologic outcome at 
Week 25,Week 4 9, and Week 97 (Part 2) .Viral resistance -associated 
substitutions
HIV-[ADDRESS_437655]: MK-8591A  46
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Objectives Endpoints
To evaluate t hechange in CD4+ T -cell counts
from both study baseline (Day 1) and Part 2 
baseline (Day 8 ) at Week 25 ,Week 49 , and 
Week 97(Part 2).CD4+ T- cell count
Tertiary/Exploratory
To evaluate the impact of study baseline (Day 1) 
resistance on primary efficacy (Day 8) (Part 1) :
-NRTI resistance on ISLantiviral activity
-NNRTI resistance on DOR antiviral activityViral resistance -associated 
substitutions
HIV-1 RNA
To evaluate the impact of DOR/ISL + OBT on 
inflammation as measured by [CONTACT_351909] (Day 1) to Week 25 , 
Week 49,and Week 97 (Part 2) in laboratory 
markers .Inflammatory markers
To describe PRO srelated to HIV disease -specific 
QoL assessed at study baseline (Day 1), Week 25, 
Week 49 , and Week 97 (Part 2) for participants 
≥18 years of age who received DOR/ISL + OBT.FAHI questionnaire: Total 
score and individual subscale 
scores
To evaluate the PK of ISL and DOR, when each is 
given in combination with failing ART (Part 1).PK values, such as AUC, 
Cmax, and C24
To evaluate the PK of ISL and DOR, when given 
in combination with OBT (Part 2).PK values, such as AUC, 
Cmax, and C24
To explore the relationship between genetic 
variation and response to the treatment(s) 
administere d, and mechanisms of disease. 
Variation across the human genome may be 
analyzed for association with clinical data 
collected in this study.Germline genetic variation
The success of the study is determined by [CONTACT_351910]/ISL is superior to placebo .
08BJ8V
PRODUCT: MK-8591A  47
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
4 STUDY DESIGN
4.1 Overall Design
This is a P hase 3, randomized, multi- site study in HTE participants infected with HIV -1 
currently on failing ART for HIV -1 infection. Following S creening, eligible participants will 
enter a Run-in Period on current failing baseline ART prior to randomization. Part 1 isa 
7-day double -blind period of QD therapy, where the investigational agent ( ISL0.75 mg,
DOR 100 mg, or DOR/ISL [100 mg/ 0.75 mg] ) or placebo 
is added to the participant’s 
current failing ART . In Part 2, all participants receive open-label DOR/ISL
(100mg/0.75 mg) added to OBT through Week 97. The study schema is shown in Figure 1.
Run-in Period : The Run-in Period will start immediately after Screening and end at 
randomization. During this time, participants will continue their failing ART regimen. 
Following confirmati on of eligibility at the S creening Visit (Visit 1) ( test results anticipated 
to take approximately 30 to 45 days) , a repeat measurement for HIV-1RNA will be 
performed at Visit 2 to confirm HIV- 1 RNA eligibility for randomization (HIV-1 RNA
≥500copi[INVESTIGATOR_014]/mL with a < 0.5 log 10decline in HIV -1 RNA from Visit 1). Participants with 
HIV-1 RNA ≥ 500copi[INVESTIGATOR_014]/mL and a ≥0.[ADDRESS_437656] 
return to the site 7to 14days after Visit 2 for a Repeat HIV -1 RNA confirmation visit 
(Visit 3). In order to be eligible for randomization, participants must have HIV -1 RNA 
≥500copi[INVESTIGATOR_014]/mL and a < 0.3log 10decline in HIV- 1 RNA from the previous result at Visit 2
(Figure 2).Randomization of eligible participants must occur within 10 days of Visit 2 (or 
Visit 3, if required) .
Participants must have 2 HIV-1RNA measurements ≥500 copi[INVESTIGATOR_014]/mL to participate in this 
study: The first measurement at theScreening V isit and the second measurement taken no 
sooner than [ADDRESS_437657] measurement , but ≤10 days prior to randomization.
Double -blind Period, Part 1(Day 1 to Day 7) : Participants will be randomized in a 1:2: 1:1 
ratio into 1 of 4 treatment groups (Figure 1).The overall goal for this study is to r andomize 
150 participants; however, a minimum sample size of 100 randomized participants is the 
target for the planned analyses ( 40 participants randomized intothe DOR treatment group 
and 20 participants randomized into each of the other treatment groups) :
Group 1 (n ~ 20): ISLQD+ failing baseline ART
Group 2 (n ~ 40): DOR QD + failing baseline ART
Group 3 (n ~ 20): DOR/ISL QD + failing baseline ART
Group 4 (n ~20): Placebo QD + failing baseline ART
Randomization will be stratified by [CONTACT_351911], the existence of M184V 
or I substitutions at baseline (see Section 6.3.2) .
Baseline ART will not be provided by [CONTACT_1034].
08BJ8V
PRODUCT: MK-8591A  48
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Open -label Period, Part 2(Day 8 to Week 97): Following the 7 -day double -blind treatment 
period, all participants will be treated with DOR/ISL and OBT from Day 8 through Week 97
(with the opportunity to continue DOR/ISL after Week 97; Section 6.7) . OBT options will be 
driven by [CONTACT_351912] , drug access ,
and acceptability t o the participant. In cases where the failing regimen cannot be optimized, 
participants will continue their failing regimen plus DOR/ISL. OBT will consist of approved 
and licensed ARTs and will not be provi ded by [CONTACT_1034].
Participants with confirmed vir emia (defined as having 2 consecutive confirmed HIV -1 RNA 
≥200 copi[INVESTIGATOR_014]/mL [at least 4 weeks apart ]after achieving HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL) or who 
discontinue d study intervention with HIV-1 RNA ≥200 copi[INVESTIGATOR_014]/mL , or who never suppressed 
(<50 copi[INVESTIGATOR_014]/mL) at Week 25 ,Week 49 , and Week 97 with HIV- 1 RNA > 200copi[INVESTIGATOR_014]/mL, will 
be assessed for development of viral drug resistance.
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
The study design is based on the schema suggested in the regulatory guidance document
[Food and Drug Administration (CDER) 2015] for a study population with multidrug 
resistant HIV -1 infection failing their current ART , when the study intervention is expected 
to offe r anti retroviral activity .The P019 study design is a modification of the above schema 
that reflects the use of a combination agent ( DOR/ISL ) rather than a single new study 
intervention.
After the Screening Visit, there is a Run-in Period before randomizat ion occurs. After at least 
7days during this period, repeat HIV- 1 RNA testing is performed to exclude responders due 
to possible improved adherence to their ongoing “failing” ART after enrolling in theclinical 
study. The efficacy analysis (Part 1) will occur after 7 days of functional monotherapy or 
FDC DOR/ISL and will compare ISL, DOR , or FDC DOR/ISL added to failing baseline 
ART to placebo. The DOR arm is over -weighted 2:[ADDRESS_437658] and the clinical relevance of NNRTI mutations on DOR 
activity.
The primary sa fety evaluation and virologic follow -up will occur after 24 weeks of study 
intervention (24weeks of open -label DOR/ISL with an optimized background regimen )to 
allow for an adequate assessment of safety and alonger observation period for virologic 
rebound or durability.
08BJ8V
PRODUCT: MK-8591A  49
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
[IP_ADDRESS].1 HIV -1 RNA Measurements
The primary efficacy endpoint in this study is the percentage of participants achieving 
≥0.5 log 10decrease in HIV -1 RNA from study baseline (Day 1) to Day 8 , a well -established 
endpoint for evaluation of efficacy in the HTE population and aligned with regulatory
guidance [Food and Drug Administration (CDER) 2015] . The antiretroviral activity of ISL
and DOR will be further evaluated through the secondary efficacy endpoints, the percentage 
of participants achieving ≥1.0 log 10decrease and the mean change in HIV -1 RNA from study 
baseline (Day 1) to Day 8.
Similar assessments of the antiretroviral activity of DOR/ISL + OBT at Week 2 5,Week 49, 
and Week 97 will be performed, along with evaluation of the percentage of participants 
achieving HIV -1 RNA < 200 copi[INVESTIGATOR_014]/mL, < 50 copi[INVESTIGATOR_014]/mL , and < 40 copi[INVESTIGATOR_014]/mL .
Clinical studies of antiretroviral agents in multiple drug classes have demonstrated that 
virologic suppression of HIV -1 RNA to <50 copi[INVESTIGATOR_014]/mL reflects a clinically relevant standard 
used across development programs for antiretroviral therapi[INVESTIGATOR_351886] 
[Vandenhende, M. A., et al 2015] .Suppressing HIV- 1 RNA to <50 copi[INVESTIGATOR_014]/mL preserves the 
immune system and minimizes the risk of opportunistic infections and disease progression.
In individuals with no remaining suppressive ART options, decreases in HIV- 1 RNA, even if 
detectable at >50 copi[INVESTIGATOR_014]/mL, have been correlated with improved mortality and outcomes.
An HIV- 1 RNA level of <2 00 copi[INVESTIGATOR_014]/mL allows for patient monitoring to reduce the risk of 
developi[INVESTIGATOR_351887] a timely manner. 
It also accounts for isolated detectable HIV -1 RNA after virologic suppression followed by a 
return to virologic suppression (ie, ‘virologic blip’) that may not be clinically meaningful.
[IP_ADDRESS] Patient -reported Outcomes
PRO scan provide unique information on the impact of HIV disease and its treatment from 
the patients’ perspective as some domains are difficult to observe or are subjective and best 
collected through patient report. HTE patients have limited treatment options including 
complex regimens that are associated with adverse effects and consequently impair ed
HRQ oL. PRO data may help clinicians and patients in making informed decision on 
appropriate c ombination ART. PROs, including HRQ oLdata, have been increasingly 
considered in drug benefit assessment and reimbursement decision -making by [CONTACT_351913]. HTA agencies in many countries recommend patient perspectives data and QoL
measurement as part of their drug benefit evaluations.
The study will include the Functional Assessment of Human Immunodeficiency Virus 
Infection ( FAHI )for participants ≥[ADDRESS_437659]: MK-8591A  50
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
treatment -related symptoms on physical, emotional, functional, social , and global well-being 
as well as cognitive functioning.
[IP_ADDRESS] Safety Endpoints
Safety evaluations will include physical examinations (including vital signs) and laboratory 
tests ( eg, hemat ology, chemistry, fasting lipid/glucose, and urinalysis) performed per the SoA 
(Section 1.3) . AEs will be evaluated at each visit and assessed according to the guidelines in 
Section 8.4 and Appendix 3. Participants may be asked to return for unscheduled visits to 
perform additional safety monitoring.
[IP_ADDRESS] Laboratory Markers
The study will assess changes in inflammation after treatment with DOR/ISL + OBT. Causes 
of persistent inflammation and thrombotic activity in patients with HIV -1 remain topi[INVESTIGATOR_351888] [Baker, J. V., et al 2011] [Knudsen, T. B., et al 2016] [Wang, 
H., et al 2016] . The following laboratory markers will be measured: 
IL-6
D-dimer
sCD-163
hs-CRP
[IP_ADDRESS] Pharmacok inetic Endpoints
PKsamples collected from all participants as described in the SoA and Section 8.6 .1will be 
used to evaluate PK concentrations of ISLand DOR in Part 1andPart 2 , and as appropriate, 
PK-efficacy, PK -pharmacodynamic, and PK -AE relationships of DOR/ISL . PK values such 
as AUC, Cmax, and C 24will be explored.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_437660] a participant’s r esponse to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and IRB/IEC allow, a sample will be collected for DNA analysis 
from consenting participants.
DNA samples may be used for research related to the study intervent ion(s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of [ADDRESS_437661]: MK-8591A  51
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
markers throughout the genome, or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to understand study disease or related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical research on specimens for which consent was 
provided during th is study. This research may include genetic analyses (DNA), gene 
expression profiling (RNA), proteomics, metabolomics (serum, plasma), and/or the 
measurement of other analytes, depending on which specimens are consented for future 
biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study) and will only be conducted on specimens from 
appropriately consented participants. The objective of collecting/retaining sp ecimens for 
future biomedical research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of future biomedical research are presented in Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
In alignment with regulatory guidance [Food and Drug Administration (CDER) 2015] , Part 1
of this study consists of a brief period (7 days) of functional monotherapy (ie, each 
component of DOR/ISL) , and the FDC DOR/ISL, orplacebo added to the participant ’s 
current failing ART .Given a non-inferiority comparison is not feasible in this population, to 
evaluate the efficacy of each component of DOR/ISL , the antiretroviral activity of ISL and 
DOR at Day 8 are ea chcompared to placebo. The functional monotherapy period is limited 
to 7 days to minimize the risk for development of resistance t o ISLor DOR or additional 
resistance to the baseline ART.
The uncontrolled (open- label) study design beyond the primary [ADDRESS_437662] loss of certainty interpreting study results isoutweighed by [CONTACT_351914].
4.2.3 Rationale for the Selected Participant Population
The rationale for the participant population selected for this study is as follows:
HTE Participants: There is an unmet medical need for new treatments in patients with 
documented baseline resistance to multiple drug classes, who are experiencing an 
ongoing inability to suppress viral replication on their current regimen and have few if 
any remaining options to construct a fully suppressive regimen . 
08BJ8V
PRODUCT: MK-8591A  52
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437663] pharmacologic distribution and a long intracellular half -life, ISLhas a 
high IQ(Ctrough/I C50)and the potential to be active against common NRTI -resistant 
variants (eg, M184I/V, K65R, L74V, Q151M, 69ins). DOR is a potent NNRTI that 
retains in vitro activity against HIV -[ADDRESS_437664] common NNRTI 
resistance mutations (eg, K103N, G190A, Y181C, and E138 A/K) . Therefore, the FDC of 
ISLand DOR has the desired properties to meet a critical unmet medical need in this 
population.
Enrollment of Pediatric Participants: The nonclinical data for DOR/ISL, and its 
individual components ( ISLand DOR), and clinical studies of DOR + ISLconducted to 
date in adults with and without HIV-[ADDRESS_437665] not demonstrated significant safety 
concerns that would preclude evaluation in pediatric participants <18years of age). 
Pediatric participants (weighing ≥35kg) are predicted to have similar plasma ISLand 
intracellular ISL-TP concentrations to the adults studied in Phase 2 and no dose 
adjustment is necessary in this age group. The use of a weight limit for pediatric
participants is in alignment with WHO pediatric HIV guidance [World Health 
Organization 2007] to administer antiretrovirals using a weight -band dosing approach .
4.2.[ADDRESS_437666] based on these parameters and to gain assurance the results
observed in the clinical study will be representative of the drug’s use in a broader patient 
population. As one examp le, non- Caucasian females and males were found to have higher 
plasma concentrations of EFV (an NNRTI) than their Caucasian counterparts , indicating an 
increased risk of EFV -induced toxicity in non-Caucasian patients [Burger, D., et al 2005] . As 
another example, among the population with HIV in the [LOCATION_002], those of African 
heritage have been found to be less likely to maintain virologic suppression compared to 
other groups and the factors contributing to this remain to be elucidated [Weintrob, A. C., et 
al 2009] [Ribaudo, H. J., et al 2013] . Thus, subgroup analyses on race and ethnicity will be 
performed to better understand how these parameters may influence clinical outcome and 
toxicity.
4.2.5 Rationale for Collecting Gender Identity Data
Transgender people, defined as those whose gender identities and/or expressions differ from 
the sex assigned to them at birth, have a hi gh prevalence and incidence of HIV infection 
globally [Poteat, T., et al 2016] . Specifically, transgender women have an increased risk of 
HIV infection attributed to challenges associated with copi[INVESTIGATOR_351889], stigmatization ,and marginalization [Centers for Disease Control and 
Prevention 2019] [Department of HIV/AIDS 2015] . When considering HIV treatment, the 
WHO considers transgender people to be a separate key population because of their specific 
08BJ8V
PRODUCT: MK-8591A  53
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
health needs and high vulnerability [Department of HIV/AIDS 2015] . Data will be collected 
in this study to assess clinical outcomes i n the transgender population.
4.2.6 Rationale for Infant Safety Data Collection
Follow -up through 1 -year of age for infants born to participants who become pregnant while 
receiving study intervention provides the ability to monitor growth and development as well
as potential adverse effects that may be associated with prenatal drug exposure. Growth 
parameters (ie, length, weight, and head circumference) within normal range at 
approximately 1- year of age are key noninvasive indicators that a serious congenital 
malformation caused by [CONTACT_140214].
4.2.7 Rationale for Continuing Study Intervention During Pregnancy
The US Department of Health and Human Services guidelines currently advise that women 
who become pregnant while receiving ART for HIV shoul d continue their regimen provided 
it is safe, well tolerated, and effective at virologic suppression since altering the regimen 
could cause an increase in viral load [Panel on Treatment of Pregnant Women with HIV 
Infection and Prev 2018] . Nonclinical developmental and reproductive toxicology studies did 
not identify any teratogenicity or other clinically relevant concerns that would preclude 
continued dosing of DOR/ISL in participants who become pregnant and consent to continue 
study intervention (where allowed by [CONTACT_427] , health authorities, and ethics 
committees and as appropriate based on available data/local standard -of-care guidelines)
(Sections [IP_ADDRESS] and 8.11. 7).
There are no clinical data currently available to support breastfeeding by [CONTACT_180617]/ISL.
4.3 Justification for Dose
IQ (C trough/I C50) is the ratio of drug exposure to viral susceptibility. In a Phase 1b proof of 
concept study (MK -8591 Protocol 003), single doses as low as 0.[ADDRESS_437667] 
antiretro viral activity at 7 days postdose ; this low single dose provided an IQ threshold of [ADDRESS_437668] the ISL-TP concentrations achieved at the 
end of Day 1 after a single dose of 0.75 mg provide IQs of 21 and 4 for wild -type and 
M184V virus, respectively. After 7 daily doses of 0.75 mg ISL, IQs increase to 113 for wild-
type virus and 23 for M184V/I virus. Antiretro viral activity against the exceedingly rare 
69ins + M184I/V mutant virus (the NRTI mutant with the highest potency reduction for ISL) 
is expected to be achieved after 7 QD doses, with an IQ of 5. Steady -state concentrations at 
later timepoints will produce even higher IQs , as there is additional accumulation of ISL-TP. 
These simulations support the selection of 0.75 mg ISLas the dose to be studied as 
monotherapy (in Part 1) and in combination with 100 mg DOR in Part 1 and Part 2.
In the Phase 2 clinical study (MK -8591 Protocol 011), 3 daily doses of ISL(0.25, 0.75, and 
2.25 mg) were evaluated in combination with DOR (100 mg) + 3TC for 24 weeks and 
subsequently with DOR alone
through Week 48. All 3 doses of ISLwith DOR+3TC 
demonstrated potent antiretroviral activity comparable with the 3- drug comparator 
08BJ8V
PRODUCT: MK-8591A  54
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
DOR/3TC/TDF ,as demonstrated by [CONTACT_22946], the proportion of 
participants with HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL, at both Week 24 and Week 48. Overall, no 
ISLdose-response for efficacy was observed. Graphical analysis of steady -state ISL-TP 
trough concentrations and viral load at Week 48 from Protocol 011 showed no trends in 
exposure- response. The totality of these efficacy data supports the conclusion that the dose
range studied (0.25 to 2.25 mg daily) is on the plateau of the dose -response curve. 
Protocol 011 also demonstrated that all doses of ISLstudied, when administered with 
DOR +3TC or DOR alone , hada favorable safety and tolerability profile through Week 48 ,
compar able with that of DOR/3TC/TDF. In addition, a 0.75 mg QD dose of ISLin 
combination with 100 mg QD DOR is predicted to provide concentrations sufficient to cover 
mutant virus strains anticipated in a nHTE patient population .
Pediatric participants (weighing ≥35kg) are predicted to have similar plasma ISLand 
intracellular ISL-TP concentrations to the adults studied in Protocol 011, and no dose 
adjustment is necessary in this age group (Section 4.2.3).
DOR will be administered at the approved dose of 100 mg. This dose has been studied in 
Phase 1 to 3 clinical studies in treatment -naïveand virologically suppressed participants with 
HIV-1 and was selected based on favorable efficacy, safety, tolerability, and metabolic 
profiles as confirmed in the Phase 3 clinical studies [Orkin, C., et al 2018] [Molina, J. M., et 
al 2018] and MK -1439A Protocol 024. Of note, among 32 participants in MK -1439A 
Protocols 024 and 030 infected with HIV -1 harboring the NNRTI resistance mutations
K103N, Y181C, and/or G190A at study entry, all achieved virologic suppression following 
48 weeks of treatment with DOR/3TC/TDF (24 of these 32 participants had been 
virologically suppressed on PI [INVESTIGATOR_180566] 8 had been TN). DOR is also expected 
to have antiviral activity against other prevalent NNRTI -associated reverse transcriptase
substitutions including L100I, E138K, H221Y, and P225H when dosed at 100 mg daily.
The DOR dose selection for adolescents was based on a physiologically based PK model that 
indicated that the 100 mg DOR tablet once daily can be safely and effectively administered 
in the adolescent population ranging from 12 to 18 years of age, and this dose is currently 
being studied in MK-1439 Protocol 0 27.
Therefore, 100 mg DOR has been selected to be studied in monotherapy (in Part 1) and in 
combination with 0.[ADDRESS_437669] p articipant (or their legally acceptable representative) 
provides documented informed consent/assent .The overall study ends when the last 
participant completes the last study- related contact , withdraws from the study, or is lost to 
follow -up (ie, the parti cipant is unable to be contact[CONTACT_19379]) .
08BJ8V
PRODUCT: MK-8591A  55
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the stud y or at (a) particular 
study site(s) may be stopped due to insufficient compliance with the protocol, Good Clinical 
Practice (GCP), and/or other applicable regulatory requirements, procedure -related problems 
or the number of discontinuations for administrative reasons is too high.
Blinded data for p articipants who fail to achieve ≥0.5 log 10decline in HIV- 1 RNA at the end 
of Part 1will be communicated to an external unblinded statistician on an ongoing basis to 
perform the futility assessment . Ifthe futility boundar y is met, early study termination may 
be considered (Section 9. 7).
5 STUDY POPULATION
HTE adult participants and pediatric participants weighing ≥35 kgwith HIV-1 who are 
currently on failing ART will be enrolled in this study.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant:
Type of Par ticipant and Disease Characteristics
1.Is HIV- 1 positive with plasma HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL at the S creening Visit and 
confirmed upon repeat testing (Visit 2 [or Visit 3 if required] ) during the R un-inPeriod.
In addition, the log change in HIV -[ADDRESS_437670] meet 1 of the following criteria at a 
confirmation visit:
-<0.5 log 10decline in HIV -1 RNA from the Screening Visit (Visit 1) to the 
Confirmation visit ( Visit 2)
OR
-If ≥0.[ADDRESS_437671] is required 
(Visit 3). In this case, there must be < 0.3 log 10decline in HIV- 1 RNA f rom Visit 2
Note: HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL must be confirmed within 10 days prior to 
randomization.
Note: Repeat HIV- 1 RNA Confirmation Visit (Visit 3) to occur 7to [ADDRESS_437672]: MK-8591A  56
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
2.Has been receiving the same baseline ART for ≥3 months prior to signing the Informed 
Consent Form /Assent Form .
3.Has at least triple -class resistance ( must include NRTI, NNRTI, and resistance to either 
PI [INVESTIGATOR_1660] I nSTI)based on anyof the following: (a) central laboratory based resistance testing 
at the Screening Visit ,(b) central laboratory based proviral DNA resistance testing at the 
Screening V isit, or (c) historical resistance testing within [ADDRESS_437673] 2 antiretroviral agent sin a particular class denotes class resistance .
Note: For purposes of determining NRTI class resistance , resistance to FTC 
(emtricitabine) and 3TC ( lamivudine) ,resistance associated with MI84V/I substitution 
must include 1additional NRTI resistance substitution .
4.Has ≤2fully active antiretroviral drugs remaining, among all antiretroviral classes ,that 
can be effectively combined to form a viable regimen based on resistance, tolerability, 
safety, drug access, or acceptability to participant.
Demographics
5.Ismale or female , adult (≥18 years of age) or pediatric participants (weigh ing≥35kgand 
<18 years of age), at the time of signing the informed consent /assent (the Screening 
Visit).
Contraception/Pregnancy
A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:
-Is nota woman of childbearing potential ( WOCBP) .
OR
-Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long 
term and persistent basis), as described in Appendix [ADDRESS_437674] 6 weeks, corresponding to the time needed to eliminate any study 
intervention(s) (eg, 5 terminal half -lives) after the last dose of study intervention. The 
investigator should evaluate the potential for contraceptive method failure (ie , 
noncompliance, recently initiated) in relationship to the first dose of study 
intervention.
-A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as 
required by [CONTACT_427]) within 24hours before the first dose of study 
intervention.
If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive .
08BJ8V
PRODUCT: MK-8591A  57
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
-Additional requirements for pregnancy testing during and after study intervention are 
located in Appendix 2.
-The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
Informed Consent /Assent
6.The participant (or legally acceptable representative ) has provided documented informed 
consent/assent for the study. The participant may also provide consent/assent for future 
biomedical research. However, the participant may participate in the main study without 
participating in future biomedical research.
5.[ADDRESS_437675] be excluded from the study if the participant:
Medical Conditions
1.Has HIV -2 infection.
2.Has hypersensiti vity or other contraindication to any of the components of the study 
interventions as determined by [CONTACT_093].
3.Has HBV co-infection (defined as HBsAg -positive or HBV DNA positive) and is not 
currently being treated for HBV .
Note: Participants coinfe cted with HBV who are currently taking oral antiviral treatment 
for hepatitis B (eg, tenofovir, entecavir, telbivudine, adefovir, lamivudine, etc .)are
eligible for enroll ment and should remain on the same treatment for their HBV 
throughout the study.
Note: Chronic HCV infection (detectable HCV RNA) and treatment with direct acting 
antiviral therapi[INVESTIGATOR_351890] a serum a lbumin 
<2.8 g/dL or an INR >1.7 in the absence of another explanation for the abnormal 
laboratory value.
4.Has a history or current evidence of any condition (including active TB co -infection) , 
therapy, laboratory abnormality ,or other circumstance (includin g drug or alcohol abuse 
or dependence) that might, in the opi[INVESTIGATOR_871], confound the results of the 
study or interfere with study participation for the full study duration.
Prior/Concomitant Therapy
5.Is taking or is anticipated to require any of the prohibited therapi[INVESTIGATOR_33944] 6.5 
from the Screening Visit and throughout the study treatment period .(See Table 3
footnote for special considerations in Part 2 of the study.)
08BJ8V
PRODUCT: MK-8591A  58
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
6.Is taking DOR as part of his/her current failing antiretroviral regimen.
7.Is taking EFV , etravirine, or nevirapi[INVESTIGATOR_050] .
Note: Although expected to be rare, these drugs are excluded because of the potential for 
decreased DOR concentrations when administered with DOR or DOR/ISL).  ( See Table 3
footnote for more information .)
Prior/Concurrent Clinical Study Experience
8.Is currently participating in or has participated in an interventional clinical study with an 
investigational compound or device from the Screening Visit through the study treatment 
period.
Note: Concurrent participation in observational or noninterventional studies may be 
permitted and should be discussed with the Sponsor prior to enrollment and through the 
study duration.
Diagnostic Assessments
9.Has exclusionary laboratory values at the Screening Visit as listed in Table [ADDRESS_437676] SGOT >5 ×ULN
ALT SGPT >5 ×ULN
Hemoglobin <9.0 g/dL (female) or <10.0 g/dL (male)
Calculated Cr CL ≤30mL/min based on the Cockcroft -Gault 
equation (Appendix 8)
ALT SGPT=alanine aminotransferase; AST SGOT=aspartate aminotransferase; CrCL=creatinine clearance; 
ULN=upper limit of normal .
Note: A single repeat of a laboratory screening test will be allowed for test results that are 
unexpected based on documented pr ior laboratory results, but the repeat test results must be 
available within the 60- day screening window .
Other Exclusions
10. Is female and is expecting to conceive or donate eggs at any time during the study.
Note: Investigators should provide appropriate guidance to female participants 
regarding egg donation after comp letion of the study treatment. Consistent with the 
08BJ8V
PRODUCT: MK-8591A  59
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437677] dose of study treatment .
Note: Donation of sperm should follow local guidelines for HIV- positive individuals.
5.3 Lifestyle Considerations
There are no lifestyle restrictions for ISLand DOR .Refer to approved labeling for any 
lifestyle restrictions with administration of ART and OBT.
5.4 Screen Failures
Screen failures are defined as participants who consent /assent to participate in the clinical 
study, but are not subsequently randomized in the study. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who discontinues from study intervention or withdraws from the study will not 
be replaced.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study p articipant according to 
the study protocol.
Clinical supplie s (study intervention[s] provided by [CONTACT_1034] )will be packaged to support 
enrollment where possible (eg, not applicable in the case where multiple lots or batches may 
be required due to the length of the study, etc .). Clinical supplies will be affixed with a 
clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study are outlined in Table [ADDRESS_437678]: MK-8591A  60
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 2 Study Intervention s
Arm Name [CONTACT_351949](s) Dosage Level(s)Route of 
Administration Treatment Period UseIMP/
NIMP Sourcing
All Groups 
(Group 1, 
2, 3, 4 )N/A Baseline ART 
regimenaDrug Per Approved 
Product LabelPer Approved 
Product LabelPer Approved 
Product LabelPer Approved 
Product LabelRun-in Period 
through Part 1 
Day 7Background 
TreatmentNIMP Local
country 
level 
Sourcingb
Group 1 Experimental ISL Drug Capsule 0.75 mg 0.75 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Experimental IMP Provided 
centrally by 
[CONTACT_351915] 1 Experimental DOR Placebo Drug Tablet 0 mg 0 mg QD Oral Part 1: Day 1 to
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351915] 1 Experimental DOR/ISL 
PlaceboDrug Tablet 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351915] 2 Experimental DOR Drug Tablet 100 mg 100 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Experimental IMP Provided 
centrally by 
[CONTACT_351915] 2 Experimental ISL Placebo Drug Capsule 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351915] 2 Experimental DOR/ISL 
PlaceboDrug Tablet 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[INVESTIGATOR_35259] r
Group 3 Experimental DOR/ISL Drug Tablet 100 mg 
DOR/0.75 mg 
ISL100 mg/0.75 mg 
QDOral Part 1: Day 1 to
Day 7 (blinded)Experimental IMP Provided 
centrally by 
[CONTACT_351915] 3 Experimental DOR Placebo Drug Tablet 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351915] 3 Experimental ISL Placebo Drug Capsule 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351915] 4 Placebo 
ComparatorISL Placebo Drug Capsule 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_2728]
08BJ8V
PRODUCT: MK-8591A  61
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Arm Name [CONTACT_351949](s) Dosage Level(s)Route of 
Administration Treatment Period UseIMP/
NIMP Sourcing
Group 4 Placebo 
ComparatorDOR Placeb o Drug Tablet 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351915] 4 Placebo 
ComparatorDOR/ISL 
Placeb oDrug Tablet 0 mg 0 mg QD Oral Part 1: Day 1 to 
Day 7 (blinded)Placebo IMP Provided 
centrally by 
[CONTACT_351916] 
(Group 1, 
2, 3, 4)Experimental DOR/I SL Drug Tablet 100 mg 
DOR/0.75 mg 
ISL100 mg/0.75 mg 
QDOral Part 2: Day 8 to 
Week 97 (open -
label)cExperimental IMP Provided 
centrally by 
[INVESTIGATOR_35259] r
All Groups 
(Group 1, 
2, 3, 4N/A Optimized 
Background 
TreatmentaDrug Per Approved 
Product LabelPer Approved 
Product LabelPer Approved 
Product LabelPer Approved 
Product LabelPart 2: Day 8 to 
Week 97 (open -
label)Background 
TreatmentNIMP Local 
country 
level 
sourcingb
ART=antiretroviral therapy; CCR5=chemokine receptor type 5; DOR=doravirine; InSTI=integrase strand transfer inhibitor; ISL=is latravir; NNRTI=non -nucleoside reverse transcriptase inhibitor; 
NRTI=nucleoside reverse transcriptas e inhibitor; OBT=optimized background therapy; PK=pharmacokinetic; QD=once daily.
aAllowed drug classes include NRTIs, NNRTIs, protease inhibitors, InSTIs, fusion inhibitors, CCR5 antagonists, and postattachment inhibitor .
bThe Sponsor will not provide ART during Part [ADDRESS_437679] regularly scheduled study visit (Week 97), study intervention will be dispensed at Week 97. In addition, their visit schedule will be extended through 
the duration of the pregnancy and study intervention will be dispensed at Weeks 109, 121, and 133, as applicable.
Definition of Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by [CONTACT_63512]. Regional and/or Country 
differences of the definition of IMP/NIMP may exist. In these circumstances, local legislation is followed.
08BJ8V
PRODUCT:   MK-8591A  62
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
All supplies indicated in Table 2 will be provided per the "Sourcing" column depending upon 
local country operational requirements. If local sourcing, every attempt should be made to 
source these supplies from a single lot/batc h number.
Refer to Section 8.1.[ADDRESS_437680].
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_437681] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountabili ty, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for re cording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
08BJ8V
PRODUCT:   MK-8591A  63
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Intervention randomization will occur centrally using an IRT system. There are 4blinded 
study intervention arms in Part 1. Participants will be assigned randomly in a 1:2:1:1ratio to 
ISL, DOR, DOR/ISL, or placebo, respectively. In Part 2, there is 1 open -label study 
intervention arm; a ll eligible participants will receive DOR/ISL + OBT.
6.3.2 Stratification
Intervention randomization will be stratified according to the following factors:
Stratum 1: Adults ( ≥18 years of age) with M184V or I substitutions.
-At least 73 participants will be enrolled into this Stratum.
Stratum 2: Adults (≥18 years of age) without M184V or I substitutions.
Stratum 3: Pediatric participants (<18 years of age) .
-Pediatric participants will not be stratified by M184V or I substitutions as few 
participants <18 years of age are expected to be enrolled into the study.
Stratification factors help ensure that the blinded treatment arms in Part 1 will be well 
balanced across the treatment groups within each stratum and the study results will not be 
confounded by [CONTACT_351917] M184V or I substitutions at 
baseline.
6.3.3 Blinding
In Part 1of this study, a double -blinding technique with i n-house blinding will be used. 
DOR , ISL ,DOR/ISL, and placebo will be packaged identically so that the blind is 
maintained. The participant, the investigator, and Sponsor personnel or delegate(s) who are 
involved in the s tudy intervention administration or clinical evaluation of the participants are 
unaware of the intervention assignments.
Clinical site personnel and participants will remain blinded to Part 1 treatment through 
Week 97while Sponsor personnel will remain b linded until the end of Part 1. Sponsor 
personnel involved in performing and reviewing results of the Part 1 analysis will be 
unblinded after the Part 1 database lock.
Part 2 of this study is open- label; therefore, the Sponsor, investigator, and participan t will 
know the intervention administered.
To allow timely completion of population PK modeling, restricted early (before database 
lock) unblinding of PK data may be requested. No personnel directly associated with study 
conduct will be unblinded. Before granting select personnel access to unblinded PK data, an 
08BJ8V
PRODUCT:   MK-8591A  64
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437682] access to unblinded PK data before 
database lock.
6.4 Study Intervention Compliance
Participants should be instructed to bring the irmedication , whether clinical supplies provided 
by [CONTACT_941] S ponsor or ART/OBT provided by [CONTACT_19288], to their visits. At each visit, the 
number of tablets or capsules remaining will be counted, reviewed, and recorded. For any 
ART/OBT that is received via injection or infusion ,the participant will provide information 
regarding dosing via a conversation with site personnel. The results will be used to assess 
participant compliance. If a discrepancy is noted, the investigator/study coordinator must 
discuss the discrepancy with the participant and the explanation must be documented. 
Participants should be reminded of the importance of taking their study intervention as 
instructed for the entire duration of the study.
Decisions to temporarily withhold study intervention because of an AE or other reason will 
be reviewed on a case -by-case basis by [CONTACT_093]. Interruptions from the protocol-
specified treatment plan that are expected to be 7 consecutive days or longer require 
consultation between the investigator and the Sponsor, and written documentation of the 
collaborative decision on participant management.
6.5 Concomitant Therapy
Medications or vaccinations specifically p rohibited in the exclusion criteria are not allowed 
during time periods specified by [CONTACT_151524]. If there is a 
clinical indication for any medications or vaccinations specifically prohibited, 
discontinuation from study intervention may be required. The investigator should discuss any 
questions regarding this with the Sponsor Clinical Director. The final decision on any 
supportive therapy or vaccination rests with the investigator and/or the participant’s primary 
physician. However, the decision to continue the participant on study intervention requires 
the mutual agreement of the investigator, the Sponsor, and the participant.
In instances where the local product circular for DOR is more restrictive with regards to 
prohi bited (ie, contraindicated or not recommended) therapi[INVESTIGATOR_014], the local product circular 
supersedes this section.
Prior and concomitant therapi[INVESTIGATOR_180568] [ADDRESS_437683] of prohibited therapi[INVESTIGATOR_351891] 3 is not comprehensive, and the investigator should 
use h is/her medical judg ment when assessing a participant’s prior and concomitant 
therapy(ies). The Sponsor Clinical Director or designee should be contact[CONTACT_180622] a therapy not in Table [ADDRESS_437684]:   MK-8591A  65
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 3 Prohibited Therapi[INVESTIGATOR_180569]3A 
inducersIncluding, but not limited to:
Carbamazepi[INVESTIGATOR_180570]. John’s Wort
Herbal remedies
Modafinil
Bosentan
Nafcillin
Non-Study ART Use of antiretrovira lsother than as components of the 
baseline ART ( Run-in Period and Part 1) orOBT (Part 2)
is not allowed, except for treatment of ongoing HBV 
infection.
Immunosuppressive therapi[INVESTIGATOR_180571], immune modulators or other 
systemic immunosuppressive therapy, including interferon -
based treatment for hepatitis
Time -limited courses of corticosteroids (eg, for asthma 
exacerbation) are permitted .
Investigational agents All non-study investigational agents including devices . 
Note: For participants with no fully active agents to 
construct optimized background therapy in Part [ADDRESS_437685] be a pproved by [CONTACT_351918].
Additional prohibited therapi[INVESTIGATOR_351892] (Part 1) or 
OBT (Part 2)Refer to the approved local label (s)
Additional prohibited therapi[INVESTIGATOR_180572]=antiretroviral therapy; CYP3A=cytochrome P450 3A; DOR=doravirine; HBV= hepatitis B Virus; 
ISL=islatravir; OBT=optimized background therapy .
Note: Efavirenz, e travirine, and nevirapi[INVESTIGATOR_351893] .If use of thes e agents is considered essential for construct ing the OBT inPart [ADDRESS_437686] discuss this with the Sponsor ’sClinical Director .Similarly ,if use of amoderate 
CYP3A inducer or immunosuppressive agent is considered essential in Part [ADDRESS_437687] 
be discussed with the Sponsor ’sClinical Director .
08BJ8V
PRODUCT:   MK-8591A  66
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification of ISL,DOR , or DOR/ISL (during Part 1) or DOR/ISL (during Part 2 ) 
is allowed during the study.
6.7 Intervention After the End of the Study
At the end of Week 97, provided development of DOR/ISL continues, all eligible 
participants will be given the option to continue receiving study intervention without 
interruption (eg, as part of a rollover study) until it becomes locally available . Eligible 
participants are those who have completed the last scheduled study visit and are considered 
by [CONTACT_351919]/ISL.
Participants who complete the Week [ADDRESS_437688] decreases in CD4+ T -
cell and/or total lymphocyte counts that meet ECI criteria (Section 8.4.7) at Week [ADDRESS_437689] a confirmation visit in this study (per Section 8.11.6 and Section 1.3.4). The 
confirmatory CD4+ T -cell count and/or total lymphocyte count will be followed in this 
study, and the participant will be concurrently enrolled in the rollover study .
Upon repeat testing, i f discontinuation criteria (Section 7.1) are confirmed, participation 
in the rollover study will be stopped. The participant will be followed monthly in this 
study until 2 values (12 weeks apart) for the CD4+ T- cell and total lymphocyte counts are 
not decreased by >10% of the average baseline value (Section 8.11.6 ).
Upon repeat testing, i f discontinuation criteria (Section 7.1) are not confirmed, the 
participant will continue to participate in the rollover study only.
Participants who decline participation in the rollover study whose Week 9 7visit shows 
decreases in CD4+ T -cell and/or total lymphocyte counts should be managed per Section 
8.11.6 .3.
6.8 Clinical Supplies Disclosure
The emergency unblinding call center will use the intervent ion/randomization schedule for 
the study to unblind participants and to unmask study intervention identity for Part 1of this 
study. The emergency unblinding call center should only be used in cases of emergency (see 
Section 8.1.10). In the event that the emergency unblinding call center is not available for a 
given site in this study, the central electronic IRT should be used to unblind participants and 
to unmask study intervention identity. The Sponsor will not provide random code/disclosure 
envelopes or lists with the clinical supplies.
08BJ8V
PRODUCT:   MK-8591A  67
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
In Part 1 of the study ( Day 1to Day 7) , all study supplies will be double -blinded; therefore, 
the participant, the study site personnel, the Sponsor and/or designee will be blinded. After 
Day 7, DOR/ISL will be provided as open -label supplies (Part 2) . Study treatment (name, 
strength, or potency) is included in the label text.
[ADDRESS_437690] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 1.[ADDRESS_437691] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is violated, o r 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.[ADDRESS_437692] be discontinued from study intervention but c ontinue to be monitored per 
Section 8.11.4 for any of the following reasons :
The participant or participant’s legally acceptable representative requests to discontinue 
study intervention.
The participant has a medical condition or personal circumstance (forpregnancy , see
Section 8.11.7) which , in the opi[INVESTIGATOR_11922]/or Sponsor, placed the 
participant at unnecessary risk from continued administration of study intervention.
The participant chooses to breastfeed.
Note: Study intervention can continue until breastfeeding i sinitiated.
The participant is considered by [CONTACT_351920]/ISL .
Occurrence of any Category C conditions included in the CDC 1993 Revised 
Classification System for HIV Infection and Expanded Surveillance Case Definition for 
AIDS Among Adolescents and Adults [Centers for Diseas e Control (CDC) 1992] .
08BJ8V
PRODUCT:   MK-8591A  68
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
The participant has an SAE or Grade [ADDRESS_437693] be discontinued from study intervention if the following criteria aremet
but continue to be monitored per Section 8.11.6 :
A ≥30% reduction from average baseline value * in CD4+ T -cell count OR in total
lymphocyte count on 2consecutive measurements taken 3 to 4 weeks apart.
*Note: The average baseline value is defined as the average value between screening 
(within [ADDRESS_437694] dose of study intervention) and Day 1.
7.[ADDRESS_437695] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits. 
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific details regarding withdrawal from future biomedical research, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedly fail 
to return for scheduled visits and/or if the study site is unable to contact [CONTACT_111953] 7.3.
7.[ADDRESS_437696] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of maintaining 
the protocol- specified visit schedule.
The investigator or designee must make every effort to regain contact [CONTACT_88684] (eg, telephone calls and/or a certified letter to the participant’s last known 
mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
8 STUDY ASSESSMENTS AND PROCEDURES
Study procedures and their timing are summarized in the SoA. 
Adherence to the study design requirements, including t hose specified in the SoA, is 
essential and required for study conduct.
08BJ8V
PRODUCT:   MK-8591A  69
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of study 
site personn el responsibilities will be docu mented in the Investigator Trial File Binder (or 
equivalent).
All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
Addition al evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulation s 
may require that additional informed consent , and assent if applicable, be obtained from 
the participant. In these cases, such evaluations/testing will be performed in accordance 
with those regulations.
The amount of blood collected from each participant over the full duration of the study is 
provided in Appendix 2.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent /Assent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent , and assent if applicable, from each potential 
participant or their legally acceptable representative prior to part icipating in thisclinical 
study or future biomedical r esearch .If there are changes to the participant’s status during the 
study (eg, health or age of majority requirements), the investigator or medically qualified 
designee must ensure the appropriate doc umented informed consent /assent is in place.
[IP_ADDRESS] General Informed Consent/Assent
Informed consent /assent given by [CONTACT_351921] a consent form . The form must include the study protocol number, 
study protocol title, dated signature, and agreement of the participant (or his/her legally 
acceptable representative) and agreement of the person conducting the consent /assent
discussion.
A copy of the signed and dated informed consent /assent form should be given to the 
participant (or their legally acceptable representative) before participation in the study.
08BJ8V
PRODUCT:   MK-8591A  70
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
The initial informed consent/assent form , any subsequent revised informed consent/assent 
form , and any written information provided to the p articipant must receive the Institutional 
Review Board/Independent Ethics Committee’s ( IRB/IEC’s )approval/favorable opi[INVESTIGATOR_130974]. The participant or his/her legally acceptable representative should be 
informed in a timely manner if new inform ation becomes available that may be relevant to 
the participant’s willingness to continue participation in the study. The communication of 
this information will be provided and documented via a revised consent /assent form or 
addendum to the original consent /assent form that captures the participant’s orthe 
participant’s legally acceptable representative’s dated signature.
Specifics about the study and the study population are to be included in the study informed
consent form.
Informed consent will adhere t o IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .The assent, as applicable will adhere to IRB/IEC requirements, 
applicable laws and regulations and Sponsor requirements.
[IP_ADDRESS] Consent /Assent and Collection of Specimens for Futur e Biomedical 
Research
The investigator or medically qualified designee will explain the future biomedical research 
consent /assent to the participant, or the participant's legally acceptable representative, answer 
all of his/her questions, and obtain documented informed consent /assent before performing 
any procedure related to future biomedical research. A copy of the informed consent /assent
will be give n to the participant before performing any procedure related to future biomedical 
research .
[IP_ADDRESS] Consent /Assent for Postnatal Infant Safety Data Collection Through One 
Year of Age
The investigator or medically qualified designee will explain the consent/assent for infant 
safety data collection to the participant, or the participant’s legally acceptable representative, 
answer all questions, and obtain documented informed consent /assent before collecting any 
data related to infant safety . A copy of the informed consent /assent will be given to the 
participant.
[IP_ADDRESS] Consent/Assent for Continuation of Study Intervention During Pregnancy
Upon learning that a participant is pregnant, the investig ator or medically qualified designee 
and the participant will discuss the potential benefits and risks of continuing (or 
discontinuing) study intervention (Section 8.11. 7). A separate consent /assent is required to 
continue study intervention in participant s who become pregnant. The investigator or 
medically qualified designee will explain the consent/assent to the participant, or the 
participant’s legally acceptable representative, answer all questions, and obtain documented 
informed consent /assent before c ontinuing study intervention. A copy of the informed 
consent /assent will be given to the participant.
08BJ8V
PRODUCT:   MK-8591A  71
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the p articipant qualifies for the study.
8.1.[ADDRESS_437697] information (including direc t 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent /assent . At the t ime of intervention
randomization, site personnel will add the treatment /randomization number to the participant 
identification card.
The participant identification card also contains contact [CONTACT_19430] a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available. 
8.1.4 Medical History
A medical history will be obtained by [CONTACT_351922].The medical history should include information pertaining to the diagnosis of HIV- 1 
and AIDS (if applicable) and year diagnosed. If the part icipant has been previously 
diagnosed with any AIDS -defining conditions or CD4 + T-cell count <200 c ells/mm3, the 
condition as well as a corresponding medical history of AIDS must be reported. In addition, 
participants’ history of smoking and alcohol consum ption should be obtained and recorded 
on the appropriate eCRF as relevant.
8.1.5 Prior and Concomitant Medications Review
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use and record prior 
medication taken by [CONTACT_351923].
All prior ARTs taken by [CONTACT_180629] (if available) will be 
recorded before the first dose of study intervention .
[IP_ADDRESS] Concomitant Medications
The investi gator or qualified designee will record medication, if any, taken by [CONTACT_19432].
The ART/OBT taken by [CONTACT_351924].
08BJ8V
PRODUCT:   MK-8591A  72
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437698] not be re -used for 
different participants.
Any participant who is re screened will retain the original screening number assigned at the 
initial Screening V isit. Specific details on the screening/rescreening visit requirements are 
provided in Section 8.11.1.
8.1.7 Assignment of Treatment/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment/randomization number at the randomization visit ( Day 1 ). The 
treatment/random ization number identifies the participant for all procedures occurring after 
treatment randomization. Once a treatment/randomization number is assigned to a 
participant, it can never be re assigned to another participant.
A single participant cannot be assi gned more than 1 treatment/randomization number.
8.1.8 Study Intervention Administration
Study intervention will be provided as per Table 2(Section 6.1) and dispensed through t he 
IRT system at visits indicated in the SoA (Section 1.3.1).
The first dose of double -blind study intervention will be administered at the study site at the 
randomization visit ( Day 1). Subsequent dosing will be performed once daily by [CONTACT_2416] (ie, unsupervised at his/her home) at approximately the same time each day .
[IP_ADDRESS] Timing of Dose Administration
All study interventions should be administered QD at approximately the same time each day 
without regard to food. The tablets or capsules from each container of study intervention 
should be taken together.
During the double -blind treatment period ( Part 1) , all participants will take 1 tablet or capsule
from each of the 3 containers QD with their failing ART.
During the open -label treatment p eriod ( Part 2) , all participants will receive open -label 
DOR/ISL andwill take [ADDRESS_437699]:   MK-8591A  73
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
If a participant misses a dose of any of the study intervention s, the following guidance should 
be followed:  
If ≤12 hours from the missed dose, the missed dose should be taken, and the normal 
dosing schedule resum ed.
If >12 hours from the missed dose, the missed dose should be skipped, and the normal 
dosing schedule resumed. The participant should not double the next dose to compensate 
for what has been missed.
If a participant misses a dose of baseline ART (duri ng Part 1 ) or OBT (during Part 2), 
guidance in the approved label (s)should be followed.
8.1.[ADDRESS_437700] an Early Discontinuation visit performed per the SoA (Section 1.3) and be 
encouraged to continue to be followed as outlined in Section 8.1 1.4. Participants who 
discontinue study intervention for decreases in CD4+ T -cell counts and/or total lymphocyte 
counts or who discontinue study inter vention for any other reason and are noted to have a 
>10% decrease from average baseline value in their CD4+ T -cell and/or total lymphocyte 
count s or have decreases in CD4+ T -cell and/or total lymphocyte counts that meet ECI 
criteria at the Early Discontinuation of Treatment Visit should be managed per Section 8.11.6
until the counts recover .
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the Early Discontinuation visit should be performed (at the time of 
withdrawal). Any AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4 and participants should 
attend the End of Treatment Follow -up visit approximately 6 weeks after discontinuing study 
intervention.
[IP_ADDRESS] Withdrawal From Future Biomedical Research
A participant’s consent for Future Biomedical Research may be withdrawn by [CONTACT_171589]’s legally acceptable representative (as appropriate) . A participant ’s consent 
may be withdrawn at any time by [CONTACT_111954]. If medical 
records for the main study are still available, the investigator will contact [CONTACT_111955] (clinical.specimen.management@ MSD .com). Subsequently, the 
participant's consent for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the 
investigator to inform the participant of c ompletion of withdrawal. Any analyses in progress 
at the time of request for withdrawal or already performed prior to the request being received 
by [CONTACT_180630]. 
No new analyses would be generated after the request is received.
08BJ8V
PRODUCT:   MK-8591A  74
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_180631]) 
or the specimens have been completely anonymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.10 Participant Blinding/Unblinding
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified des ignee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered, he/she will contact [CONTACT_88693] a request for emergency unblinding. As reques ted by [CONTACT_19445], the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Prior to contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is a qualified physician should make reasonable attempts to enter the 
intensity of the AEs observed, the relation to study intervention, the reason thereof, etc., in 
the medical chart. If it is not possible to record this assessment in the chart prior to the 
unblinding, the unblinding should not be delayed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblin ding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel are unblinded so that appropriate follow- up m edical care can be provided 
to the participant.
Additionally, the investigator or medically qualified designee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. In the event that the 
emergency unblinding call center is not available for a given site in this study, the IRT 
system should be used for emergency unblinding in the event that this is required for 
participant safety.
8.1.11 Calibration of Equipment
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrat ed and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site.
08BJ8V
PRODUCT:   MK-8591A  75
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
8.1.12 Administration of Patient Questionnaires
Adult participants ( ≥18 year sat the time of consent ) will complete the FAHI at Day 1, 
Week 25, Week 49, Week 97, and/or the Early Discontinuation visit. Participants are to 
complete th e questionnaire on their own at the site on paper during the appropriate study visit 
(see SoA, Sect ion 1.3) prior to being seen by [CONTACT_093] , receiving study intervention , 
discussing any medical conditions with the study personnel, or receiving any med ical results. 
The questionnaire will not be administered to participants if native language tran slation isnot 
available.  
The partici pant responses to the questionnaire will be entered into the appropriate eCRF by 
[CONTACT_351925].
8.2 Efficacy Assessmen ts
The primary efficacy measurement is HIV -1 RNA. Additional efficacy m easurements 
include CD4+ T- cell counts ,viral resistance testin g, and proviral DNA resistance testing. 
Blood will be collected as indicated in the SoA (Section 1.3).
8.2.1 HIV -1 RNA
Plasma HIV -1 RNA quantification will be performed at the central laboratory using an 
Abbott Real Time PCR assay with a lower limit of detection of 40 copi[INVESTIGATOR_014]/mL .  
8.2.2 Management of Study Participants with Viremia
When viremia (HIV -1 RNA ≥ 200 copi[INVESTIGATOR_014]/mL after participant has achieved HIV -1 RNA of 
<50 copi[INVESTIGATOR_014]/mL) is detected, the investigator should query the participant regarding adherence 
to study therapy, intercurrent illness, or recent immunization. All cases of viremia must be 
confirmed, and the participant should continue to take the assigned dosage of study 
intervention while awaiting confirmation .
HTE patients may derive clinical benefit from declining HIV -1 RNA levels even if complete 
viral suppression is not achieved. Participants with HIV -1 RNA ≥ 200 copi[INVESTIGATOR_014]/mL during the 
open -label treatment period ( Part 2) who are considered by [CONTACT_351926]/ISL .
[IP_ADDRESS] Viremia Confirmation
Confirmation of viremia requires 2 consecutive plasma HIV -1 RNA results of ≥ 200 
copi[INVESTIGATOR_014]/mL after aparticipant previously achieved H IV-1 RNA of <50 copi[INVESTIGATOR_014]/mL. The second 
sample collected at a “Viremia Confirmation” visit at least 4 weeks from the date of the 
initial sample . This timeframe may be extended if study intervention is interrupted for one of 
the following circumstances:
Intercurrent illness : Redraw 2 to 4 weeks following resolution of the illness, during 
which time the participant should continue to receive the assigned dosage of study 
intervention without interruption;
08BJ8V
PRODUCT:   MK-8591A  76
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Immunization : Redraw approximately 4 weeks following any immunization, during 
which time the participant should continue to receive the assigned dosage of study 
intervention without interruption;
Toxicity management, noncompliance , or other reason : Redraw 2 to 4 weeks 
following resuming the assigned dosage of study intervention .
[IP_ADDRESS] Viral Drug Resistance Testing
Phenotypic and genotypic HIV -1 drug resistance testing will be performed on plasma 
samples per the SoA (Section 1.3) to determine resistance to ISL, D OR, and other ARTs. 
Samples collected at Day 1 (baseline) ,Day 8 ,and samples with HIV- 1 RNA ≥200 copi[INVESTIGATOR_014]/mL 
for participants who never suppressed at Week [ADDRESS_437701] ing will be collected per the SoA (Section 1.3) .Postrandomization whole blood 
samples in participants with plasma HIV-1 RNA ≥200 copi[INVESTIGATOR_014]/mL at Week 25 , Week 49,and 
Week 97 and those that were collected either to confirm viremia or at discontinuation will be 
analyzed for proviral DNA resistance testing.
All viral resistance testing will be performed by [CONTACT_2237].
8.2.3 T-and B -Lymphocyte and Natural Killer Cell Profile (TBNK)
A TBNK Panel ,including CD4+ T cell count ,will be performed at the central laboratory
(Appendix 2) .Refer to Section 8.11.6 for guidance on management of participants with 
decreased CD4+ T- cell counts and/or decreased total lymphocyte counts.
8.3 Safety Assessments
Details regarding specific safety p rocedures/assessments to be performed in this study are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the study, 
including approximate blood volumes drawn/collected by [CONTACT_180635], can be f ound in Appendix 2 .
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted at the randomization visit (Day 1) by [CONTACT_111959] (consi stent with local requirements) as per 
institutional standard. The complete physical examination will include examination of body 
systems (including, but not limited to, general appearance, skin, neck, eyes, ears, nose, throat, 
breast, lungs, heart, abdomen, back, lymph nodes, extremities, and nervous system).
08BJ8V
PRODUCT:   MK-8591A  77
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
A directed physical examination will be conducted as indicated in the SoA (Section 1.3) by 
[CONTACT_19444] (consistent with local requirements) per 
institutional standar d, sign -and symptom -directed, and based on the participant’s condition 
and circumstances. The investigator should note any changes in the participant’s condition 
(body systems) since the last examination .This does not preclude examination of any of the 
body system as clinically indicated.
Height and weight will also be measured and recorded at the visits specified in the SoA 
(Section 1.3). Height measurements are recommended to be taken by [CONTACT_2363] a stadiometer, 
however not required.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
8.3.[ADDRESS_437702] and will include 
temperature, pulse, respi[INVESTIGATOR_697], and systolic and di astolic blood pressure.
Note: Oral temperatures are preferred
, but not required . 
8.3.3 Electrocardiograms
A single 12-lead ECG will be obtained and reviewed by [CONTACT_113803] (consistent with local requirements) as outlined in the SoA (see Section 
1.3.1) using an ECG machine that automatically calculates the heart rate and measures PR,
QRS, QT, and QTc intervals. 
8.3.[ADDRESS_437703]:   MK-8591A  78
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437704] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
The investigator or medically qua lified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_78259]'s condition.
All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_437705] be 
conducted in accordance with the laboratory manual and the SoA .
If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laborato ry require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 42days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a ne w baseline is established as determined by [CONTACT_093] .
Note: Management of decreases in CD4+ T- cell and/or total lymphocyte counts is 
described in Section 8.11. 6.
8.3.6 HBV Assessments
Participants who become HBsAg or HBV DNA positive after study entry may be allowed to 
continue study treatment if deemed medically appropriate upon consultation with the 
Sponsor.
8.3.7 Tobacco and Alcohol Assessments
Participants’ use of tobacco and alcohol will be obtained and recorded at Week 97.
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix [ADDRESS_437706]:   MK-8591A  79
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299]
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.4.[ADDRESS_437707] be reported immediately to the Sponsor 
if the event is considered related to study intervention. 
For infants born to participants who become pregnant and consent to infant safety data 
collection, SAEs (including perinatal HIV -1 infection) occurring through [ADDRESS_437708] 
be reported by [CONTACT_140235] 24 hours of learning of the event.
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table [ADDRESS_437709]:   MK-8591A  80
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
For participants who continue in a rollover study , the collection requirements of AEs, SAEs, 
and other reportable safety events in this protocol are amended as follows:
AEs, SAEs, and other reportable safety events will be collected and recorded through the 
last study visit in this protocol.
Pregnancy outcome and infant SAEs will be captured in this protocol, if pregnancy 
expo sure is reported in this protocol.
The last coll ection of nonserious AEs (including cancer that does not meet serious 
criteria) will be at the last study visit in this protocol.
Note: All new SAEs (including those considered related to study intervention) and other 
new reportable safety events (including pregnancy exposure) that occur after the last 
study visit will be collected in the rollover study.
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Eve nts
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol- specified 
Follow -up PeriodReporting Time Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Information 
to Sponsor:
Nonserious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run-
in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run-
in treatmentReport all Report if:
-drug/vaccine related.
(Follow ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow to 
completion/termination; 
report outcomeWithin [ADDRESS_437710] 
(require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-Potential drug -
induced liver injury 
(DILI)
-Require regulatory 
reportingNot required Within [ADDRESS_437711]:   MK-8591A  81
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol- specified 
Follow -up PeriodReporting Time Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Information 
to Sponsor:
Event of Cli nical Interest 
(do not require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 
calendar days 
of learning of 
event
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving placebo 
run-in or other run-
in medication Report all Not required Within 5 
calendar days 
of learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred m ethod to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, events of clinical interest (ECI s), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AEs that occur in
randomized participants for outcome. Further information on follow -up procedures is given 
in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_88701] a study interventio nunder clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply wth country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUS ARs) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.
08BJ8V
PRODUCT:   MK-8591A  82
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE ) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements.
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to t he completion/termination of the pregnancy. 
Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Med ical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
For infants born to participants who become pregnant and consent to infant safety data 
collection, SAEs (in cluding perinatal HIV -1 infection ) occurring through [ADDRESS_437712] 
be reported by [CONTACT_140235] 24 hours of learning of the event.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This section is not applicable to the study.
8.4.[ADDRESS_437713] (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study include:
An elevated AST or ALT lab value that is greater than or equal to 3X the upper l imit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by [CONTACT_13149] -specified laboratory 
testing or unscheduled laboratory testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional e valuation for an underlying etiology. The study site guidance for 
assessment and follow -up of these criteria can be found in the Investigator Study File 
Binder (or equivalent).
A ≥30% decrease from average baseline** values of CD4+ T- cell count or total
lymphocyte count values while on study intervention. 
**The average baseline value is defined as the average value between screening (within 
60days prior to the first dose of study intervention) and Day [ADDRESS_437714]:   MK-8591A  83
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Note: The first on- treatment value that meets the above CD4+ T -cell or total lymphocyte 
criteria should be reported as an ECI. See Section 8.11.6 for further guidance on the 
management of participants meeting CD4+ T -cell or total lymphocyte criteria.
8.5 Treatment of Overdose
In this study, an overdose is any dose higher than the prescribed dose of study intervention.
No specific information is available on the treatment of overdose. 
Decisions regarding dose interruptions will be made by [CONTACT_180636].
8.6 Pharmacokinetics
8.6.1 Blood Collection for Plasma ISLand DOR
Venous blood samples will be collected for measurement of ISLand DOR . Sample 
collection, storage, and shipment instructions for plasma samples wi ll be provided in the 
operations/laboratory manual.
Population PK samples will be collected from all participants as outlined in Table 5 . The 
time of the doses of study interventions taken prior to the sample collection will be verbally 
reported to study staff by [CONTACT_351927]. 
Investigational PK samples will be collected from all participants as outlined in the SoA 
(Section 1.3) . Analysis of these samples will be triggered by [CONTACT_25753].
For participants who become pregnant and consent to continue DOR/ISL, PK samples will be 
collected to evaluate DOR and ISL concentration levels per Table 6in Section 8 .11.7 .1.
Table 5 Collection of Population PK Samples
Study Visit Time relative to dose
Day 1 Predose
Day 8 Sample collected irrespective of time of dose (time of last dose and 
time of PK sample collection must be documented) , but prior to 
initiation of open -label DOR/ISL + OBT (Part 2)
Week 3 Sample collected irrespective of time of dose (time of last dose and 
time of PK sample collection must be documented)
Week 13 Sample collected irrespective of time of dose ( time of last dose and 
time of PK sample collection must be documented)
Week 25 Sample to be collected predose and within 0.5 and 2 hours postdose*
08BJ8V
PRODUCT:   MK-8591A  84
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study Visit Time relative to dose
Week 37 Sample collected irrespective of time of dose (time of last dose and 
time of PK sample collection must be documented)
Week 49 Sample to be collected predose and within 0.5 and 2 hours postdose*
*For participants who take their study intervention during the day, samples should be collected predose 
and postdose. For participants who take th eir study intervention in the evening, only a postdose sample 
should be collected the following day irrespective of time of dose (time of last dose and time of PK 
sample collection must be documented).
8.7 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8 Biomarkers
8.8.1 Planned Genetic Analysis Sample Collection
The planned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored fo r future biomedical research if the participant 
provides documented informed consent for future biomedical research .If the planned genetic 
analysis is not approved, but future biomedical research is approved and consent is given, 
this sample will be colle cted for the purpose of future biomedical research.
Sample collection, storage, and shipment instructions for Planned Genetic Analysis samples 
will be provided in the operations/ laboratory manual.
8.8.2 Inflammation
Blood samples will be collected to evaluate th e inflammatory and thrombotic response as 
measure dby [CONTACT_180638] (Section 1.3) .
IL-6
D-dimer
sCD-163
hs-CRP
08BJ8V
PRODUCT:   MK-8591A  85
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437715] 8 hours prior to Day 1 (Visit 4) and Day 8 
(Visit 5) where blood will be taken to measure glucose, HDL -C, TGs, TC, and non -HDL -C.
Participants with normal fasting lipid and metabolic profiles will repeat measurements at 
Week 49 (Visit 12), Week 73 (Visit 14), and Week 97 ( Visit 16) . Participants with abnormal 
measurements at Day [ADDRESS_437716] repeat testing at Week 25 (Visit 10).
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR , the following specimens 
will be obtained as part of future biomedical research:
Leftover extracted DNA for future research
Leftover main study plasma from HIV -1 RNA quantification
Leftover main study plasma from HIV drug resistance samples
Whole blood for FBR
Sample collection, storage, and shipment instruction for whole blood FBR samples will be 
provided in the operations/laboratory manual. Refer to the SoA (Section 1.3) for timing of 
sample collection.
8.10 Heal th Economics Medical Resource Utilization and Health Economics
Medical Resource U tilization and Health Economics are not evaluated in this study.
8.11 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.11.1 Screening /Rescreening
Screening
Approximately [ADDRESS_437717]:   MK-8591A  86
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437718] few or no options for an effective treatment, it is necessary to 
consider the circumstances where a participant may not meet eligibility criteria at the current 
time, but due t o the progression of their HIV -1disease ,they may qualify at a later time (eg,a 
participant not having a high enough HIV -1RNA at Screening or a participant not having 
NRTI or NNRTI resistance on the screening resistance test ). Participants may be allowe d to 
rescreen following consultation with the Sponsor. Once a participant has started the 
rescreening process, a new screening period (ie, an additional 60-day window) will begin, 
during which time screening procedures may be repeated.
The following asses sments must be repeated for participants who are rescreened:
Vital signs, weight, and directed physical examination
Review medical history and prior/concomitant medications for new information
All laboratory assessments (includes serum hCG pregnancy testing for WOCBP)
HIV-1 drug resistance testing will be repeated only if determined to be required
Review of AEs
Documented informed consent /assent provided during the original screening period should 
be reviewed with the participant and verbal reconsent to continue in the study should be 
documented.
If a participant had a Day 1 ECG during the original screening period, it should be repeated 
(at the Day 1 visit or within 7 days prior).
8.11.2 Run-in Period
The Run-in Period begins immediately after S creening and ends at randomization. This 
period is designed to allow detection of participants who are failing their baseline regimen 
due to nonadherence. HIV-1 RNA testing will be repeated at Visit 2 to confirm study 
eligibility (HIV -1 RNA ≥500 copi[INVESTIGATOR_014]/mL with a < 0.5 log 10decline in HIV- 1 RNA from Visit 
1).Participants at Visit [ADDRESS_437719] HIV-1 RNA ≥ 500 copi[INVESTIGATOR_014]/mL and a ≥0.[ADDRESS_437720] return to the site 7to 14 days after Visit 2 for a R epeat HIV -1 RNA 
confirmation visit (Visit 3). In order to be eligible for randomization, participants must have 
HIV-1 RNA ≥ 500 copi[INVESTIGATOR_014]/mL and a < 0.[ADDRESS_437721]:   MK-8591A  87
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
8.11.3 Treatment Period
[IP_ADDRESS] Fasting
Visits at Day 1 (Visit 4) , Day 8 (Visit 5) , Week 49 (Visit 12) , Week 73 (Visit 14), and Week 
97 (Visit 16) require that participants fast (ie, do not consume any food or beverages except 
water) for at least 8 hours prior to the visit. The investigator/study coordinator are 
responsible to remind participants to fast prior to these visits and to confirm with participants 
their fasting status in the appropriate source documentation. 
Participants may need to fast at the Week 25 (Visit 10) visit as well depending on the 
outcome of the fasting lipid profile and fasting glucose measurement at Day 8 (see 
Section8.8.3).
[IP_ADDRESS] Double -blind (Part 1)
All procedures should be completed prior to intervention randomization as per the SoA 
(Section 1.3.1). R andomization should occur within 10 days after confirmation of HIV -1 
RNA eligibility. Participants who are eligible will enter the 7- day double -blind treatment 
period (Part 1) . Participants will continue on their failing ART during Part [ADDRESS_437722] (ie, do not consume any food or beverages 
except water) for at least 8 hours prior to the visit. The investigator/study coordinator are 
responsible to remind participants to fast prior to this visit and to confirm with participants 
their fasting status in the appropriate source documentation.
[IP_ADDRESS] Open -label (Part 2)
Participants who complete the 7 -day double -blind treatment period (Part 1) will continue to 
the open-label treatment per iod(Part 2 ). Participants will take OBT along with open-label 
DOR/ISL for 96 weeks. 
[IP_ADDRESS] Optional Nurse Visits and Telephone Visits
A visiting nurse service may be u sed(if locally available and approved for use) at any visit 
after a participant is randomized . If a visiting nurse service is used for any visit, the 
investigator should contact [CONTACT_180640], or as 
soon as possible to perform an investigator AE assessment . Refer to the nursing manual for 
additional de tails.
For visits conducted by [CONTACT_180641], whole blood for proviral DNA resistance and FBR 
samples (for those participants who consent to FBR) will not be collected by [CONTACT_351928]. Participants should be instructed to return to the site with in 2to4 weeks from the 
scheduled visit for collection of whole blood for proviral DNA resistance and FBR, when 
possible. If an unscheduled visit for collection of whole blood for proviral DNA resistance 
08BJ8V
PRODUCT:   MK-8591A  88
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
testing and FBR is not possible, the sample should be drawn at the next scheduled visit at the 
site.
[IP_ADDRESS] End of Study Week 97 Visit
Week 97 represents the end of this study.
Participants will be given 2 options at the Week 97 visit:
1.End participation in this study and resume locally available treatment of their choice. 
These participants should have an End of Treatment Follow -up visit approximately 42 
(+7) days (6 weeks) after the last dose of study intervention.
2.Provide documented consent to participate in the rollover study. The rollover study will 
provide o pen-label DOR/ISL to participants.
Participants who are pregnant at Week 97 will be managed per Section 8.11.7.
Management of participants with decreased CD4+ T- cell counts and/or total lymphocyte 
counts is as follows:
See Section 6.[ADDRESS_437723] 
CD4+ T- cell count and/or total lymphocyte count decreases that meet ECI criteria at 
their last study visit in this study (ie, rollover enrollment visit).
Participants not participating in the rollover study wh o have decreases in CD4+ T -cell 
and/or total lymphocyte counts that meet ECI criteria or are decreased by >10% of 
their average baseline value require additional follow -up monitoring of CD4+ T- cell 
and lymphocyte counts per Section 6.[ADDRESS_437724] both an Early Discontinuation of Treatment visit (Section [IP_ADDRESS] ) 
and an End of Treatment Follow -up visit (Section [IP_ADDRESS] ) conducted. After the visit 
procedures are completed, the participant will be withdrawn from the study and managed for 
treatment of HIV -[ADDRESS_437725] -of-care.
Guidance for management of participants who discontinue study intervention due to 
confir med decreased CD4+ T- cell counts and/or decreased total lymphocyte counts is 
provided in Section 8.11.6.
If participants discontinue study intervention for other reasons and the CD4+ T -cell 
counts and/or total lymphocyte count sat Early Discontinuation of Treatment visit are 
08BJ8V
PRODUCT:   MK-8591A  89
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
decreased by >10% of their average baseline value, additional monitoring is required per 
Section 8.11.6.
[IP_ADDRESS] Early Discontinuation of Treatment
Participants that discontinue treatment early for any reason should have an Early 
Discontinuatio n of Treatment visit as outlined in Section 1.3.2. If early discontinuation 
occurs during the timeframe of a scheduled study visit, the assessments for the Early 
Discontinuation of Treatment visit should be conducted.
[IP_ADDRESS] End of Treatment Follow- Up Visit
Parti cipants who discontinue study intervention at any time prior to the Week 97 visit for any 
reason(s) and participants who will not continue study intervention after Week 97will have 
anEnd of Treatment Follow -up visit in the clinic approximately [ADDRESS_437726] an End of Treatm ent Follow -up visit.
Participants discontinuing study intervention with specified decreases in CD4+ T -cell and/or 
total lymphocyte counts will be followed monthly for monitoring of CD4+ T- cell and/or total 
lymphocyte counts per Section 8.11.6.
8.11.5 Viremia Conf irmation
If a participant meets the criteria for viremia (see Section 8.2.2) , a Viremia Confirmation 
visit must be conducted at least [ADDRESS_437727] be collected.
8.11.6 Management of Participants with Decreases in CD4+ T -cell Counts and/or 
Total Lymphocyte Counts
Management of participants with decreases in CD4+ T -cell counts and/or total lymphocyte 
counts is explained below.
[IP_ADDRESS] Participants Whose CD4+ T -cell Count and/or Total Lymphocyte Count 
Decreases Meet Criteria for Events o f Clinical Interest While on Study 
Intervention
Participants whose decreases in CD4+ T- cell counts and/or total lymphocyte counts meet 
ECI criteria (Section 8.4.7) must have a confirmation visit in 3 to 4 weeks* . 
Upon repeat testing at the confirmation vi sit (Section 1.3. 4), if the discontinuation criteria are 
met (Section 7.1) , participant smust be discontinued from study intervention and managed 
per Section 8.11.[ADDRESS_437728]:   MK-8591A  90
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
[IP_ADDRESS] Participants Discontinued from Study Intervention Due to Decreased CD4+ 
T-cell Count an d/or Total Lymphocyte Count
After discontinuation from study intervention, participants will be managed for treatment of 
HIV-[ADDRESS_437729] of care .
Participants discontinued from study intervention due to specified decreases in CD4+ T -cell 
and/or total lymphocyte counts should undergo assessments as specified for the Early 
Discontinuation of Treatment Visit and the End of Treatment Follow -up Visit (Section 
1.3.4) . Participants will then be monitored monthly until 2 values (12 weeks apart) of CD4+ 
T-cell counts and total lymphocyte counts are not decreased by >10% of the average baseline 
value.
[IP_ADDRESS] Participants Discontinued from Study Intervention ForOther Reasons 
AND Have Decreases in CD4+ T -cell Count and/or Total Lymphocyte 
Count
Participants who discontinue study intervention for any other reason or decline participation 
into the rollover study who are found to have decreases in CD4+ T -cell and/or total 
lymphocyte counts >10% of average baseline values, or that meet ECI criteria at the Early 
Discontinuation of Treatment Visit should undergo assessments specified at the End of 
Treatment Follow -upat Day 42 (Section 1.3.5).
If the decrease of >10% of average baseline is confirmed at this visit, participants should 
continue to be monitored monthly until 2 values 12 weeks apart of CD4+ T -cell counts 
and total lymphocyte counts are not decreased by >1 0% of the average baseline value.
If the decrease of >10% of average baseline is not confirmed at this visit, then no further 
follow -up for CD4+ T cell and/or total lymphocyte counts is required . 
8.11.7 Clinical Management of Participants Who Become Pregnant
If a participant becomes pregnant (confirmed by a positive serum pregnancy test), the 
investigator should refer her to a local provider for appropriate obstetric (prenatal) care per 
local standard- of-care. All pregnancies must be followed to completion or ter mination of the 
pregnancy by [CONTACT_180643] 8.4.5. Severity assessment of AEs that are 
pregnancy -related complications should follow guidance provided as part of the DAIDS table 
version 2.1 “Addendum 1: Female Genital Grading Table for Use in Microbicide Studies,” 
particularly the section “Complications of Pregnancy .”
The site will discuss with the participant:
Joining a pregnancy registry (the Antiretroviral Pregnancy Registry), which collects 
information about the outcome of the pregnancy,
Consenting to infant safety data collection per Sections [IP_ADDRESS] and 8.11. 7.4,
Her intended breastfeeding status (Section 8.11. 7.3),
08BJ8V
PRODUCT:   MK-8591A  91
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Appropriateness of continuing study intervention based on available data and local 
standard- of care guidelines (where allowe d by [CONTACT_427], health authorities, and 
ethics committees) .
[IP_ADDRESS] Continuing Study Intervention
Participants who become pregnant and consent to continue study intervention 
(Section [IP_ADDRESS]) should complete all remaining protocol -specified visits and proc edures per 
the regular schedule in the SoA (Section 1.3.1). As the SoA specifies study visits at least 
every [ADDRESS_437730] a study visit approximately during each trimester and 
postpartum (ie, the first visit after delivery [~12 weeks af ter the 3rdtrimester visit and 
≤8weeks after delivery]). 
The participant’s prenatal care should be coordinated between the investigator and the local 
obstetric care provider. The investigator (or designee) is responsible for obtaining relevant 
clinical and laboratory data from the obstetric care provider to monitor the safety and well -
being of the mother and fetus. Relevant data obtained by [CONTACT_180644]. The participant’s medical records will be 
collected and reviewed by [CONTACT_180645]:
Clinical safety laboratory assessments
Plasma HIV -1 RNA level
Results of Week 20 to 22 or second trimester ultrasound(s) providing gestational age and 
anatomic survey
Any complications associate d with the pregnancy
Outcome of pregnancy
Information that could indicate congenital abnormalities
For participant swho are pregnant at the last regularly scheduled study visit (TW 97) , their
visit schedule will be extended through the duration of the preg nanc y to allow assessments 
through each trimester and postpartum (Section 1.3.3). At the completion of the pregnancy, 
continued access to DOR/ISL will be offered per Section 6.7. 
For participants who continue DOR/ISL, PK samples will be collected at their scheduled visit 
during the 1st, 2nd, and 3rdtrimesters and postpartum to evaluate DOR and ISL concentration
levels per Table 6. These samples will be used to characterize the PK profile of DOR/ISL 
during pregnancy.
08BJ8V
PRODUCT:   MK-8591A  92
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 6 Collection of Population PK Samples During Pregnancy and Postpartum
Study Visit Time Relative to D ose
1stTrimesteraPredose
2ndTrimester Predose AND 
0.5 to 2 hours AND 4 to 6 hours postdose
3rdTrimester Predose AND 
0.5 to 2 hours AND 4 to 6 hours postdose
PostpartumbPredose
PK=pharmacokinetic.
aCollected in the 1sttrimester at a scheduled visit when a participant reports gravid status.
bThe first visit after delivery; ~12 weeks after the 3rdtrimester visit and ≤8 weeks after delivery. 
[IP_ADDRESS] Discontinuing Study Intervention
Participants who become pregnant and discon tinue study intervention should have an Early 
Discontinuation of Treatment visit per the SoA (Section 1.3.2). If the decision to discontinue 
study intervention occurs during the timeframe of a scheduled study visit, the assessments for 
the Early Discontinuation of Treatment visit should be conducted at that time. In addition, 
these participants will have an End of Treatment Follow -up visit in -clinic  42 (+7) days after 
the last dose of study intervention (Section 1.3.2).
The investigator (or local HIV care provider, if not the study site) should develop a new 
treatment plan per local standard- of-care before discontinuing study intervention to minimize 
the risk of a gap in ART.
[IP_ADDRESS] Participants Who Choose to Breastfeed
If a participant chooses to breastfeed, she should discontinue study intervention before 
initiating breastfeeding (Section 7.1) and be followed in the study per Section 8.11. 7.2. The 
investigator (or local HIV care provider, if not the study site) should make every effort to 
develop a new treatment plan (per local guidelines) withinsufficient time prior to delivery to 
minimize the likelihood of a gap in ART.
[IP_ADDRESS] Infant Safety Data Collection
For participants who become pregnant while receiving study intervention ,or within [ADDRESS_437731]- of-care.
Infant SAEs, including perinatal HIV-1 infection, will be collected as per Section 8.4.1 and 
should be reviewed at the participant’s scheduled study visits that occur during this time.
08BJ8V
PRODUCT:   MK-8591A  93
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Infant safety data collection will be captured in this study, if exp osure during pregnancy is 
reported in this study.
[IP_ADDRESS].1 Schedule of Activities: Infant Safety Data Collection
Timepoint At Birtha1 Year 
After Birtha,b
Visit Name N/A Infant -Follow Up -1
Administrative and Safety Procedures
Infant i nformed consent Xc
Gestational age at birth X
Apgar score X
Length X X
Weight X X
Head Circumference X X
Directed pediatric examination X
Concomitant medications reviewdX X
Review infant SAEse---------------------------------- X--------------------------------
HIV=human immunodeficiency virus; SAE=serious adverse event.
aData to be collected and entered at the site within 12 weeks of each timepoint.
bIf a participant withdraws from the study, data from 1 year after birth should be collected at the time of withdrawal.
cConsent for infant safety data collection can be obtained from the mother at any time following confirmation of 
pregnancy.
dConcomitant medications taken by [CONTACT_58076] (for SAEs or HIV postpartum prophylaxis).
eCollect SAEs, including any congenital anomalies and HIV infection in the infant , per Section 8.4.1 and review at 
participant’s regularly scheduled study visits.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. If, after the 
study has begun, but prior to final database lock, changes are made to primary hypothes is, or 
the statistical methods related to this hypothes is, then the protoc ol will be amended 
(consistent with ICH Guideline E -9). Changes to exploratory or other non confirmatory 
analyses made after the protocol has been finalized, but prior to final database lock, will be 
documented in a nsSAP and referenced in the CSR for the s tudy. Post hoc exploratory 
analyses will be clearly identified in the CSR.
9.1 Statistical Analysis Plan Summary
Key elements of the S AP are summarized below; the comprehensive plan is provided in 
Section 9.[ADDRESS_437732]:   MK-8591A  94
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study Design 
OverviewA Phase 3, Randomized, Clinical Study in HIV -1-Infected Heavily Treatment -
Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir 
(ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to 
Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open -Label 
DOR/ISL.
Treatment
AssignmentRun-in Period :Participants will continue to take their current failing baseline ART .
Part 1: Participants will be randomized in a 1:2: 1:1 ratio into 1 of 4 treatment groups
stratified by [CONTACT_351929] 6.3.2 .The goal is to randomize 150 participants; 
however, a minimum of 100 randomized participants is targeted for the planned 
analyses .
Group 1 (n ~ 20): ISL QD + failing baseline ART
Group 2 (n ~ 40): DOR QD + failing baseline ART
Group 3 (n ~ 20): DOR/ISL QD + failing baseline ART
Group 4 (n ~20): Placebo QD + failing baseline ART
Part 2: All participants will be treated with DOR/ISL and OBT for 96weeks (with 
the opportunity to continue DOR/ISL after Week 97). OBT options will be driven by 
[CONTACT_351930]. 
Analysis 
Populat ionsEfficacy: FAS , Per-Protocol Analysis Set ,and Resistance Analysis Subset
Safety : APaT
Primary 
Endpoint(s)Percentage of participants achieving ≥0.5 log 10decrease in HIV- 1 RNA from 
study baseline (Day 1) toDay 8 in the DOR/ISL group
Number of participants experiencing AEs and discontinuing study intervention
due to A Esthrough Week 25 and Week 49 .
Key Secondary 
EndpointsPercentage of participants achieving ≥0.5 log 10decrease in HIV- 1 RNA from 
study baseline (Day 1) to Day 8 in the ISL group and DOR group
Percentage of participants achieving ≥0.5 log 10decrease in HIV- 1 RNA from 
study baseline (Day 1) and Part 2 baseline (Day 8) to Week 25,Week 49 , and 
Week 97
Percentage of participants achieving ≥1.0 log 10decrease in HIV- 1 RNA from 
study baseline (Day 1) to Day 8 , Week 25 ,Week 49 , and Week 97 , and from Part 
2 baseline (Day 8) to Week 25 ,Week 49 , and Week 97
Percentage of participants with HIV -1 RNA <200 copi[INVESTIGATOR_014]/mL , <50 copi[INVESTIGATOR_014]/mL , and 
<40copi[INVESTIGATOR_014]/mL at Week 25, Week 49, and Week 97
Mean change in HIV -1 RNA from study baseline (Day 1) to Day 8, Week 25 ,
Week 49, and Week 97 and from Part 2 baseline (Day 8) to Week 25 ,Week 49, 
and Week 97
Mean c hange in CD4+ T -cell count from study baseline (Day 1) and Part 2 
baseline (Day 8 ) toWeek 25,Week 4 9, and Week 97
Viral resistance- associated substitution s
Number of participants experiencing AEs and discontinuing study intervention 
due to AEs through Week 97.
08BJ8V
PRODUCT:   MK-8591A  95
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Statistical Methods 
for Key Efficacy/
Immunogenicity/ 
Pharmacokinetic 
AnalysesToevaluate the primary efficacy hypothesis , superiority of DOR/ISL compared to 
placebo with respect to the percentage of participants achieving ≥0.5 log 10decrease 
in HIV -1 RNA from study baseline (Day 1) to Day 8 will be calculated using the 
stratified Miettinen and N urminen method with CMH weights (stratified by 
[CONTACT_351931] S ection 6.3.2 ). Superiority will be concluded if the lower 
bound of the multiplicity -adjusted 95% CI for the difference is greater than 0. 
To assess the secondary efficacy objective regardi ng the treatment effect of ISLand 
DOR each compared to placebo with respect to the percentage of participants 
achieving ≥0.5 log 10 decrease in HIV -1 RNA from study baseline (Day 1) to Day 8 , 
the stratified Miettinen and Nurminen method with CMH weights will be used to 
estimate the nominal 95% CI for the differenc e.Similar methodology will be used to 
estimate all other between -group differences and the associated nominal 95% CIs 
with respect to the percentage of participants achieving ≥0.5 log 10decrease and ≥1.[ADDRESS_437733] .
For p articipants with HIV -1 RNA < 200 copi[INVESTIGATOR_014]/mL , those with HIV- 1 RNA <50 
copi[INVESTIGATOR_014]/mL ,and those with HIV -1 RNA < 40copi[INVESTIGATOR_014]/mL at Week 25,Week 49, and 
Week 97, the relevant percentages will be tabulated, and the within -group nominal 
95% CIs will be presented using the Clopper Pearson method.
Statistical Methods 
for Key Safety 
AnalysesSafety and tolerability will be assessed by [CONTACT_14339]. 
Of primary interest will be a descriptive summary of the safety and tolerability of 
DOR/ISL . Safety summaries will be presented by [CONTACT_351932] 8; in 
addition, a pooled summary will be presented for data collected through Week 25 and 
Week 49. The Clopper Pearson method will be used to compute within -group 
nominal 95% CIs for selected binary parameters. CIsfor change from baseline 
parameters will be comput ed based on the t-distribution .
Interim Analyses Three types of interim analyses are planned in this study.
Periodic reviews of safety and efficacy data (conducted by [CONTACT_10981], 
unblinded eDMC ).
Futility assessment .HIV-1 RNA at the end of Part 1 will be tracked and provided 
to an external unblinded statistician to perform the futility assessment . Details on 
futility boundaries arepresented in Section 9.7.2. Ifany of the futility boundaries 
aremet, an ad hoc eDMC review will be triggered andthe eDMC may recommend 
the study be stopped; the eDMC will review the totality of the available data at the 
time of thisad hoc interim analysis before making such a recommendation.
Analysis for testing the primary efficacy hypothesis .This analysis will be 
conducted by [CONTACT_351933] 1 . Results will be shared with the eDMC .
Multiplicity For statistical rigor, a small amount of alpha ( α=0.[ZIP_CODE]) will be set aside for the 
futility assessment and each eDMC evaluation. The Type I error rate for testing the 
primary hypothesis at Day [ADDRESS_437734]:   MK-8591A  96
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor. 
Part 1 of this study ( Day 1 through Day 8) will be conducted as a double -blind study under 
in-house blinding procedures. The official, final database for Part 1 will not be unblinded 
until medical/scientific review has been performed, protocol deviations have been identified, 
and data have been declared final and complete for Part 1. The clinical database and all 
Sponsor personnel will become unblinded to Part 1 intervention assignment at the time of the 
Part 1 analysis, although study participants and site personnel will remain blinded until 
Week 97. Part 2of this study ( Day 8 through Week 97) will be conducted as an open -label
study. Results of Part 2 will be presented in the CSR along with results of Part 1.
PK data may be unblinded earlier for the purpose of preparing a population PK model. A 
separate team from the Sponsor protocol team will be unblinded for the purpose of preparing 
the population PK model. Efficacy and safety data will not be unblinded for the purpose of 
PK analysis. Interim data or results will not be shared with the Sponsor protocol team before 
unblinding of the Sponsor.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study intervention assignment. Randomization will be implemented via an IRT.
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objectives and hypothesis of the study are stated in Section 3.
9.4 Analysis Endpoints
Efficacy and safety endpoints for the study , which will be evalua ted for within- and/or 
between -treatment differences, are listed below, followed by [CONTACT_180650]. 
9.4.1 Efficacy/Pharmacokinetics Endpoints
[IP_ADDRESS] Primary Efficacy En dpoint
An initial description of efficacy measures is pro vided in Section 4.
Percentage of participants with ≥0.5 log 10decrease in HIV -1 RNA from study baseline
(Day 1) to Day 8in the DOR/ISL group
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 
40copi[INVESTIGATOR_014]/mL will be used to measure the HIV -1 RNA level in blood samples obtained at 
each visit. The evaluation of the primary efficacy objective (including the primary efficacy 
08BJ8V
PRODUCT:   MK-8591A  97
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
hypothes is) will be based on the percentage of participants with ≥0.5 log 10decrease in HIV -1 
RNA from study baseline (Day 1) to Day 8 in the DOR/ISL group .  
[IP_ADDRESS] Secondary Efficacy Endpoints
Percentage of participants with ≥0.5 log 10decrease in HIV -1 RNA from study baseline 
(Day 1) to Day 8 in the ISL group and DOR group
Percentage of participants with ≥0.5 log 10decrease in HIV -1 RNA from study baseline
(Day 1) and Part 2 baseline (Day 8) to Week 25, Week 49 , and Week 97
Percentage of participants with ≥1.0 log 10decrease in HIV -1 RNA from study baseline
(Day 1) to Day 8, Week 25 ,Week 49 ,andWeek 97 and from Part 2 baseline (Day 8) to 
Week 25 ,Week 49 , and Week 97
Percentage of participants with HIV- 1 RNA <200 copi[INVESTIGATOR_014]/mL ,<50 copi[INVESTIGATOR_014]/mL ,and 
<40copi[INVESTIGATOR_014]/ mLat Week 25 , Week 49, and Week 97
Antiretroviral activity will also be assessed on the basis of the percentage of participants with 
HIV-1 RNA <200 copi[INVESTIGATOR_014]/mL, <50 copi[INVESTIGATOR_014]/mL, and <40 copi[INVESTIGATOR_014]/mL. These endpoints will be 
estimated at each time point at which HIV-[ADDRESS_437735] at 
Week 25, Week 49, and Week 97 to support the secondary objectives.
Change in HIV -1 RNA from study baseline (Day 1) toDay 8 , Week 25, Week 49 , and 
Week 97 and from Part 2 baseline (Day 8) to Week 25 ,Week 49 , and Week 97
For calculations of change from baseline in HIV -1 RNA, both study baseline (Day 1) and the 
Part 2 baseline (Day 8) HIV -[ADDRESS_437736] measurement within the screening window will be used as 
the study baseline (Day 1) when available, and the last measurement in Part 1 prior to Day 8 
intervention will be used as Part 2 baseline (Day 8) when available . These rules will also 
apply to define the baseline measuremen ts for calculation of change from baseline in CD4+ 
T-cell count, and for other laboratory tests.
Change in CD4 + T -cell Count from study baseline (Day 1) and Part 2 baseline (Day 8)
at Week 25 ,Week 49 , and Week 97
Change in CD4+ T- cell count from baseline will be estimated at each time point at which 
CD4+ T- cell count is collected. A secondary objective will assess the change in CD4+ T- cell 
count from study baseline (Day 1) and Part 2 baseline (Day 8) baseline at We ek 25 ,
Week 49, and Week 97.
Viral resistance -associated substitutions
Participants who meet the definition of confirmed vir emia (defined as having 2 consecutive 
confirmed HIV -1 RNA ≥200 copi[INVESTIGATOR_014]/mL [at least 4 weeks apart] after achieving HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL ), or who discontinue study intervention with HIV-1 RNA ≥200 copi[INVESTIGATOR_014] /mL,or 
who never suppressed (<50 copi[INVESTIGATOR_014]/mL) at Week25, Week 49, and Week [ADDRESS_437737]:   MK-8591A  98
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
RNA >200 copi[INVESTIGATOR_014]/mL ,will be assessed for development of vira l drug resistance. Among 
such participants, those with HIV -1 RNA ≥400 copi[INVESTIGATOR_014]/mL will be included in resistance 
analyses. In addition, anyone for whom available genotypic or phenotypic data show 
evidence of resistance, irrespective of viral load, will also be included in resistance analyses. 
The resistance analysis will summarize the number of participants who have resistance -
associated substitutions associated with each study intervention and will be summarized with 
primary interest at Day 8, Week 25, Week 49, and Week 97 .
[IP_ADDRESS] Pharmacokinetics Endpoints
PK samples collected from all participants as described in the SoA (Section 1.3) and 
Section 8.6 will be used to evaluate PK concentrations of ISLand DOR , and as appropriate, 
PK-efficacy, PK -pharmacodynamic, and PK -AE relationships of ISL or DOR . 
9.4.2 Safety Endpoints
An initial description of safety measures is provided in Section 4.
Adverse Events
The following clinical and laboratory adverse events will be summarized: 1) participan ts with 
at least 1 AE; 2) participants with at least 1 drug- related AE; 3) participants with at least 1 
SAE; 4) participants with at least 1 Grade 3 to 4 AE; 5) participants with at least 1 serious 
and drug -related AE; 6) participants with at least 1 AE whichis both Grade 3 to 4 and drug-
related; 7) participants who discontinued study intervention due to a drug -related and 
nondrug -related AE; and 8) participants with AE(s) leading to death.
Predefined Limits of Change in Laboratory Parameters
For the summa ries of laboratory tests, participants must have both a study baseline (Day 1) or 
Part 2 baseline (Day 8) and postrandomized on- treatment measurement to be included. 
Participants’ laboratory values (based on their most abnormal laboratory test values, in t he 
direction of interest, while on study intervention) will be classified as to whether or not they 
fall outside of the PDLC and are worse in grade (ie , more abnormal in the direction of 
interest) than at baseline. The criteria are adapted from DAIDS table for Grading the Severity 
of Adult and Pediatric Adverse Events, July 2017, Version 2.1 (Appendix 3). A listing of the 
participants who meet the criter ia will also be provided.
These PDLC summaries will be performed for the following:
Day 1 (study baseline) to Day 8 (end of blinded treatment period)
Day 1 (study baseline) to Week 25
Day 1 (study baseline) to Week 49
Day 1 (study baseline) to Week [ADDRESS_437738]:   MK-8591A  99
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Day 8 (Part 2 baseline) to Week 25
Day 8 (Part 2 baseline) to Week 49
Day 8 (Part 2 baseline) to Week 97
Measures of Inflammation
Change from baseline in IL -6, D-dimer, sCD-163, and hs- CRP from study baseline (Day 1) 
to Week 25, Week 49, and Week 97 will be an alyzed. 
9.4.3 Patient -reported Outcome Endpoints
An initial description of patient -reported outcome measures is provided in Section [IP_ADDRESS] of 
the protocol.  
Patient -reported outcomes from each questionnaire at Day 1 ,Week 25,Week 49, and Week 
97will be summarized for participants ≥18 years of age at the time of consent in each 
treatment group. A total FAHI score and score for individual subscales (physical, emotional, 
functional, social, and global well-being as well as cognitive functioning) will be 
summarized.
9.5 Analysis Populations
9.5.1 Efficacy Analysis Population s
Details on the approach to handling missing data for efficacy analyses are provided in 
Section 9.6.1.
[IP_ADDRESS] Full Analysis Set
The FAS will serve as the primary population for the analysis of efficacy data in this study. 
The FAS population consists of all randomized participants who:
Receive at least 1 dose of study intervention
Have baseline data for those analyses that require baseline data
Participants will be include d in the treatment group to which they are randomized for the 
analyses of efficacy data using the FAS population. 
[IP_ADDRESS] Per-protocol Analysis Set 
The secondary analysis set for the efficacy analyses is defined as the PP analysis set, which 
will include all par ticipants in the FAS who have not committed any major protocol 
violations that could impact the assessment of efficacy. Participants will be grouped 
according to the treatment to which they are randomized.
08BJ8V
PRODUCT:   MK-8591A  100
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Participants who are nonadherent to study intervention ( ie, participants with a study 
intervention compliance rate <95%) or who become pregnant will be excluded from the PP 
analysis set .
The additional criteria resulting in exclusion from the PP analysis set will be provided in the 
sSAP and will be identified prior to unblinding and completion of Part 1.
The composition of the PP analysis set will vary by [CONTACT_180651], based on the 
number of participants who satisfy the PP criteria at that timepoint.
[IP_ADDRESS] Resistance Analysis Subset
The resistance analysis subset will include all participants in the FAS with confirmed HIV-1 
RNA ≥400 copi[INVESTIGATOR_014]/mL and any participant for whom available genotypic or phenotypic data 
show evidence of resistance irrespective of viral load.  
9.5.[ADDRESS_437739] 1 dose of 
study intervention is required for inclusion in the analysis of each specific parameter. To 
assess change from baseline, a baseline measurement is also required.  
Details on the approach to handling missing data for safety analyses are provided in 
Section 9.6.2.
9.6 Statistical Methods
This section describes the statistical methods that address the primary and secondary 
objectives. M ethods related to PK analysis and modeling will be described in a separate 
modeling and simulation plan authored by [CONTACT_351934] (QP2). Methods related to other exploratory objectives will be described in 
the sSAP.
9.6.[ADDRESS_437740]:   MK-8591A  101
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
within a window will be used for analyses at a specific time point, unless otherwise specified. 
Results from additional time points beyond Week 97may be summarized, and day -range 
rules for determining the analysis time windows will follow the same pattern where the 
ranges start and end at the midpoints between target days.
Table 7 Definitions of Study Time Points
Treatment 
PhaseTreatment 
PeriodVisit Day-Range Rules Target Daya
Pretreatment Screening Day 1b≤1 1
TreatmentPart 1 Day 8‡≥2and ≤14 8
Part 2Week 3 ≥15 and ≤35 22
Week 7 ≥ 36and ≤70 50
Week 13 ≥71and ≤112 92
Week 19 ≥113and ≤154 134
Week 25 ≥155and ≤217 176
Week 37 ≥218and ≤301 260
Week 4 9 ≥ 302and ≤385 344
Week 61 ≥385and ≤469 428
Week 73 ≥470and ≤553 512
Week 85 ≥554and ≤637 596
Week 97 ≥638and ≤[ADDRESS_437741] to complete 
Day 8 assessment before entering study Part 2 ;Day 8 window will not overlap with start of OBT.
bDay 1 is also referred to as the Study Bas eline. Day 8 is also referred to as the Part 2 Baseline.
FDA Snapshot Algorithm and Missing Data Approaches
There are 3 types of missing values:
Intermittent missing values due to a missed or skipped visit or due to an inadequate
sample;
Nonintermittent missing values due to premature study intervention discontinuations 
because of treatment -related reasons such as, “clinical adverse experience” (regardless of 
relationship to study intervention), “laboratory adverse experience” (regardless of 
relationship to study intervention), and “withdrew based on HIV -1 RNA results”;
Nonintermittent missing values due to premature study intervention discontinuations 
because of other reasons which are not related to treatment such as loss to follow -up, 
protocol violation, participant withdrew consent, etc.
08BJ8V
PRODUCT:   MK-8591A  102
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Three approaches will be used to handle missing values. The primary approach for the 
analysis of binary efficacy endpoints ( eg, assessing percentage of participants with ≥0.5 log 10
or a ≥1.0 log 10decrease in HIV -1 RNA from baseline ;assessing the percentage sof 
participants with HIV -1 RNA <200 copi[INVESTIGATOR_014]/mL, <50 copi[INVESTIGATOR_014]/mL, and <40 copi[INVESTIGATOR_014]/mL) is the 
FDA “snapshot” algorithm [Food and Drug Administration (CDER) 2015] . Under this 
approach, the binary outcomes will be defined according to the following categories:
Success : depending on the analysis and endpoint, success could mean ≥0.5 log10 
decrease in HIV -1 RNA from baseline ;≥1.0 log10 decrease in HIV -1 RNA f rom 
baseline ;HIV-1 RNA <200 copi[INVESTIGATOR_014]/mL, <50 copi[INVESTIGATOR_014]/mL, or <40 copi[INVESTIGATOR_014]/mL . This category 
includes p articipants who have the last available on -treatment HIV -[ADDRESS_437742] analysis window specified in 
Table 7 .
Failure : depending on the analysis and endpoint, failure could mean <0.5 log10 decrease 
in HIV -1 RNA from baseline ;<1.0 log 10decrease in HIV -1 RNA from baseline ;HIV-1 
RNA ≥200 copi[INVESTIGATOR_014]/mL, ≥50 copi[INVESTIGATOR_014]/mL, or ≥40 copi[INVESTIGATOR_014]/mL. This category include s the 
following participants:
1)Those whose last available on -treatment HIV -[ADDRESS_437743] analysis window specified in Table 7
2)Those w hodo not have on- treatment HIV -[ADDRESS_437744] 
analysis window and 
Who discontinue study intervention prior to or in the time point of interest 
analysis window due to lack of efficacy, or
Who discontinue study intervention prior to or in the time point of interest 
analysis window due to reasons other than lack of efficacy andAE/death and 
whose last available on -treatment HIV -1 RNA fails to meet the success criteria .
No Virologic Data in Specified Analysis Time Window: this includes participants who 
do not have on -treatment HIV -[ADDRESS_437745] analysis window 
because of the following:
1)Discontinued study intervention due to A Eor death : this includes participants who 
discontinued study intervention because of an AE or death at any time point from Day 
1 through the analysis window if this resulted in no on -treatment virologic data
during the specified window .
2)Discontinued study intervention for other r easons : this includes participants who 
discontin ued study intervention prior to or in the time point of interest analysis 
window due to reasons other than lack of efficacy or AE/Death (ie,lost to follow -up, 
noncompliance with study intervention, physician decision, protocol deviation, 
withdrawal by [CONTACT_257675], etc.) and have the last available on- treatment HIV -[ADDRESS_437746]:   MK-8591A  103
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
3) On study intervention, but missing data in window : only data in the predefined 
analysis window can be used for the statistical analysis at a given time point for 
participants remaining on study intervention. Participants with HIV -1 RNA results 
outside of this window will be classified as “on study intervention , but missing data 
in window” regardless of the HIV- 1 RNA results.
In Part 2 of the study, any c hange s to the OBT regimen due to lack of efficacy will be 
imputed as failure using the FDA snapshot approach. For participants who become pregnant 
during the study, modification of the OBT will not be imputed as failure unless the change 
was due to lack of efficacy. Additionally, changes to the OBT regimen due to delayed drug 
sourcing or other extraneous circumstances will not be imputed as failure .
For the primary evaluation of superiority based on those with a ≥0.5 log 10decrease in HIV -1 
RNA, the parameter for evaluation is the number of participants classified as “success” 
according to the FDA snapshot algorithm defined above, divided by [CONTACT_351935]. Similar logic will also be used to define the percentage of 
participants with a ≥1.0 log 10decrease in HIV -1 RNA from baseline and the percentage of 
participants with HIV -1 RNA <200 copi[INVESTIGATOR_014]/mL, <50 copi[INVESTIGATOR_014]/mL, and <40 copi[INVESTIGATOR_014]/mL in 
accordance with the relevant secondary endpoints. It is noted that those classified as having 
no data in the specified analysis window will contribute to the denominator (as these 
participants are included in the FAS), but are effectively treated as failures under this 
approach as they do not contribute to the numerator.  
A second approach, the missing data treated as treatment failure (M=F) approach, will be 
performed as a sensitivity analysis. Under this approach, participants who 1) have at least one 
on-treatment HIV -[ADDRESS_437747] available on -treatment measurement within the window 
meeting the success criterion for the endpoint will be classif ied as “success” at the time point 
of interest, OR 2) are on study intervention and have no HIV -[ADDRESS_437748] both the 
immediately preceding and immediately subsequent on- treatment HIV -1 RNA measurements 
meeting the success criterion will be classified as “success” at the time point of interest. 
Participants with other reasons for missi ng data will be classified as a “failure ”at the time 
point of interest. 
A third approach, the Observed Failure (OF) approach will also be performed as a sensitivity 
analysis for these efficacy endpoints. Under this approach, participants with nonintermittent 
missing data who prematurely discontinue study intervention due to lack of efficacy or who 
discontinue study intervention for other reasons and are failures at the time of study 
intervention discontinuation are considered as failures at time points thereafter. Participants 
who discontinue study interve ntion for reasons other than lack of efficacy and who are not 
failures at the time of study intervention discontinuation will be excluded from the analyses 
at subsequent time points. Participants with intermittent missing data will be considered as 
success es if both the immediately preceding and immediately subsequent on -treatment HIV -1 
RNA measurements meet the success criterion; all other intermittent missing results will be 
imputed as failures.
08BJ8V
PRODUCT:   MK-8591A  104
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
In accordance with the FDA snapshot algorithm and to provide a full pi[INVESTIGATOR_351894] 8, Week 25, Week 49, and Week 97, participants will be classified as either 
“success”, “failure”, or as having “no virologic data within the time window”. Participants 
with no virologic data within the time window will be further classified by [CONTACT_48933]:  1) 
discontinued study intervention due to AE or death, 2) discontinued study intervention for 
other reasons (includes withdrawal of consent, loss to follow -up, moved, etc.), or 3) on study 
intervention, but missing data in window.
Percentag e of participants achieving ≥0.5 log 10or ≥1.0 log 10decrease in HIV -1 RNA 
from study baseline (Day 1) and Part 2 baseline (Day 8)
For the evaluation of the primary hypothesis , superiority of DOR/ISL compared to placebo
with respect to the percentag e of participants achieving ≥0.5 log 10decrease in HIV-1 RNA
from study baseline (Day 1) to Day 8 will be calculated using the Miettinen and Nurminen 
method with CMH weights (stratified by [CONTACT_351936] S ection 6.3.2) . Superiority 
will be concluded if the lower bound of the multiplicity -adjusted 95% CI for the difference 
(DOR/ISL minus placebo) is greater than 0.
To assess the secondary objective regarding estimation of the treatment effect of ISL
monotherapy and DOR monotherapy compared to placebo with respect to the percentage of 
participants achieving ≥0.5 log 10decrease in HIV -1 RNA from study baseline (Day 1) to 
Day 8, the M iettinen and Nurminen method with CMH weights will also be used to estimate 
the nominal 95% CI for the treatment difference ( ISLminus placebo , DOR minus placebo ). 
Similar methodology will be used to estimate between -group differences and the associated 
nominal 95% CIs for the percentage of participants achieving ≥0.5 log 10decrease from Part 2 
baseline (Day 8) to Week 25, Week 49 , and Week 97 , as well as for the per centage of 
participants achieving ≥1.0 log 10decrease from study baseline (Day 1) to Day 8, Week 25, 
Week 49, and Week 97, and from Part 2 baseline (Day 8) to Week 25, Week 49, and Week 
97.
It is noted that the enrollment into Stratum 2and Stratum 3 (as d efined in Section 6.3.2 )are 
likely to be low. I f there are fewer than 5 participants randomized into one of these strata 
(which would be a complete randomization block) , Strata 2 and 3 will be combined for the 
purposes of conducting all stratified analyse s. If after combining Strata 2 and 3 there are still 
<2 participants in a treatment group, the unstratified Miettinen and Nurminen method would 
be used instead for that analysis.
Percentage sof participants with HIV- 1 RNA <200 copi[INVESTIGATOR_014]/mL , <50 copi[INVESTIGATOR_014]/mL ,and 
<40copi[INVESTIGATOR_014]/mL
For the secondary endpoints associated with Week 25, Week 49, and Week 97 , the relevant 
percentages will be tabulated and the within- group 95% CIswill be presented using the 
Clopper Pearson method . Since all participants will have received DOR/ISL , these r esults 
will also be pooled across the original treatment groups at Week 25, Week 49, and Week [ADDRESS_437749]:   MK-8591A  105
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Mean c hange in HIV -1 RNA from study baseline (Day 1) and Part 2 baseline (Day 8)
Change in HIV -1 RNA from study baseline (Day 1)toDay 8, Week 25 ,Week 49, and Week 
97, and from Part 2 baseline (Day 8) to Week [ADDRESS_437750] analysis window specified in Table 7 in order 
to be included in the analyses of the mean change from baseline in HIV- RNA. Supportive 
analyses will also be provided using the LOCF method to account for missing data.
Mean c hange in CD4+ T -cell count from study baseline (Day 1) and Part 2 b aseline
(Day 8) to Week 25 ,Week 49 , and Week 97
Change from baseline in CD4+ T- cell count will be summarized at each time point at which 
CD4+ T- cell count is collected with primary interests at W eek25,Week 49, and Week 97.
Descriptive statistics will be provided including point estimates and corresponding 
confidence intervals based on thet-distribution. Change from baseline in CD4+ T- cell count 
will be summarized by [CONTACT_9524] [ADDRESS_437751] analysis window specified in Table 7 in order 
to be included i n the analyses of the mean change from baseline in CD4+ T -cell count. 
Supportive analyses will also be provided using the baseline observation carried forward 
(BOCF )method to account for missing data.
Viral resistance -associated substitutions
The number o f participants in the resistant analysis subset with ge notypic and/or phenotypic 
resistance to each study intervention will be summarized for each treatment group with 
primary interests at Day 1, Day 8, Week 25, Week 49, and Week 97.
Unblinding of Participants During the Study
Given the objective nature of the efficacy endpoint HIV -1 RNA, if a participant becomes 
unblinded during the study for any reason not related to efficacy (eg, due to a safety event, 
acute infection/reactivation of HBV or pregn ancy that requires unblinding, or accidental 
unblinding), such participants will not be treated as treatment failures in the primary efficacy 
analyses on the FAS population due to the unblinding alone. If the unblinding is due to acute 
infection/reactivation of HBV or pregnancy tha trequires discontinuation of study 
intervention or if the clinical management of the HBV requires the addition of a concomitant 
therapy that is also active against HIV -1, such participants will be censored from that point 
forward and will be handled in the primary efficacy analyses according to the FDA snapshot 
algorithm classification rules.
08BJ8V
PRODUCT:   MK-8591A  106
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437752] and will be 
handled in the primary efficacy analyses following the FDA snapshot algorithm classification 
rules.
Table 8 summarizes the key efficacy analyses of the study.
Table 8 Analysis Strategy for Key Efficacy Variables
Endpoint/Variable 
(Description, Time Point)Primary vs. 
Supportive 
ApproachStatistical Methoda Analysis 
PopulationMissing 
Data 
Approach
Percentage of participants 
achieving ≥0.5 log 10decrease 
in HIV -1 RNA from study 
baseline (Day 1) to Day 8, 
Week 25 ,Week 49 , and Week 
97, and from Part 2 baseline 
(Day 8) to Week 25 ,Week 49 , 
and Week 97P M&N method with CMH 
weightsFAS Snapshotb
S M&N method with CMH 
weightsFAS M=F
S M&N method with CMH 
weightsPP OF
Percentage of participants 
achieving ≥1.0log 10decrease 
in HIV -1 RNA from study 
baseline (Day 1) to Day 8, 
Week 25 ,Week 49 , and Week 
97, and from Part 2 baseline 
(Day 8) to Week 25 ,Week 49 , 
and Week 97P M&N method with CMH 
weightsFAS Snapshotb
S M&N method with CMH 
weightsFAS M=F
S M&N method with CMH 
weightsPP OF
Percentage of Participants with 
HIV-1 RNA < 200 copi[INVESTIGATOR_014]/mL ,
those with HIV- 1 RNA < 50 
copi[INVESTIGATOR_014]/mL , and those with 
HIV-1 RNA <40 copi[INVESTIGATOR_014]/mL at 
Week 25 , Week 49, and Week 
97P Clopper Pearson FAS Snapshotb
S Clopper Pearson FAS M=F
S Clopper Pearson PP OF
Change in HIV -1 RNA from 
study baseline (Day 1) to Day 
8, Week 25, Week 49 , and 
Week 97 , and from Part 2 
baseline (Day 8) to Week [ADDRESS_437753]:   MK-8591A  107
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Endpoint/Variable 
(Description, Time Point)Primary vs. 
Supportive 
ApproachStatistical Methoda Analysis 
PopulationMissing 
Data 
Approach
Change in CD4+ T -cell count 
from study baseline (Day 1) 
and Part 2 baseline (Day 8) to 
Week 25 ,Week 49 , and Week 
97P Within -group summaries 
using the t- distributionFAS DAO
S Within -group summaries 
using the t -distributionFAS BOCF
ANCOVA=analysis of covariance; BOCF=Baseline Observation Carried Forward; CMH=Cochran -Mantel- Haenszel; 
DAO=Data as Observed; FAS=Full Analysis Set; HIV-1 =human immunodeficiency virus Type 1 ; LOCF=Last 
Observation Carried Forward; M=F=Missing=Failure; OF=Ob served Failure; P=Primary approach; PP=Per- Protocol 
Analysis Set; RNA=ribonucleic acid; S=Supportive approach .
aThe Miettinen and Nurminen method with CMH weights will be stratified by [CONTACT_351937] 
6.3.[ADDRESS_437754] will be a descriptive summary of the safety and tolerability of DOR/ISL . 
Upon the completion of Part 1, safety data from Day 1 through Day 8 will be summarized by 
[CONTACT_1570] . At Week 25 , Week 49, and Week 97, safety data will be summarized by 
[CONTACT_351938] ; the safety data from Day 8 in the 
placebo group and the safety data from Day 1 in all other treatment groups will be pooled for 
these summaries .A summary of the a nalysis strategy for the safety parameters is provided in
Table 9 . The Clopper Pearson method will be used to compute within -group 95% CIs for 
selected binary parameters. C onfidence intervals for change from baseline parameters will be 
computed using the t -distribution.
Missing values will be handled using the DAO approach, that is, any participant with a 
missing value will be excluded from the analysis. C hange from baseline summaries require a 
baseline value. B aseline measurements are defined as either the Day 1 value (study baseline) 
or Day 8 value (Part 2 baseline) for each participant , depending on the analysis/summary . In 
the rare event when study baseline data are missing, the value obtained at the most recent 
Screening V isit will be used as the Day 1 baseline. If no pretreatment result is available, that 
participant will not be included in the summary. Similarly, if no Day 8 value is available, that 
participant will not be included in summaries involving the Part 2 baseline. 
For participants who b ecome pregnant during the study, safety parameters assessed during 
the pregnancy period (estimated date of conception to date of conclusion of the pregnancy) 
may be summarized separately from the primary and secondary safety analyses. For 
continuous measures that are considered to be Tier 2 events, data collected after the 
estimated date of conception will be excluded from the analyses. Infant safety data will be 
reported separately. Additional details on how pregnancy and infant data will be handled in 
safety analyses will be provided in the sSAP and/or CSR.
08BJ8V
PRODUCT:   MK-8591A  108
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 9 Analysis Strategy for Safety Parameters
Safety ParametersWithin -Group 
95% CIaDescriptive 
Statistics
The percentage of participants with an AE in each of the following 
categories: one or more AE(s); drug -related AE(s), serious AE(s), Grade 
3 to 4 AE(s), AE(s) which are both drug -related and serious, AE(s) 
which are both Grade 3 to 4 and drug -related, AE(s ) [drug -related and 
nondrug -related] leading to discontinuation of study intervention, and 
AE(s) leading to death 
The percentage of participants with a cardiac SAE
Specific AEs (preferred terms), SOCs, or PDLCs occurring with an 
incidence ≥10% in one of the groups
Change from baseline in markers of inflammationX X
Specific AEs (preferred terms), SOCs, or PDLCs occurring with an 
incidence < 10% in all groups
Change from baseline in laboratory measurements and vital signsX
AE(s)=adverse event(s); CI=confidence interval; PDLC=Pre defined Limit of Change ; SAE=serious adverse event; 
SOC=System Organ Class; X=results will be provided.
a95% CIs will be calculated using the Clopper Pearson method for binary parameters and the t-distribution for change 
from baseline measures.
9.6.3 Summaries of Baseline Characteristics, Demographic, and other Analyses
[IP_ADDRESS] Demographic and Baseline Characteristics
The comparability of the treatment groups for each relevant demographic and baseline 
charact eristic will be assessed by [CONTACT_113827]/or graphs . No statistical hypothesis 
tests will be performed on these characteristics. The number and percentage of participants 
screened andrandomized andthe primary reasons for screening failure and discontinuation 
will be displayed. Demographic variables (eg, age, gender, race, region, etc.), baseline 
characteristics (eg, prior AR Tclass exposure, known resistance [both phenotypic and 
genotypic ]to all drugs in class) , primary and secondary diagnoses, a nd prior and concomitant 
therapi[INVESTIGATOR_351895].
9.7 Interim Analyses
There are possibly 4 types of analysis that will be performed at interim time points 
(Section 9.7.1 to Section 9.7.4 ). Study enrollment is likely to be ongoing at the time of some 
interim analyses. B linding to Part [ADDRESS_437755]:   MK-8591A  109
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
modifications to the design of the protocol or discontinuation of the study, this executive 
committee (and potentially other limited Sponsor personnel) may be unblinded to results at 
the treatment level in order to act on these recommendations. The extent to which individuals 
are unblinded with respect to results of interim analyses will be documented by [CONTACT_351939]. Additional logistical details will be provided in the eDMC Charter.
Treatment -level results from the interim analyses will be provided to the eDMC by [CONTACT_351940] 1 
analysis. P rior to final study unblinding, the external unblinded statistician will not be 
involved in any discussions regarding modifications to the protocol, statistical methods, 
identification of protocol deviations, or data validation efforts after the interim analyses. 
Following the unblinding of the Sponsor after Part 1 analysis, the responsibility for providing 
subsequent interim analysis results to t he eDMC may transfer to unblinded Sponsor 
personnel.
9.7.1 Safety Monitoring
A periodic review of safety and efficacy data will be conducted by [CONTACT_10981], 
unblinded, eDMC. A description of the structure and function of the eDMC, along with the 
timing and content of the review, will be outlined in the DMC charter. 
9.7.2 Futility Monitoring
HIV-1 RNA at Day 8 (the end of Part 1) will be tracked and provided to an unblinded 
statistician on an ongoing basis to perform futility assessment. Table 10 lists the futility 
boundaries corresponding to each possible sample size in the DOR/ISL group. For example, 
based on the futility boundary with a sample size of up to and including 20, if 12 or more 
participants who receive DOR/ISL in the double -blind trea tment period (Part 1) fail to 
achieve ≥0.5 log 10decline in HIV- 1 RNA at the end of Part 1, an eDMC review will be 
triggered. This futility criterion corresponds to an OFrate of 60%. If such a futility analysis 
is triggered, the results will be shared wit h the eDMC who will make recommendations for 
discontinuation of the study or protocol modifications to the study Executive Oversight 
Committee ( EOC ). The Sponsor will not be informed if an eDMC review is triggered due to 
meeting the futility boundaries.
08BJ8V
PRODUCT:   MK-8591A  110
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 10 Futility Boundary That Would Trigger Ad Hoc eDMC Review C orresponding to 
Current Possible S ample Size in DOR/ISL G roup
Current Sample Size 
in DOR/ISL GroupFutility Boundary 
(Number of Participants 
with <0.5 log 10Decline in 
HIV -1 RNA at Day 8)Observed Failure 
Rate (<0.5 log 10
Decline in HIV- 1 
RNA)Observed Rate with 
≥0.5 log 10Decline in 
HIV -1 RNA
≤20 12 ≥60.0% ≤40.0%
21 12 57.1% 42.9%
22 13 59.1% 40.9%
23 13 56.5% 43.5%
24 14 58.3% 41.7%
25 14 56.0% 44.0%
26 15 57.7% 42.3%
27 15 55.6% 44.4%
28 16 57.1% 42.9%
29 16 55.2% 44.8%
30 17 56.7% 43.3%
DOR=doravirine; HIV -1=human immunodeficiency virus Type 1; ISL=islatravir; RNA=ribonucleic acid .
9.7.3 Interim Analysis for Potential Marketing Authori zation Application
Prior to the formal unblinded IA in Section 9.7.4, a blinded interim data summary may be 
conducted to support any potential marketing authorization application of DOR/ISL . In such 
an event, blinded efficacy and safety summaries from Part [ADDRESS_437756]:   MK-8591A  111
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
If the study is stopped early, the CSR will include all available data up to and including the 
close -out visits. This appr oach to include all available information is in line with the ICH -E9 
guideline .
9.8 Multiplicity
As noted in Section 9.7, an eDMC will convene at routine intervals to monitor efficacy, 
safety ,and tolerability. There is no intention of stoppi[INVESTIGATOR_351896] t o positive efficacy at 
any of these reviews. Nevertheless, since unblinded summaries of HIV-1 RNA values may 
be included in these reviews, a small amount of alpha (α=0.00 001) will be allocated for each 
of these looks, purely for statistical rigor. An allow ance will be made such that a total of up 
to 5 of these unblinded eDMC reports (including the futility assessment if the eDMC review 
is triggered) may be presented prior to the evaluation of the primary efficacy hypothesis
(DOR/ISL vs. placebo) at Day 8.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Efficacy Analyses
[IP_ADDRESS] Futility Criteria and Superiority Testing
All the calculations in this section are conservatively based on a sample size of 20 in the 
DOR/ISL group. As the sample size may be larger, these calculations are expected to 
represent the minimum power.  
As described in Section 9.8, the alpha level used in the final analysis (corresponding to the 
multiplicity -adjusted 95% CI) will account for the actual num ber of eDMC evaluations 
conducted in the study. For the purposes of the power calculations, 5 eDMC evaluations are 
assumed, leaving α=0.[ZIP_CODE] (one -sided) available for the final analysis of the Part 1 
hypothesis .
The power calculation sshown in Table 11 incorporate the futility stoppi[INVESTIGATOR_1877]. Based on the 
futility rule, the study may stop if 12 or more out of 20 partici pants who receive DOR/ISL in
the double -blind treatment period (Part 1) fail to achieve ≥0.5 log 10decline in HIV- 1 RNA at 
the end of Part 1. Table 11displays t he probability of this study meeting the stoppi[INVESTIGATOR_1877] ,
andthe overall power to demonstrate superiority of DOR/ISL compared to placebo under a 
variety of response assumptions. For example, if the true response rate for DOR/ISL
recipi[INVESTIGATOR_301775] 1 is 80%, there is a 0.01 % chance of meeting the futility rule. In addition, if 
the true response rate for the placebo recipi[INVESTIGATOR_283289] 3%, the probability of demonstrati ng
superiority of DOR/ISL compared to placebo at Day 8 is > 99.9%.
08BJ8V
PRODUCT:   MK-8591A  112
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 11 Probability of Meeting Futility Criteria and the O verall S tudy Power for Various 
Underlying True Response Rates Assuming the Response R ate is 3% or 10% for Placebo 
Recipi[INVESTIGATOR_351897] (N=20)True Response 
Rate for DOR/ISL
Recipi[INVESTIGATOR_840] (N=20)Probability of Meeting 
Futility CriteriaaProbability O f Demonstrating 
Superiority Of DOR/ISL Over 
Placebo A t Day 8b
3% 30% 88.7% 7.3%
40% 59.6% 33.9%
50% 25.1% 71.3%
60% 5.6% 93.6%
70% 0.5% 99.4%
80% 0.01% >99.9%
90% <0.001% ≥99.9%
10% 30% 88.7% 3.9%
40% 59.6% 24.1%
50% 25.1% 60.9%
60% 5.6% 89.1%
70% 0.5% 98.7%
80% 0.01% >99.9%
90% <0.001% ≥99.9%
DOR=doravirine; HIV -1=human immunodeficiency virus Type 1 ; ISL=islatravir; RNA=ribonucleic acid.
aCalculated using the binomial distribution. Under the minimum sample size of 20, t he cutoff for futility is 12 
participants, meaning if 12 or more out of 20 participants who receive DOR/ISL in the double -blind treatment period 
(Part 1) fail to achieve ≥0.5 log 10decline in HIV -1 RNA at the end of Part 1, the study may be stopped.
bOverall power to demonstrate superiority of DOR/ISL compared to placebo are calculated based on one -sided 
α=0.[ZIP_CODE].
[IP_ADDRESS] Evaluation of the Primary Hypotheses
This section pr ovides further description of the power calculations for the primary analysis of 
superiority of DOR/ISL over placebo . In contrast to the power shown in Table 11, the power 
calculations shown in Table 12do not account for the futility analysis and instead assume the 
futility criteria are not met . 
The study power of demonstrating superiority of DOR/ISL over placebo under various 
assumptions is presented in Table 12, with assumed true response rates ranging from 70% to 
90% for DOR/ISL and rates from 3% to 25% for placebo. For example, if the true rate of 
DOR/ISL participants achieving a ≥0.5 log 10decrease in HIV -1 RNA is 83%, and the 
corresponding true rate in placebo recipi[INVESTIGATOR_283289] 3%, this study has >99.9% power to 
demonstrate superiority of DOR/ISL over placebo .
08BJ8V
PRODUCT:   MK-8591A  113
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 12 Power (%) to Establish Superiority†Under Various Response Rate Assumptions 
(20DOR /ISLRecipi[INVESTIGATOR_842] 20 Placebo Recipi[INVESTIGATOR_840])
True Response Rate for 
Placebo Recipi[INVESTIGATOR_351898]/ISL Recipi[INVESTIGATOR_840]
70% 78% 83% 88% 90%
3% >99.9% > 99.9% >99.9% >99.9% >99.9%
10% 99.2% >99.9% > 99.9% > 99.9% >99.9%
20% 92% 98.2% 99.5% >99.9% > 99.9%
25% 84% 95% 98.3% 99.6% 99.8%
DOR=doravirine; ISL=islatravir.
†Overall power to demonstrate superiority of DOR/ISL compared to placebo is calculated based on one -sided α=0.[ZIP_CODE].
9.9.[ADDRESS_437757] one AE for a given incidence rate is 
summarized in Table 13 for a variety of underlying AE incidence rates. For example, in a 
treatment group with 20 participants (such as Group 1 in the double -blind treatment period 
[Part 1]), if the underlying incidence of a particular AE is 10%, there is a 87.8% chance of 
observ ing at least 1 participant with that particular AE among 20 participants receiving 
DOR/ISL through Day 8.
Table [ADDRESS_437758] One Event in a 
Treatment Group of Size 
N=20Probability of Observing 
At Least One Event in a 
Treatment Group of Size 
N=40Probability of Observing 
AtLeast One Event in a 
Treatment Group of Size 
N=100
0.1% 2.0% 3.9% 9.5%
0.5% 9.5% 18.2% 39.4%
1.0% 18.2% 33.1% 63.4%
3.0% 45.6% 70.4% 95.2%
5.0% 64.2% 87.1% 99.4%
10.0% 87.8% 98.5% >99.99 %
AE=adverse event.
The estimate and associated upper bound of the 95% CI for the underlying percentage of 
participants with an AE given various hypothetical observed number of participants with the 
AE are provided in Table 14for treatment groups of varying size. These calculations are 
08BJ8V
PRODUCT:   MK-8591A  114
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437759] binomial method proposed by [CONTACT_93325] [Clopper, C. J. and 
Pearson, E. S. 1934] .  
Table 14 Estimate of Incidence of AEs and 95% Upper Confidence Bound Based on 
Hypothetical Numbers of Participants with AEs
Sample SizeHypothetical Number 
of Participants with 
Adverse EventObserved AE In cidence 
Rate95% CI Upper 
Bounda
200 0% 13.9%
1 5% 24.8%
2 10% 31.7%
3 15% 37.9%
4 20% 43.7%
5 25% 49.1%
400 0% 7.2%
1 2.5% 13.2%
2 5% 16.9%
4 10% 23.7%
8 20% 35.6%
12 30% 46.5%
15 37.5% 54.2%
1000 0% 2.9%
1 1% 5.4%
2 2% 7.0%
4 4% 9.9%
8 8% 15.2%
12 12% 20.0%
15 15% 23.5%
20 20% 29.2%
AE=adverse event; CI=confidence interval
aBased on the two -tailed exact confidence interval for a binomial proportion [Clopper, C. J. and Pearson, 
E. S. 1934] . In the 0 event case, the 95% CI is one- sided (α=0.05 all in the upper tail).  
08BJ8V
PRODUCT:   MK-8591A  115
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437760] (with a n ominal 95% Miettinen and Nurminen CI unadjusted 
for stratification factor s)for the primary endpoint will be calculated within each category of 
the following classification variables:
Age group (<18, ≥18 years of age )
Sexat birth
Gender identity
Race (White, Black, Asian, Other) 
Region (North America, South America, Europe, Asia, Africa, etc.) 
Ethnicity (Hispanic/Latino, not Hispanic/Latino)
Randomization stratum
Number of fully active and available drugs in the OBT
Baseline CD4 + T-cell count category ( 50 to <200 cells/mm3, <50 cells/m m3)
Baseline HIV- 1 RNA (≤100,000, > 100,000 copi[INVESTIGATOR_014]/mL)
Baseline NNRTI mutations
Baseline NRTI mutation s
The snapshot approach will be used to handle missing values in these subgroup analyses.
9.11 Compliance (Medication Adherence)
In this study, as part of the routine recording of the amount of study intervention taken by 
[CONTACT_351941], the number of tablets or capsules
remaining in study packaging will be counted and reviewed at regular intervals. These 
results will be used to calculate participant compliance.
For the main analysis of compliance in this study, a day within the study wil l be considered 
an “OnTherapy ” day if the participant takes at least 1 tablet or capsule from any bottle 
provided for this study.
The “Number of Days Should be On Therapy” is the total number of days from Day [ADDRESS_437761] dose of study inte rvention for each participant. As such, the “Number of Days 
Should be On Therapy” will be the number of days from Day [ADDRESS_437762]:   MK-8591A  116
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
For partici pants who discontinue study intervention early (ie, prior to completion of the study 
at Week 97), the “Number of Days Should be O n Therapy” will be the number of days from 
Day 1 to the date of discontinuation of study intervention.
For each participant, pe rcent compliance will then be calculated using the following formula:
Summary statistics will be provided on percent compliance by [CONTACT_180666].  
9.12 Extent of Exposure
The extent of exposure to study therapy for all randomized and treated participants will be 
summarized. The number of participants exposed to each intervention for defined periods of 
time will be listed, along with a summary of the mean (range) duration participants were 
exposed to each intervention . 
08BJ8V
PRODUCT:   MK-8591A  117
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_437763] for Clinical Trials
[COMPANY_006] Sharp &Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Tria ls
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing ,and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design and conduct of clinical trials . In all cases, M SD clinical trials will be con ducted 
in compliance with local and/or national regulations , and International Council for Harmonisation Good Clinical 
Practice ( ICH-GCP) ,and also in accordance with the ethical principles that have their origin in the Declaration of 
Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g. , contract research organizations, 
collaborative research efforts ). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Co nduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. Alternatively, M SD
may conduct outco mes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e. , participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Pr actice
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per M SD policies and procedures, if fraud, 
08BJ8V
PRODUCT:   MK-8591A  118
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
scientific/research misc onduct or seri ous GCP -non-compliance is suspected, the issues are investigated. 
When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review 
committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish theprimary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing ;in such cases, publication of result s may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_111965] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutiona lReview Board [IRB ]/Independent Ethics 
Committee [IEC])
All protocols and pr otocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form , investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eli minate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval.  
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national r egulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. A t 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], o nly the investigator, Sponsor ( or individuals acting on behalf of MSD), ethics committee, and/or regulatory 
authorities will have access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
08BJ8V
PRODUCT:   MK-8591A  119
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible partic ipants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SD,and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g. , to scientific meetings, investigator mee tings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commitment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these et hical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to determ ine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_941] S ponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) furth er agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
08BJ8V
PRODUCT:   MK-8591A  120
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437764] be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_351942] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality wit h such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this pro tocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_296489]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496].
10.1.4 Committees Structure
[IP_ADDRESS] Scientific Advisory Committee (SAC)
This study was d eveloped in collaboration with a SAC. The SAC is comprised of both 
Sponsor and non -Sponsor scientific experts who provide input with respect to study design, 
interpretation of study results, and subsequent peer -reviewed scientific publications.
08BJ8V
PRODUCT:   MK-8591A  121
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
[IP_ADDRESS] Executive Oversight Committee
The EOC is comprised of members of Sponsor Senior Management. The EOC will receive 
and decide upon any recommendations made by [CONTACT_113836].
[IP_ADDRESS] External Data Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants (Section 9.7 [Interim 
Analys es]) and recommend to the EOC whether the study should continue in accordance 
with the protocol.
Specific detail s regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
ofDMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
10.1.[ADDRESS_437765] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its re sults are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
08BJ8V
PRODUCT:   MK-8591A  122
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437766] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP :Consolidated Guideline and other generally 
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations tha t govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
provi ders, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
08BJ8V
PRODUCT:   MK-8591A  123
PROTOCOL/AMENDMENT NO.:   [ADDRESS_437767] maintain accurate documentation (sour ce data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be prom ptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_351943], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants' documented informed consent pertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that includ e allpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or th e discrepancies must be explained. The 
08BJ8V
PRODUCT:   MK-8591A  124
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee ma y stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s) .
08BJ8V
PRODUCT:   MK-8591A  125
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 15will be perfo rmed by [CONTACT_2237].
Local laboratory results are only required in the event that the central laboratory results 
are not available in time for either study intervention administration and/or response 
evaluation. I f a local sample is required, it is important that the sample for central 
analysis is obtained at the same time. Additionally, if the local laboratory results are used 
to make either a study intervention decision or response evaluation, the results must be
entered into the CRF.
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
-Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
-Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the absence 
of pregnancy at any time during the subject's participation in the study.
Table 15 Protocol -required Laboratory Assessments
Laboratory Assessments Parameters
Hematology Platelet Count 
Red blood cell ( RBC) Count
Hemoglobin
Hematocrit
RBC Indices:
Mean corpuscular volume ( MCV )
Mean corpuscular hemoglobin ( MCH )
MCH concentration
Red cell distribution width (RDW)
White blood cell ( WBC )count with Differential (%; absolute) :
Neutrophils , total
Lymphocytes
Monocytes
Eosinophils
Basophils
08BJ8V
PRODUCT:   MK-8591A  126
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Laboratory Assessments Parameters
CD4 + T-cell count/TBNK 
PanelT-cell, B -cell and Natural Killer cell panel includes:
CD3+ Percent
CD3+ Value/Absolute Count
CD3+CD4+ Percent
CD3+CD4+ Value/Absolute Count
CD3+CD8+ Percent
CD3+CD8+ Value/Absolute Count
CD3 -CD19+ Percent
CD3 -CD19+ Value/Absolute Count
CD16+CD56+ Percent
CD16+CD56+ Value/Absolute Count
CD3+CD4+CD8+ Percent
CD3+CD4+CD8+ Value/Absolute Count
CD4/CD8 Ratio
Coagulation Prothrombin time /International normalized ratio (INR )
Chemistry
(nonfasting)Alanine Aminotransferase (ALT)
Albumin
Alkaline Phosphatase
Amylase
Aspartate Aminotransferase (AST)
Bicarbonate
Blood Urea Nitrogen (BUN)
Calcium
Chloride
Creatinine
Creatine Kinase
Glucose ( nonfasting)
Lipase
Magnesium
Phosphorous
Potassium
Sodium
Total bilirubin
Direct bilirubin
Indirect bilirubin
Total Protein
08BJ8V
PRODUCT:   MK-8591A  127
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Laboratory Assessments Parameters
Additional c hemistry at 
fasting visit (fasting for at 
least 8h)Glucose [fasting]
High -density lipoprotein (HDL -C)
Low-density lipoprotein (LDL -C)
Triglycerides (TGs)
Total Cholesterol (TC)
Non-HDL -C
Renal Function Creatinine clearance will be measured by [CONTACT_3158] -Gault (see Appendix 8) 
and e stimated glomerular filtration rate ( eGFR )by [CONTACT_303366] ( MDRD )equation
Routine Urinalysis Blood
Bilirubin
Glucose
Ketones
Leukocyte s
Nitrite
pH
Protein
Specific gravity
Urobilinogen
Pregnancy Testing Serum β human chorionic gonadotropin (β hCG) test (as needed for 
WOCBP)
Urine β human chorionic gonadotropin (β hCG) test (as needed for 
WOCBP)
Hepatitis Serology (at 
Screening)Hepatitis B virus surface antigen (HBsAg)
Hepatitis B virus (HBV) surface antibody
Anti-HBc (hepatitis B core antibody)
HBV DNA 
Hepatitis C antibody plasma
HCV RNA (hepatitis C virus quantitative test)
HIV-1 Serology HIV-1/-2 antigen/antibody screen
Virology HIV-1 viral RNA quantification (Real time polymerase chain reaction 
[PCR ])
HIV-1 drug resistance
Proviral DNA Resistance Testing (GenoSure Archive)
Inflammatory Markers D-dimer
IL-[ADDRESS_437768]:   MK-8591A  128
PROTOCOL/AMENDMENT NO.:   019 -09  
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08BJ8V
PRODUCT: MK-8591A  129
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Table 16 Blood Volume by [CONTACT_351944] -1 RNA 
ConfirmationRepeat
HIV -1 RNA 
ConfirmationaIntervention End of Treatment
Double -
Blind 
(Part 1)Open -Label
(Part 2)
Viremia 
Confirmation
CD4+ T -cell / 
Lymphocyte 
Confirmation
Early D/C of 
Treatment
CD4+ T-cell / 
Lymphocyte 
Monitoringd
End of
Treatment F/U
Scheduled 
Day/Week
Screen
≤10 days prior 
to Day 17-14 days after 
Visit 2
Day 1 
(Fasting)
Day 8 
(Fasting)
TW3
TW7
Unscheduled
TW19
TW25
TW37
TW49 
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Unscheduled
Unscheduled
Unscheduled
Unscheduled
Unscheduled
Blood Parameter Approximate Blood Volume (mL)
Hematology 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Chemistry 
(includes serum 
pregnancy at 
Screening and 
Early 
Discontinuation)6 6 6 6 6 6 6 6 6 6 6 6 6
Renal FunctionNA; eGFR 
by [CONTACT_351945] (β -hCG; 
WOCBP only)Included 
in 
Chemistry
Fasting 
Lipi[INVESTIGATOR_805]/GlucoseIncluded 
in 
Chemistry
PT/INR 2.7
HIV-1/2 and 
hepatitis serologyb 6
HBV DNA 6 6
HCV RNA 6 6
HIV-1 viral RNA 
Quantification 
(Real Time PCR)6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
HIV Confirmation 
Geenius1
CD4+ T -cell 
count /TBNK Panel4 [ADDRESS_437769]: MK-8591A  130
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Study Period ScreeningHIV -1 RNA 
ConfirmationRepeat
HIV -1 RNA 
ConfirmationaIntervention End of Treatment
Double -
Blind 
(Part 1)Open -Label
(Part 2)
Viremia 
Confirmation
CD4+ T -cell / 
Lymphocyte 
Confirmation
Early D/C of 
Treatment
CD4+ T-cell / 
Lymphocyte 
Monitoringd
End of
Treatment F/U
Scheduled 
Day/Week
Screen
≤10 days prior 
to Day 17-14 days after 
Visit 2
Day 1 
(Fasting)
Day 8 
(Fasting)
TW3
TW7
Unscheduled
TW19
TW25
TW37
TW49 
(Fasting)
TW61
TW73 
(Fasting)
TW85
TW97 
(Fasting)
Unscheduled
Unscheduled
Unscheduled
Unscheduled
Unscheduled
HIV-1 drug 
resistance16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16
Whole blood for 
Proviral DNA 
resistance testing3 3 3 3 3 3 3
Blood (plasma) for 
ISL and DOR PK4 4 4 4 8 4 8
Blood (plasma) for 
Investigational PK4 4 4 4 4
Blood (Plasma) for 
DOR and ISL PK 
During Pre gnan cy<-------------------------------------- Xc------------------------------------ >
Genetic Analysis 8.5
FBR 8 8 8 8 8 8
Inflammatory 
Markers10.7 10.7 10.7 10.7
Total Blood 
Volume per Visit58.7 6 6 65 .2 38 26 26 38 26 63.7 38 75.7 34 34 34 55.7 37 6 49 6 41
anti-HBc=hepatitis B core antibody; DNA=deoxyribonucleic acid; DOR=doravirine; eGFR=estimated glomerular filtration rate; FBR=future biomedical research; HBsAg=hepatitis B surface antigen; 
HBV=hepatitis B virus; HIV -1=human immunodeficiency virus -1; INR=international normalized ratio; ISL=islatravir; MDRD=Modification of Diet in Renal Disease; NA=Not Applicable; 
PCR=polymerase chain reaction; PK=pharmacokinetic(s) PT=prothrombin time; RNA=ribonucleic acid; TBNK=T -and B -lymphocyte and natural killer cell profile ;WOCBP=women of childbearing 
potential.
aThe Repeat HIV -1 Confirmation Visit is only for those participants with HI V-1 RNA ≥500 copi[INVESTIGATOR_014]/mL at Visit 2 AND with a ≥0.5 log10 decline in HIV -1 RNA from the Screening Visit; these 
participants will be required to return to the site for a Repeat HIV -1 RNA Confirmation Visit (Visit 3). At Visit 3, in order to be eligible for ra ndomization, participants must have HIV -1 RNA ≥500 
copi[INVESTIGATOR_014]/mL and a <0.3 log10 decline in HIV -1 RNA from the previous result at Visit 2.
bHIV-1/2 and hepatitis serology includes: HBsAg, HBsAb, anti -HBc total, HCV Ab, and HIV -1/2 antigen/antibody test. 
c PK samples collected during pregnancy per Section 8.11. 7.1. During the 1sttrimester and postpartum study visits, 4mL of blood will be collected for PK sampling. During the 2ndand 3rdtrimester 
study visits, 12mL of blood will be collected for PK sampling.
dBlood volumes collected at the CD4+ T- cell Count/Lymphocyte Count Monitoring Visit represent single monthly monitoring visits.
08BJ8V
PRODUCT: MK-8591A  131
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437770] regularly 
scheduled study visit ( ie, Week 97) and whose visit schedule will be extended through the 
duration of the pregnancy to allow assessments through each trimester and postpartum.
Table 17 Blood Volumes: Participants Whose Pregnancy or Postpartum Visit(s) Extends 
Beyond Week 97
Visit Number 17 18 19 20
Scheduled Week
Week 10 9
Week 121
Week 133 Week 145Blood Parameter Approximate Blood Volume (mL)
Plasma HIV -1 RNA Quantification (Real Time PCR) 6 6 6 6
CD4+ T -cell Count /TBNK panel 4 4 4 4
Plasma for HIV Viral Drug Resistance Testing 15 15 15 15
Chemistry 6 6 6 6
Hematology 2 2 2 2
Blood (Plasma) for DOR and ISL PK <--------------- Xa-------------- >
Whole Blood for FBR 8 8 8 8
Total Blood Volume per Visit (mL)a53 53 53 53
DOR=doravirine; FBR=future biomedical research; HIV -1=human immunodeficiency virus Type 1; ISL= islatravir; 
PCR=polymerase chain reaction; PK=pharmacokinetic(s); RNA=ribonucleic acid; TBNK=T- and B -lymphocyte and 
natural killer cell profile .
aPK samples collected during pregnancy will be collected per Section 8.11. 7.1. During the 1sttrimester and p ostpartum 
study visits, [ADDRESS_437771]: MK-8591A  132
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
NOTE: For purposes of AE defi nition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run- in intervention) , manufactured by, licensed 
by, provided by, or distributed by [CONTACT_63553].
Events meeting the AE definition
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline ,considered clinically significant in the medical 
and scientific judgment of the investigator.
Exacerbation of a chronic or interm ittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdo se without adverse effect.”
Any new cancer or progression of existing cancer.
08BJ8V
PRODUCT: MK-8591A  133
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Events NOT meeting the AE d efinition
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
Surgery planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
Refe r to Section 8.4.[ADDRESS_437772] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
-The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
-Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing c ondition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/incapacity
-The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
-This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomit ing, diarrhea, influenza, 
08BJ8V
PRODUCT: MK-8591A  134
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
-In offspring of participant taking the prod uct regardless of time to diagnosis.
f.Other important medical events
-Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
-Example s of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require reporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
Is a cancer
Is associated with an overdose 
10.3.4 Recording AE and SAE
AE and SAE r ecording
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
08BJ8V
PRODUCT: MK-8591A  135
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437773] s before submission to the 
Sponsor.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
The investigator will make an assessm ent of intensity for each AE and SAE (and other 
reportable safety event) by [CONTACT_111970], version 2.1. Any AE which 
changes DAIDS grade over the course o f a given epi[INVESTIGATOR_19362]/worksheets.
-Grade 1 Mild event: Mild symptoms causing no or minimal interference with usual 
social and functional activities with intervention not indicated.
-Grade 2 Moderate event: M oderate symptoms causing greater than minimal 
interference with usual social and functional activities with intervention indicated.
-Grade 3 Severe event: Severe symptoms causing inability to perform usual social and 
functional activities with intervention or hospi[INVESTIGATOR_374].
-Grade 4 Potentially life -threatening event: Potentially life -threatening symptoms 
causing inability to perform basic self -care funtions with intervention indicated to 
prevent permanent impairment, persistent disability, or dea th.
-Grade 5 Death: Deaths related to an AE.
Assessment of c ausality
Did the Sponsor’s product cause the AE?
The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
The following components are to be us ed to assess the relationship between the 
Sponsor’s product and the AE ; the greater the correlation with the components and 
08BJ8V
PRODUCT: MK-8591A  136
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
their respective elements (in number and/or intensity), the more likely the Sponsor’s 
product caused the AE:
-Exposure: Is there evid ence that the participant was actually exposed to the 
Sponsor’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_9650], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite 
in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor’s product? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor’s product discontinued or dose/exposure/frequency 
reduced?
oIf yes, did the AE resolve or improve?
oIf yes, this is a positive dechallenge.
oIf no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulte d in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_55530]’s product; 
(3) the study is a single -dose drug study; or (4) Sponsor’s product(s) is/are only used 1 
time.)
-Rechallenge: Was the participant re -exposed to the Sponsor’s product in this study?
oIf yes, did the AE recur or worsen?
oIf yes, this is a positive rechallenge.
oIf no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability , or (2) the study is a single -dose drug study; or (3) Sponsor’s product(s) is/are 
used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370]’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC.
08BJ8V
PRODUCT: MK-8591A  137
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
-Consistency with study intervention profile: Is the clinical/pathological 
prese ntation of the AE consistent with previous knowledge regarding the Sponsor’s 
product or drug class pharmacology or toxicology?
-The assessment of relationship will be reported on the case report forms/worksheets 
by [CONTACT_19427] a qualified physici an according to his/her best clinical 
judgment, including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
-Yes, there is a reasonab le possibility of Sponsor’s product relationship:
oThere is evidence of exposure to the Sponsor’s product. The temporal sequence of 
the AE onset relative to the administration of the Sponsor’s product is reasonable. 
The AE is more likely explained by [CONTACT_10577]’s product than by [CONTACT_5748].
-No, there is not a reasonable possibility of Sponsor’s product relationship:
oParticipant did not receive the Sponsor’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor’s product i s not reasonable OR 
the AE is more likely explained by [CONTACT_26372]’s product. 
(Also entered for a participant with overdose without an associated AE.)
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with t he updated causality assessment.
The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations , or 
consultation with other health care professionals.
New or updated information will be recorded in the CRF.
08BJ8V
PRODUCT: MK-8591A  138
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
The primary mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
oReference Section 8.4.1 for reporting time requir ements.
The site will enter the SAE data into the electronic system as soon as it becomes 
available.
After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
If a site r eceives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
Conta cts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent).
08BJ8V
PRODUCT: MK-8591A  139
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable.
08BJ8V
PRODUCT: MK-8591A  140
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions 
Women of Nonchildbearing Potential (WONCBP)
Women in the following categories are considered WONCBP:
Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with perm anent infertility due to an alternate medical cause other than 
the above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion 
should be applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
Postmenopausal female
-A postmenopausal state is defined as no menses for [ADDRESS_437774] discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
Women of Childbearing Potential (WOCBP)
A woman (including a transgender man who is assigned female gender at birth and is 
transitioning toward maleness) is considered fertile following menarche and until becoming 
postmenopausal unless permanently sterile (see below) :
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
08BJ8V
PRODUCT: MK-8591A  141
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Transgender women (assigned male gender at birth and transitioning toward femaleness).
Premenarchal
Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
oA high follicle stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not usin g hormonal 
contraception or hormone replacement therapy (HRT). However, in the absence 
of [ADDRESS_437775]: MK-8591A  142
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.5.2 Contraception Requirements
Female Participants
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctly.
 Progestogen -only contraceptive implantc
 IUSd
 Non-hormonal IUD
 Bilateral tubal occlusion
 Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP 
and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be 
used. A spermatogen esis cycle is approximately 90 days.
Note: Documentation of azoospermia can come from the site personnel’s review of the participant’s medical records, 
medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are Use r Dependentb
Failure rate of <1% per year when used consistently and correctly.
- Combined (estrogen -and progestogen -containing) hormonal contraceptionc
 Oral
 Intravaginal
 Transdermal
 Injectable
- Progestogen -only hormonal contraceptionc
 Oral
 Injectable
Sexual Abstinence
 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
 Progesterone -only hormonal contraception where inhibition of ovulation is not the primary mode of action
 Male or female condom with or without spermicide
 Cervical cap, diaphragm, or sponge with spermicide
 A combination of male condom with either cervical c ap, diaphragm, or sponge with spermicide (double barrier 
methods)e
a. Contraceptive use by [CONTACT_93339].
b. Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
c. If locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to those 
which inhibit ovulation. 
d. IUS is a progestin releasing IUD.
e. Acombination of male condom with either cap, diaphragm, or sponge with spermicide are considered 
acceptable, but not highly effective, birth control methods. 
Note: The following are not acceptable methods of contraception:
- Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
- Male and female condom should not be used together (due to risk of failure with friction).
08BJ8V
PRODUCT: MK-8591A  143
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
oThe biology of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_193451]/vaccines may interact with
oThe biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individua ls 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3. Summary of Procedures for Future Biomedical Research.
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research
08BJ8V
PRODUCT: MK-8591A  144
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during S creening for protocol enrollment from all participants or legal guardians, at a 
study visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_351946].
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical r esearch will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant ’clinical information with future test results. In 
fact little or no research can be conducted withou t connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described bel ow.
At the clinical study site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
08BJ8V
PRODUCT: MK-8591A  145
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437776] party (eg, a university investigator) designated by 
[CONTACT_1034]. The investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent. 
Future biomedical r esearch specimens remaining with the third party after spec ific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Partic ipants may withdraw 
consent at any time by [CONTACT_111954]. If medical records 
for the main study are still available, the investigator will contact [CONTACT_111972] (clinical.specimen.management@ MSD .com). Subsequently, the 
participant’ s specimens will be flagged in the biorepository and restricted to main study 
use only. If specimens were collected from study participants specifically for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroyed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. It is the responsibility of the investigator to inform the 
participant of completion of the withdrawal and/or destruction, if applicable. Any 
analyses in progress at the time of request for withdrawal/destruction or already 
performed prior to the request being received by [CONTACT_259711]. No new a nalyses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_111974]) or the spe cimens have been completely anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specime ns
Future biomedical r esearch specimens will be stored in the biorepository for potential 
analysis for up to [ADDRESS_437777]: MK-8591A  146
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437778] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_88651]. Participants will not be 
identified by [CONTACT_88726].
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address par ticipant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly to 
clinical.specimen.management@ MSD .com.
08BJ8V
PRODUCT: MK-8591A  147
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms ?cdrid=[ZIP_CODE]
2.International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
for Human Use [Internet] : E15: Definitions for Genomic Biomarkers, 
Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. 
Available f rom http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -
genomic -data-and-sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope 
and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informa tional Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/
08BJ8V
PRODUCT: MK-8591A  148
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.7 Appendix 7: Country -specific Requirements
10.7.[ADDRESS_437779] for Russia
In Russia, only adult ( ≥18 years of age) participants will be enrolled in this study.
In Russia, if a participant becomes pregnant (has a positive serum pregnancy test), study 
intervention must be discontinued and the participant’s HIV -[ADDRESS_437780] -of-care. Therefore, the following section s of the protocol are 
not applicable:
Section 4.2.7: Rationale for Continuing Study Intervention During Pregnancy
Section [IP_ADDRESS]: Consent/Assent for Continuation of Study Intervention During 
Pregnancy
Section 8.11.7 .1: Continuing Study Intervention
10.7.[ADDRESS_437781] for Australia
In Australia, only adult ( ≥18 years of age) participants will be enrolled in this study.
10.7.[ADDRESS_437782] for [LOCATION_013]
In [LOCATION_013], only adult ( ≥18 years of age) participants will be enrolled in this study.
10.7.[ADDRESS_437783] for Ukraine
In Ukraine, only adult ( ≥18 years of age) participants will be enrolled in this study.
08BJ8V
PRODUCT: MK-8591A  149
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.8 Appendix 8: Calculation of Creatinine Clearance
Cockcroft -Gault equations
If male:
CrCL(mL/min) = (140-age [y]) × weight [kg])   
                          72 × serum creatinine (mg/dL)
If female:
CrCL(mL/min) = (140-age [y]) × weight [kg])     × 0.85
                         72 × serum creatinine (mg/dL)
08BJ8V
PRODUCT: MK-8591A  150
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
10.9 Appendix 9: Abbreviations
Abbreviation Expanded Term
3TC Lamivudine
AE adverse event 
AIDS Acquired Immune Deficiency Syndrome
ALT alanine aminotransferase
ANCOVA analysis of covariance
APaT All Participants as Treated
ART antiretroviral therapy
AST aspartate aminotransferase
AUC area under the curve
BOCF baseline observation carried forward
C24 concentration after 24 hours
CI confidence interval
Cmax maximum (peak) observed drug plasma concentration
CMH Cochran -Mantel -Haenszel
CONSORT Consolidated Standards of Reporting Trials
CR CL creatinine clearance
CRF Case Report Form 
CSR Clinical Study Report
eCTA exploratory Clinical Trial Application
CTCAE Common Terminology Criteria for Adverse Events
CTFG Clinical Trial Facilitation Group 
Ctrough lowest concentration reached by a drug before the next dose is administered
DAIDS The Division of AIDS
DAO data as observed
DDI drug-drug interaction
DHHS US Department of Health and Human Services
DMC Data Monitoring Committee
DOR Doravirine
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
eDMC External Data Monitoring Committee
EE ethinyl estradiol
EFV Efavirenz
EMA European Medicines Agency
EOC Executive Oversight Committee 
FAHI Functional Assessment of Human Immunodeficiency Virus Infection
FAS Full Analysis Set
FBR Future Biomedical Research
FDA Food and Drug Administration
FDC Fixed-Dose Combination
FSH follicle stimulating hormone 
FTC emtricitabine
GCP Good Clinical Practice 
HBsAG Hepatitis B surface antigen
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HDL -C High -density lipoprotein cholesterol
08BJ8V
PRODUCT: MK-8591A  151
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
Abbreviation Expanded Term
HIV Human Immunodeficiency Virus
HIV-1 Human Immunodeficiency Virus Type 1
HIV-2 Human Immunodeficiency Virus Type 2
HRQo L health -related quality of life
hs-CRP High Sensitivity C -Reactive Protein
HTA Health Technology Assessment
HTE Heavily Treatment -Experienced
IB Investigator’s Brochure 
IC50 concentration of drug needed to inhibit 50% of viral growth
ICF Informed Consent Form 
ICH International Co uncil for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
IEC Independent Ethics Committe e
IL-[ADDRESS_437784]: MK-8591A  152
PROTOCOL/AMENDMENT NO.: 019-[ADDRESS_437785] upper limit of normal
VL viral load
WHO World Health Organization
WOCBP woman/women of childbearing potential 
WONCB woman/women of nonchildbearing potential 
08BJ8V
PRODUCT: MK-8591A  153
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
11 REFERENCES
[Baker, J. V., et al 
2011]Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy 
R, Belloso WH, De Wit S. et al. Changes in 
inflammatory and coagulation biomarkers: a 
randomized comparison of immediate versus 
deferred antiretroviral therapy in patients with 
HIV infection. J Acquir Immune Defic Syndr. 
2011 Jan 1;56(1):36 -43.[04MWL0]
[Burger, D., et al 
2005]Burger D, van der Heiden I, la Porte C, van der 
Ende M, Groeneveld P, Richter C, et al. 
Interpatient variability in the pharmacokinetics of 
the HIV non- nucleoside reverse transcriptase 
inhibitor efavirenz: the effect of gender, rac e, and 
CYP2B6 polymorphism. Br J Clin Pharmacol. 
2005;61(2):148- 54.[057GSX]
[Centers for Disease 
Control (CDC) 1992]Centers for Disease Control (CDC). 1993 Revised 
classification system for HIV infection and 
expanded surveillance case definition for AID S 
among adolescents and adults. MMWR 
1992;41(RR -17):1- 17.[03RH6J]
[Centers for Disease 
Control and 
Prevention 2019]Centers for Disease Control and Prevention. HIV 
and transgender communities. Atlanta (GA): U.S. 
Department of Health and Human Services (HHS); 
2019 Apr; 4 p.[05BCMG]
[Clopper, C. J. and 
Pearson, E. S. 1934]Clopper CJ, Pearson ES. The use of confidence or 
fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404- 13.[00V5VX]
[Department of 
HIV/AIDS 2015]Departmen t of HIV/AIDS. Transgender people 
and HIV. Geneva (Switzerland): World Health 
Organization (WHO); 2015 Jul. 32 p.[05BDGP]
[Food and Drug 
Administration 
(CDER) 2015]Food and Drug Administration (CDER). Human 
Immunodeficiency Virus -1 Infection: Developi[INVESTIGATOR_351899] [Internet]. Silver Spring, MD: U.S. 
Department of Health and Human Services; 2015. 
Available from: 
https://www.fda.gov/downloads/drugs/guidanceco
mplianceregulatoryinformation/guidances/ucm 355
128.pdf.[04MT4V]
08BJ8V
PRODUCT: MK-8591A  154
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
[Knudsen, T. B., et al 
2016]Knudsen TB, Ertner G, Petersen J, Moller HJ, 
Moestrup SK, Eugen -Olsen J. et al. Plasma 
Soluble CD163 Level Independently Predicts All -
Cause Mortality in HIV -1-Infected Individuals. J 
Infect Dis. [ADDRESS_437786] 15;214(8):1198- 204.[04MWL7]
[Michailidis E 2014] Michailidis E, et al. 4- Ethynyl -2-fluoro-2-
deoxyadenosine (EFdA) Inhibits HIV -1 Reverse 
Transcriptase with Multiple Mechanisms. J Biol 
Chem 2014; 289(35):[ZIP_CODE]- [ZIP_CODE].[04PXGP]
[Molina, J. M., et al 
2018]Molina JM, Squires K, Sax PE, Cahn P, Lombaard 
J, DeJesus E, et al. Doravirine versus ritonavir -
boosted darunavir in antiretroviral -naive adults 
with HIV- 1 (DRIVE- FORWARD): 48 -week 
results of a randomised, double -blind, phase 3, 
non-inferiority trial. Lance t HIV. In press 2018.[04WHL3]
[Orkin, C., et al 
2018]Orkin C, Squires KE, Molina JM, Sax PE, Wong 
WW, Sussmann O, et al. 
Doravirine/lamivudine/tenofovir disoproxil 
fumarate is non- inferior to 
efavirenz/emtricitabine/tenofovir disoproxil 
fumarate in trea tment -naive adults with human 
immunodeficiency virus- 1 infection: week [ADDRESS_437787] 
Dis. In press 2018.[050SC7]
[Panel on Treatment 
of Pregnant Women 
with HIV Infection 
and Prev 2018]Panel on Treatment of Pregnant Wom en with HIV 
Infection and Prevention of Perinatal 
Transmission. Recommendations for the use of 
antiretroviral drugs in pregnant women with HIV 
infection and interventions to reduce perinatal HIV 
transmission in the [LOCATION_002]: Dec 2018. 
Washington (DC): Department of Health and 
Human Services (HHS). [Last updated: 2018 Dec 
7]. 365 p.[05BXZW]
[Poteat, T., et al 
2016]Poteat T, Scheim A, Xavier J, Reisner S, Baral S. 
Global epi[INVESTIGATOR_351900]. J Acquir 
Immune Defic Syndr. 2016 Aug 15;72(suppl 
3):S210- 9.[05BDHN]
08BJ8V
PRODUCT: MK-8591A  155
PROTOCOL/AMENDMENT NO.: 019-09
MK-8591A -019-09FINAL PROTOCOL 26-SEP-2022
[Ribaudo, H. J., et al 
2013]Ribaudo HJ, Smith KY, Robbins GK, Flexner C, 
Haubrich R, Chen Y, et al. Racial differences in 
response to antiretroviral therapy for HIV 
infection: an AIDS Clinical Trials Group (ACTG) 
study analysis. Clin Infect Dis. 2013 Dec 
1;57(11):1607- 17.[057GSZ]
[Vandenhende, M. 
A., et al 2015]Vandenhende MA, Ingle S, May M, Chene G, 
Zangerle R, Van Sighem A, et al. Impact of low -
level viremia on clinical and virological outcomes 
in treated HIV -1-infected patients. AIDS. 
2015;29(3):373- 83.[056V0P]
[Wang, H., et al 
2016]Wang H, Lu X, Yang X, Xu N. The efficacy and 
safety of tenofovir alafenamide versus tenofovir 
disoproxil fumarate in antiretroviral regimens for 
HIV-1 therapy: Meta -analysis. Medicine 
(Baltimore). [ADDRESS_437788];95(41):e5146.[04MWLQ]
[Weintrob, A. C., et 
al 2009]Weintrob AC, Grandits GA, Agan BK, Ganesan 
A, Land rum ML, Crum -Cianflone NF, et al. 
Virologic response differences between African 
Americans and European Americans initiating 
highly active antiretroviral therapy with equal 
access to care. J Acquir Immune Defic Syndr. 
2009 Dec 15;52(5):574 -80.[0576P6]
[World Health 
Organization 2007]World Health Organization. Preferred 
antiretroviral medicines for treating and preventing 
HIV infection in younger children: report of the 
WHO paediatric antiretroviral working group. 
Geneva (Switzerland): World Health Orga nization 
(WHO); 2007. 32 p.[057Z5Q]
08BJ8V